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Zusammenfassung 
Das Humane Immundefizienz-Virus Typ 1 (HIV-1) ist das Pathogen, welches verantwortlich 
ist für das erworbene Immundefizienzsyndrom (AIDS). Die Verbreitung von HIV-1 hat sich 
zu einer Pandemie entwickelt, mit weltweit mehr als 35 Millionen infizierten Menschen und 
jährlich neuen Infektionen. Trotz der verfügbaren, effizienten antiretroviralen Therapie (ART) 
steigt das Erscheinen von Medikamentenresistenz mit der Zeit und der Zugang zu ART ist 
beschränkt in Entwicklungsländern. Aus diesem Grund ist es notwendig, neue Strategien zu 
entwickeln für das Blockieren der Virusreplikation und nach einer permanenten Heilung zu 
suchen.  
Eines der Ziele dieser Doktorarbeit war die Identifizierung neuer zellulärer anti-HIV-1 
Wirtsfaktoren, welche potenziell als neue therapeutische Ansätze benutzt werden können. Die 
meisten der bisher identifizierten Restriktionsfaktoren sind IFN--induzierbar und werden 
neutralisiert durch akzessorische HIV-1 Proteine. Wir suchten nach Restriktionsfaktoren in 
CD4+ T-Zellinien, in denen die HIV-1 Replikation stark inhibiert wurde durch IFN-. Wir 
identifizierten 44 mögliche Kandidaten in den beiden Zellinien, die möglicherweise zwischen 
der reversen Transkription und Integration eingreifen.  
Ein zweites Ziel dieser Doktorarbeit war es, ein verbessertes Wissen  über den Beitrag der 
Hypermutationsaktivität des bekannten Restriktionsfaktors APOBEC3G (A3G) zur HIV-1 
Evolution in vivo zu erlangen. A3G wurde hauptsächlich in vitro auf seine mutagene 
Kapazität untersucht. Zu diesem Zweck verwendeten wir die humanisierte Maus als Modell 
für die HIV-1 Infektion. In humanisierten Mäusen ist das Immunsystem defizient und wird 
rekonstituiert mit humanen hämatopoetischen Vorläuferzellen, die ein Immunsystem humaner 
Herkunft entwickeln, welches die HIV-1 Infektion in Mäusen erlaubt. Wir studierten 
Virusreplikation und Diversifizierung in Mäusen, die mit einer HIV-1 Mutante infiziert 
worden waren, welche unfähig ist, die Hypermutationsaktivität von A3G vollständig zu 
neutralisieren (Vif 45G). Wir beobachteten, dass die Infektion mit dieser Mutante nicht in 
einem erhöhten Erscheinen der Medikamentenresistenz resultierte, wie bisherig angenommen, 
sondern eher die virale Fitness von HIV-1 unter selektivem Druck erhöhte. 
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Summary 
Human immunodeficiency virus type -1 (HIV-1) is the pathogen responsible for the acquired 
immunodeficiency syndrome (AIDS). HIV-1 is pandemic, affecting more than 35 million 
people worldwide and there are newly infected people every year. Despite the efficient anti-
retroviral therapies (ART) available, the emergence of drug resistance increases overtime and 
the access to ART is very limited in developing countries. Therefore it is necessary to develop 
new strategies to block viral replication and to seek for a permanent cure.  
Restriction factors are cellular proteins aiming at inhibiting pathogen invasion. One of the 
aims of this thesis was to identify new cellular host HIV-1 restriction factors, which 
potentially can be used as a new therapeutic approach. Key features or signatures of currently 
known restriction factors are i) IFN-α-inducible and ii) counteracted by HIV-1 accessory 
proteins. We screened for restriction factors in CD4+ T-cell lines in which HIV-1 replication 
was strongly inhibited by IFN-α. We identified 44 possible candidates that might act between 
viral reverse transcription and integration in two cell lines.  
A second aim of this thesis was to evaluate or explore the contribution of the hypermutation 
activity of the known restriction factor APOBEC3G (A3G) to HIV-1 evolution in vivo. A3G 
has been mainly characterized in vitro for its mutagenic capacity. To this end, we used the 
humanized mouse as a model for HIV-1 infection. In humanized mice, the immune system is 
deficient and reconstituted with human hematopoietic precursor cells, which develop an 
immune system of human origin, allowing HIV- infection in mice. We studied viral 
replication and diversification in mice infected with a HIV-1 mutant which is unable to 
completely counteract A3G’s hypermutation activity (Vif 45G). We observed that infection 
with this mutant did not result in an increased drug resistance appearance, as previously 
thought, but it rather increased the viral fitness of HIV-1 under selective pressure. 
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1. Introduction 
 
 
 
 8 
 
The introduction of this thesis consists of three main parts. First, there is a short general 
overview about HIV-1. Second, a review focusing on the role of IFN-α in HIV-1 restriction, 
which will give the basis to the working hypothesis of this thesis. The working hypothesis is 
that there are several unknown IFN-α-dependent cellular factors that are able to restrict HIV-1 
replication in CD4+ T cells. Third, there is a second review describing the use of the 
humanized mice for studying HIV-1, since the other part of my thesis work was focused on 
the study of the restriction factor APOBEC3G in vivo, using the humanized mouse model and 
also because I was involved in the experiments of my colleagues Marc Nischang and Renier 
Myburgh using the humanized mouse as a tool for novel anti-HIV therapies in vivo and for in 
vivo gene therapy against HIV-1, respectively (see manuscripts below). 
1.1 The human immunodeficiency virus (HIV) type-1 
HIV-1 results in a chronic infection and eventually in the acquired immunodeficiency 
syndrome (AIDS)[1]. HIV-1 belongs to the retroviridae family and in particular to the sub-
family lentivirinae and the Lentivirus genus. Apart from HIV-1, there is a 2
nd
 human 
pathogenic HIV strain, i.e., HIV-2 which, however, is much less pathogenic than HIV-1[2]. 
HIV-1 (subtypes M, N and O) is closely related to the simian immunodeficiency virus (SIV) 
of chimpanzees[3] or of gorillas (HIV-1 subtype P)[4]. HIV-2, is related to SIV from African 
green monkeys[2, 5]. HIV-1 is pandemic, while HIV-2 is limited to West Africa. 
1.1.1 HIV epidemiology 
According to the UNAIDS in 2013 35.3 million people on average were living with HIV and 
2.3 million were newly infected in 2013. 1.6 million people died due to AIDS-related 
complications worldwide. Since the identification of AIDS in 1981, approximately 60 million 
people have been infected and 30 million already died (UNAIDS, Global report 2013).  
Sub-Saharan Africa is the most affected region, with a prevalence of 4.9% accounting for 
69% of total HIV infections. In South, East and South-East Asia, 5 million people are 
infected, representing 12% of all HIV infections. Finally, the Caribbean, Eastern Europe and 
Central Asia represent the third biggest reservoir of HIV-infected people, where 1% of the 
infected people live (UNAIDS, Global report 2012).  
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1.1.2 HIV Genome 
All retroviruses are composed of two copies of positive single-stranded RNA (ssRNA) and 
their genomes contain i) the gag encoding for the matrix, capsid, nucleocapsid and p6, which 
make up the core of the virion , ii) the pol encoding for the HIV-1 enzymes, i.e.,  protease 
(PR), reverse transcriptase (RT) and integrase (IN) and iii) the env encoding the envelope 
protein which engages cell surface receptors for cellular entry[6-8]. The HIV genome with a 
length of ~9000 bp[9],which is a complex retrovirus as opposed for example to the moloney 
murine leukemia virus[10], encodes for (i) two regulatory proteins, Tat[11] and Rev[12], 
compulsory for transcription elongation and export of the unspliced RNA to the cytosol, 
respectively, and (ii) four accessory proteins including Vif, Vpr, Vpu and Nef for HIV-1 
(reviewed in[13-15]) and Vif, Vpx, Vpr and Nef for HIV-2 (reviewed in[15]) (Fig. 1). The 
accessory proteins are essential for virulence in vivo (see below). 
 
Fig. 1. Structure of the HIV-1 genome. The HIV-1 genome is composed of nine genes and is flanked on each 
side by the HIV LTR. Two of these genes, namely gag and env, code for structural proteins, pol codes for the 
enzymes of the virus, tat and rev for regulatory proteins, and vif, vpr, vpu and nef for accessory proteins.  
1.1.3 HIV structure 
The two molecules of RNA forming the HIV genome, which serve as genomic template for 
the next infected cell, are packaged into the conical viral capsid (composed of several copies 
of the p24 protein) together with the nucleocapsid protein p7, the reverse transcriptase, the 
protease and the integrase. The capsid is surrounded by a matrix (composed of the protein 
p17), which is surrounded itself by a host cell-derived envelope carrying cellular proteins and 
viral glycoproteins including the HIV envelope glycoprotein (gp)160 which consists of the 
transmembrane gp41 and the docking gp120[16-19] (Fig. 2). 
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Fig. 2. The HIV-1 viral particle. HIV-1 virion consists of a capsid in which two RNA copies are packaged with 
the integrase, protease and reverse transcriptase, surrounded by a matrix and a lipid membrane originated from 
the host cell containing the HIV envelope gp120/gp41. 
 
1.1.4 HIV replication cycle 
HIV entry into cells requires the expression of the CD4 cell surface molecule[20] and a co-
receptor, either CCR5 or CXCR4[21-25]. Binding of the HIV Env gp120 to CD4 results in a 
conformational change of gp120, which in turn facilitates the binding to the co-receptor[26-
28]. This allows the HIV Env gp41 to fuse with the cellular membrane leading eventually to 
cellular entry[29].  
CCR5-tropic (R5-tropic) strains are the strains primarily transmitted and also the strains 
which predominate until late stage disease (reviewed in[30]). Accordingly to the receptor 
complex HIV needs for cellular entry, HIV has a particular tropism for memory CD4+ T 
cells, macrophages, dendritic cells (DC) and monocytes, which express the CCR5 co-
receptor[24].  
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In some cases, CXCR4-tropic (X4-tropic) strains, emerge in late stage disease [31, 32], with a 
tropism for naïve T lymphocytes[33], dendritic cells, Langerhans cells, monocytes, and 
CD34+ progenitor cells[33-35].  
Subsequent to cell entry, HIV disassembles, reverse transcription ensues generating a double-
stranded DNA from the HIV RNA[36-38]. To do so, the HIV own RT generates a 
complementary DNA (non-coding DNA) from the HIV RNA template. Subsequently, the RT 
which in addition to the RNA-dependent DNA polymerase activity has also ribonuclease 
activity (RNase H activity), degrades the HIV RNA [39, 40] and finally it synthesizes the 
other DNA strand (coding DNA) with its DNA-dependent DNA polymerase activity resulting 
in a double-stranded DNA[41].  
The HIV DNA in concert with cellular proteins (i.e. importins) and HIV proteins (matrix, 
Vpr, integrase) will then form the pre-integration complex (PIC). The association of cellular 
and viral proteins with the viral DNA impedes the degradation of the latter and makes its 
integration into the cell genome possible. The HIV DNA integrates in a random position and 
its integration is much favored when the infected cell is activated. Once integrated, the HIV 
DNA is then called “provirus” (reviewed in[42]). The provirus will remain in the cell genome 
as long as the infected cell lives. This ability to remain latent in the cells is one of the main 
reasons why patients will not get cured although ART is very efficient to suppress HIV 
replication. For instance, the half-life of the latent reservoir is around 44 months, which 
means that for 10
5
 latently infected cells, it would take 60 years until all these latently infected 
cells die[43, 44]. Thus, it is unrealistic that ART alone will able to eradicate HIV from an 
infected person and thus result in a cure. Moreover, interruption of ART results inevitably in 
HIV rebound from the viral reservoir.  
When the cell is productively infected, HIV hijacks the cellular machinery to induce 
transcription of its gene products in order to produce progeny viruses. Cell activation goes 
along with up-regulation of NF-κB which is the primordial transcription factors binding to the 
LTR and driving HIV replication [45, 46]. Initially, fully spliced mRNAs are generated that 
code for the Tat, Rev and Nef proteins: Tat increases the rate of transcription and allows for 
the transcription elongation of a full-length genomic RNA[47, 48]; Rev regulates the export 
of unspliced HIV RNAs (Gag-Pol and Env RNA) from the nucleus to the cytoplasm, in 
combination with a specific cis-acting sequence for its function, called rev-response element, 
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which is a 520 bp fragment located in the env genomic region[49-51]; otherwise, without 
Rev, no single spliced or unspliced mRNA is exported which encode for the structural 
proteins Gag and Env and the HIV genome which will be incorporated into new virions. 
Finally, Nef plays a multitude of roles increasing HIV pathogenesis[52]. 
The structural HIV proteins will be post-transcriptionally modified either prior to assembly or 
within the immature virions; in particular, the Env polyprotein, into the envelope 
glycoproteins, gp41 and gp120[53, 54]. Similarly, the structural proteins which form the 
capsid, nucleocapsid and matrix, are encoded by a precursor protein that is processed (Gag 
p55) by the protease. Subsequently, the p55 and the Gag-Pol polyprotein (p160) are 
transported to the plasma membrane where HIV particles are assembled for viral budding[55, 
56]  
The HIV particles released have yet to mature for being infectious. Maturation is performed 
by the HIV protease, which cleave the polyproteins into functional structural proteins or 
active enzymes[56] (Fig. 3).  
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Fig. 3. The HIV replication cycle. HIV starts its replication cycle by binding (1) to the cell surface molecule 
CD4 and a co-receptor (CCR5 or CXCR4) (2) for cellular entry (fusion and decapsidation) (3). Key steps are 
reverse transcription (4) of the ss HIV RNA into DNA and its integration (5) into the host chromosome. 
Integrated proviral HIV DNA serves as template for the transcription (6) and translation of viral proteins (8) or 
to generate the HIV RNA (7) for its incorporation into newly produced viral particles (9). The structural viral 
proteins and the viral genomic RNA, together with the integrase, protease and RT, are assembled at the plasma 
membrane, where the budding (10) of the viral particles takes place and a new replication cycle  starts (adapted 
from[57]). 
 
1.1.5 HIV sequence evolution 
A particular and very important property of HIV is its viral diversification within the host. In 
the current paradigm, transmission occurs with one or at most a few founder viruses within a 
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very short time frame viral diversification takes place generating thousands of distinct HIV 
strains (quasi-species). This viral diversification is due to i) the lack of proofreading activity 
of the RT[58, 59], ii) recombination events and iii) hypermutation by the APOBEC3 system. 
 The lack of proofreading of the RT makes the process of reverse transcription highly 
failure-prone: it results in 1 error for each 10’000 to 100’000 nucleotides incorporated[60, 
61]. Since 10
8
 virions are produced every day[62], it means that there are 10
3 
to 10
5
 
mutations produced every day in the viral population. Thus, several mutations on the HIV 
genome appear in a very short time frame in every single patient. 
 The recombination  occurs when a cell is infected at the same time by at least two 
different HIV strains or different viruses[63]. During reverse transcription in the next 
replication cycle, the RT “jumps back and forth” among the two RNA molecules, which 
produces a recombinant viral DNA[64]. Consecutively, all virions produced by this 
recombinant viral DNA will harbor the recombinant genotype[64].  
 APOBEC3G/F acts as restriction factors by hypermutating the HIV genome (G-to-A 
mutations)[65, 66]. Although the accessory protein Vif generally counteracts 
APOBEC3G/F by sending them to the proteasome for their degradation[67], some Vif 
variants, partially neutralize these enzymes, promoting viral sequence diversification and 
increased pathogenesis[68, 69]. The role of APOBEC3G/F in the viral sequence evolution 
will be described more in details in the sections below. 
The rapid viral diversification enables HIV to escape immune responses or drug pressure 
(immune escape variants, drug resistant HIV). It also represents a major hurdle for the 
generation of an efficient vaccine.  
 
1.1.6 HIV infection 
HIV is transmitted by body fluids (blood, semen, pre-ejaculatory fluid, vaginal secretions and 
breast milk[70]). The transmission modes are sexual intercourse, blood exchange, either by 
sharing needles or inadequate screening of blood donations, and mother-to-child transmission 
(vertical transmission)[71]. 
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The main transmission worldwide is heterosexual intercourse (UNAIDS Global report 2012). 
Factors which increase the risk for transmission are i) mode of sexual intercourse with anal 
intercourse carrying the highest risk, ii) the height of plasma viral load in the HIV-positive 
partner and iii) presence of additional sexually transmitted infections such as Herpes simplex 
virus (HSV) mediated genital ulcers.  
Vertical transmission takes place mainly during delivery, followed by breast milk-feeding and 
finally during pregnancy (in utero)[72]. Mothers which are efficiently antiretroviral therapy 
(ART) treated have a very low risk of transmitting the virus to their kids; indeed ART 
treatment is recommended before getting pregnant, or, in case of treatment-naïve pregnant 
women, it is recommended to start treatment at the beginning of the 2
nd
 trimester of 
pregnancy (EACS Guidelines, 2014). 
During the delivery, if the viral load in the blood of the mother is elevated, it can potentially 
infect the newborn due to the blood contamination during partum. Additionally, caesarean 
operation decreases this risk by preventing the newborn to get in touch with the blood from 
the mother. Since HIV is present in the body fluids, including milk, breast-feeding is an 
additional transmission route for the newborn and therefore should be avoided[72]. However, 
some or most of these preventive procedures cannot be implemented in the third world 
countries for infrastructure or political acceptance or willingness[73-77].  
HIV infection can be divided into three main phases: acute infection, chronic infection and 
AIDS. The first one refers to the primary infection, which defines the time period after 
transmission and up to three months after infection. While HIV infection is characterized by 
the presence of a large number of diverse strains, known as “quasi-species”[78], those HIV 
strains that are transmitted are only a few or even single viruses, also called founder 
viruses[79, 80]. Primary HIV infection presents as a flu-like disease which is not 
distinguishable from other viral diseases, with fever in >80% and rash in >50% of cases, oral 
ulcers, arthralgias, pharyngitis, malaise and diarrhea[81]. These symptoms manifest usually 
within the first 2-4 weeks after HIV transmission and may last a couple of days to some 
weeks (5-60 days). At this stage of HIV infection, the HIV RNA copy numbers in the plasma 
may peak with levels higher than 10
6
 copies/ml[82-85], in parallel, the CD4+ T cell count 
drastically diminishes. As soon as HIV-specific  CD8+ T cells are generated, the HIV RNA 
copy numbers decrease and the CD4+ T cell count recovers partially[86-88].   
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In the chronic phase following primary infection the patient is asymptomatic, however the 
disease continues: at around 3-6 months, the HIV RNA copy numbers (viral load) will reach a 
quasi-steady state called viral set-point[89]; this height of the viral set-point predicts the 
disease progression rate, which is monitored in clinical practice by measuring the CD4+ T 
cell number over time[90].  
In average there are 800-1200 CD4+ T cells/μl of blood in a healthy person[91]. Some 
immunodeficiency is observed at CD4 T-cell numbers below 500 cells/µl, with opportunistic 
infections such as candidiasis, Kaposi sarcoma (caused by Human Herpes Virus-8) and 
tuberculosis (reviewed in[92]). Severe immunodeficiency is present when CD4+ cells are < 
200 cells/µl, with wasting syndrome and opportunistic infections, such as  extensive or 
disseminated Herpes, Cytomegalovirus (CMV) infection, cerebral toxoplasmosis, pneumonia 
with Pneumocystis jirovecii (formerly known as Pneumocystis carinii), among many other 
diseases (reviewed in[93]). A patient loses between 70-250 CD4+ T cells/μl per year[94] and 
thus it takes on average around 10 years to reach the critical threshold of 200 CD4+ T 
cells/μl[90]. This stage is best known as AIDS. Without ART, the life expectancy of patients 
with AIDS is most likely less than two years (Fig. 4).  
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Fig 4. Natural HIV infection depicting the acute infection, the chronic infection and the AIDS stage 
(adapted from[95]).  
In 1996 first data were reported from HIV+ patients treated by a regimen consisting of two 
nucleoside analogues combined with a protease inhibitor: this antiretroviral treatment (ART) 
showed a dramatic decrease of the HIV viral load and a substantial increase in the CD4+ T 
cell counts[96, 97]. Moreover, a new drug class, non-nucleoside analogues, was also 
introduced in 1996[98, 99]; most recently, integrase inhibitors were approved for the clinics in 
2007[100].  Today, the clinician has a choice of 34 drugs which may be differentially 
combined[101], e.g., two nucleoside analogues (13 different ones) and either a non-nucleoside 
analogue (6 different ones), a protease inhibitor (11 different ones) or an integrase inhibitor (2 
different ones), reducing viral replication almost completely and increasing the recovery of 
the immune system (Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults 
and Adolescents, 2014).   
Thus, HIV infection is not anymore the deadly disease as in the eighties and early nineties, at 
least in the wealthy countries. However, the widespread use of ART also revealed 
disadvantages such as adverse events, emergence of resistant strains in the case of poor 
adherence, psychological dependence and life-long intake. Very importantly, ART was not 
successful to stop the HIV pandemic. 
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1.2 IFN-α-induced cellular restriction factors and HIV-1 accessory 
proteins  
Authorship contributions 
I wrote all the review and did all the figures and tables present. Annette Audigé and Roberto 
Speck corrected the text and the figures. 
Introduction 
The human immunodeficiency virus (HIV) type-1 belongs to the lentivirinae, a sub-family of 
the retroviridae family, which are single-stranded RNA viruses. Common to all members of 
the retroviridae family are the structural genes capsid (gag), polymerase (pol), and envelope 
(env), encoding the Capsid and the Matrix; the enzymes, i.e., Reverse Transcriptase, Protease 
and Integrase; and the Envelope, respectively[1-3]. The lentiviridae are also named complex 
retroviridae because they have regulatory or virulence genes in addition to the structural 
genes. HIV-1 is the prototype lentivirus with six additional genes, two coding for the 
regulatory proteins Rev[4] and Tat[5] and four for the so-called “accessory proteins” Vif 
(acronym for viral infectivity)[6], Vpr (for viral protein R)[7], Vpu (for viral protein U)[8] 
and Nef (for negative factor)[9]. 
The term “accessory proteins” is misleading: it dates back to cell culture experimentations 
where the accessory proteins, according to the cell model used, were dispensable for HIV-1 
replication[10-13]. In fact, HIV-1 strains deficient in a distinct accessory protein show a 
dramatic decrease in replication capacity or even only abortive infection in vivo. Each 
accessory protein has its individual role(s) in HIV-1 replication: Vif increases HIV’s 
infectivity[6], Vpr amplifies its rate of replication and cytopathic effects[7], Vpu enhances its 
viral production and transmission[14], and finally Nef increases HIV-1’s infectivity[12, 15]. 
All these effects of the accessory proteins occur through interfering with or exploiting host 
cellular proteins (reviewed in[16]).  
On the one hand, HIV-1 hijacks cellular proteins required for viral replication in each single 
step, from viral entry[17-19] to viral production[20]. The host, on the other hand, interferes 
with HIV-1 replication at different steps in the HIV-1 replication cycle with its antiviral 
proteins (reviewed in[21]). These antiviral proteins are also called HIV-1 restriction factors. 
 19 
 
They are constitutively expressed and/or upregulated by interferon (IFN). IFNs belong to the 
first cytokines secreted subsequent to invasion by pathogens and have manifold, very potent 
anti-viral effects[16]. To replicate efficiently despite the IFN response, HIV-1 has developed 
different counter-strategies.   
This review focuses on the IFN-α-mediated anti-HIV mechanisms and the counteracting 
strategies employed by HIV-1, in particular of APOBEC3G/F and Vif , Tetherin and Vpu, 
SAMHD1 and Vpx, and finally TRIM5α and the Capsid protein. Table 1 shows the main 
IFN-stimulated restriction factors against HIV-1, indicating their antiviral function and their 
upregulation by the different IFN types. 
Table 1. Main anti-HIV restriction factors and their upregulation by IFN.   
Host restriction factor 
Restriction 
mechanism 
IFN upregulation 
APOBEC3F/G 
Hypermutation of the 
nascent cDNA, other 
mechanisms 
IFN-α[22-24] 
Bst-2/Tetherin 
Tethering of viral 
particles to the cell 
surface for subsequent 
endocytosis and 
degradation 
IFN-α[25, 26] 
CNP 
Binding to Gag, 
blocking viral particle 
assembly 
IFN Type I[27, 28] 
HERC5 
Arresting Gag particles 
at the assembly site on 
the plasma membrane. 
IFN-β[29] 
IFITM 1, 2, 3 
Inhibition of viral 
entry, negative effect in 
Gag expression 
IFN type I and II[28, 
30] 
ISG15 
Inhibition of viral 
budding and release 
IFN-α[31] 
MX2 
Inhibition of nuclear 
import 
IFN-α[32, 33] 
PKR 
Inhibition of protein 
translation 
IFN-α[34] 
Rnase L/2-5A Viral RNA degradation 
IFN type I and II[35, 
36] 
SAMHD1 
Depletion of dNTP 
pool during reverse 
transcription 
IFN-α and IFN-γ[37, 
38] 
SLFN11 
Inhibition of viral 
protein synthesis, 
codon-usage-dependent 
manner 
IFN Type I[39, 40] 
TRIM5α Premature uncoating of IFN type I and II[41, 
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the viral capsid or 
capsid degradation 
42] 
TRIM22 
Transcription 
inhibition, alteration of 
Gag trafficking 
IFN type I and II[43] 
IFN-α in HIV-1 infection 
IFN-α signaling 
IFN type I comprises IFN-α as well as IFN-β, -ω, -ε, -κ, -δ, -ξ and –τ (reviewed in[44, 45]). 
There are 13 isoforms of IFN-α in humans with 75 to 99% of amino acid homology, which 
are encoded by at least 14 different genes in chromosome 9. IFNs are produced and released 
upon the stimulation of cells by structural motifs of pathogens containing so-called pattern 
recognition motifs. These pattern recognition motifs are present in double-stranded RNA 
(dsRNA), double-stranded DNA (dsDNA), DNA:RNA hybrids and single stranded RNA 
(ssRNA) from pathogens and are recognized by toll-like receptors (TLR) 3, 7/8  and -9, 
cytosolic sensors like RIG-I, MDA5[46-48], LPG2 [49], DAI[50] and IFI16[51, 52]. 
Additionally, IFN type I production is enhanced by cytokines like interleukin-4 (IL-4), -7 and 
-15[53].  
Plasmacytoid dendritic cells (pDCs) are the main producers of IFN-α upon viral infection, 
although almost all cells are capable of producing IFN-α[54-57]. Once IFN-α is produced and 
binds the type I IFN receptor complex on a target cell, it triggers the dimerization of the 
interferon alpha receptor (IFNAR) 1 and 2, leading to the activation of the JAK/STAT 
pathway[58]. It eventually culminates in the translocation of the IFN-stimulated gene factor 3 
(ISGF3) complex to the nucleus and the transcription of hundreds of IFN-stimulated genes 
(ISGs). There are other “non-canonical pathways” of IFN-α signaling that also induce ISGs 
(reviewed in[59]). These include (i) the v-crk sarcoma virus CT10 oncogene homolog (avian)-
like (CRKL) pathway, which binds to the IFN-γ–activated sites (GAS)[60, 61], (ii) the 
phosphoinositide 3-kinase (PI3K) pathway and (iv) the NF-κB cascade which result in the 
upregulation of pro-survival signals and increase of many GTP-binding proteins[62, 63], and 
finally (iv) the mitogen activated protein kinase (MAPK) pathway, which is important for 
antiviral properties of IFN-α, regulation of cell growth and cellular differentiation[64, 65].  
Most of the ISGs identified so far have multiple functions including host defense and in 
particular antiviral defense, immune modulation, inflammation and apoptosis but also 
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functions unrelated to the immune system, such as metabolic enzymes activation, adhesion, 
transcriptional factor and cell signaling[66]. 
IFN-α sets the cell in an antiviral state, i.e., a subset of the ISGs is active against the invading 
pathogen or interferes with the replication cycle by blocking key cellular functions. Among 
the multiple IFN-α-mediated antiviral effects, the best studied ones include inhibition of viral 
and cellular translation[67-69], induction of apoptosis[70, 71], degradation of both cellular 
and viral RNA[72, 73] and inhibition of nuclear import[74]. 
IFN-α signaling also results in activation of DCs[75], natural killer (NK) cells [76], B 
cells[77, 78] and naïve T cells[79]. Additionally, IFN-α leads to MHC class I and II 
upregulation, which subsequently activates CD8+ and CD4+ T-cells, respectively, making a 
link between the innate and the adaptive immune system[80].  
IFN-α signature in HIV-1 infection 
As stated above, pDCs are the main producer of IFN-α. HIV-1 induces IFN-α production by 
infecting pDC precursors[81], or by infecting directly pDCs[82-84]. A productive infection is 
not required for IFN-α induction since the recognition of HIV-1 ssRNA by either TLR7 or 9 
subsequent to HIV-1 particle endocytosis triggers the production of IFN-α. Binding or fusion 
does not result in any IFN-α production[84]. It was recently reported that ssDNA from HIV-1 
stimulates IFN-α expression in primary macrophages via its sensing by the IFN-inducible 
protein 16 (IFI16)[85]. Knockdown of IFI16 decreases the expression of several ISGs and 
increases viral infection in macrophages. However, these experiments were conducted by 
transfecting ssDNA into macrophages. Data so far from productively HIV-1-infected 
monocyte-derived macrophages (MDMS) do not support that this mechanism is operative in 
vivo, since HIV-1 infection of macrophages does not lead to IFN-α production[86]. 
Similarly to macrophages, HIV-1 infection of CD4+ T-cells does not result in any IFN-α 
production[87]. Several potential mechanisms may explain this phenomenon: i) lack of TLR7 
and 9 expression in CD4+ T-cells, ii) IFI16, which senses incomplete DNA reverse transcripts 
(dsDNA), abundant in abortively infected cells, like resting CD4+ T-cells[52]. This sensing 
leads to the activation of caspase-1, which in turn induces a fulminant cell death of these cells 
through a process called pyroptosis iii) SAM domain and HD domain-containing protein 1 
(SAMHD1) (described in details below) prevents IFN-α production in CD4+ T-cells and 
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myeloid cells by blocking infection during reverse transcription, preventing HIV-1 DNA 
accumulation[88, 89]. However, the Vpx protein of HIV-2 and of several simian 
immunodeficiency viruses (SIVs) is able to degrade SAMHD1 and rescue infection in the 
myeloid cells[90], inducing IFN-α production[91] and iv) Three prime repair exonuclease 1 
(TREX1), which digests excessive proviral HIV-1 DNA after reverse transcription of the viral 
RNA[87]. TREX1 is present in macrophages[92], as well as B-cells and T-cells[93]. In the 
latter two cases, the proviral DNA could theoretically be sensed and stimulate IFN-α 
production.  
The IFN-α produced by the pDCs results in a clear IFN-α signature with the upregulation and 
downregulation of hundreds of genes in vitro and in vivo in CD4+ T-cells and macrophages 
(70% of upregulated and 30% downregulated) and reduces viral replication in CD4+ T-
cells[94]. This IFN-α signature has been associated with hyper-immune activation of the 
CD4+ T-cells, leading to apoptosis[95], as well as the induction of apoptosis as a direct effect 
of IFN-signaling[70, 71]; both mechanisms may contribute to the progressive CD4+ T-cell 
depletion. Table 2 summarizes ISGs reported concomitantly in 4 different publications (Table 
2). 
Table 2. Most common ISGs.  
ISG 
GenBank 
accession 
number 
Audigé et al[94]. 
Rotger et 
al[96]. 
Sedaghat et al[95]. Woelk et al[97]. 
ADAR AB209891 
 
x 
  
APOBEC3F JF262037 x x 
  
APOBEC3G BC024268 x x 
  
APOBEC3H BC069023 
 
x 
  
BST2 BC033873 x x 
  
CCL2 M26683 
   
x 
CCL8 Y16645 
   
x 
CIG5 AF026941 
   
x 
DDX58 BC136610 x x 
  
EIF2AK2 BC101475 
 
x 
  
G1P2 (ISG15) AA203213 x 
 
x x 
GBP1 BC002666 x 
   
IFI6 BC015603 x x x x 
IFI16 BC017059 x 
   
IFI27 BC015492 
  
x 
 
IFI35 BC001356 x x 
  
IFI44 BC022870 x 
 
x 
 
IFI44L BC015932 x 
 
x 
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IFIH1 BC111750 x x 
  
IFIT1 M24594 x x x x 
IFIT2 BC032839 x 
   
IFIT3 BC001383 x x x 
 
IFIT4 AF026939 
   
x 
IFIT5 BC025786 x 
   
IFITM1 J04164 x x x x 
IFITM3 X57352 x 
  
x 
IFNAR1 BC021825 
 
x 
  
IFNAR2 BC002793 
 
x 
  
IFNG BC070256 
 
x 
  
IFNGR1 BC005333 
 
x 
  
IFNGR2 BC003624 
 
x 
  
IFRG28 BC013161 x 
   
IRF1 BC009483 
 
x 
  
IRF7 BC136555 x 
 
x 
 
IRF9 BC035716 x x 
  
ISG15 M13755 
 
x 
  
ISG20 BC000575 x 
   
JAK1 AB219242 
 
x 
  
JAK2 BC039695 
 
x 
  
MX1 M33882 x x x x 
MX2 M30818 x 
  
x 
OAS1 X04371 x x x x 
OAS2 BC069052 x x x 
 
OAS3 AF063613 x x x 
 
OASL BC117410 
 
x x 
 
PIAS1 BC118587 
 
x 
  
PLSCR1 AB006746 x 
  
x 
PSMB8 BC001114 
 
x 
  
PTPN2 BC016727 
 
x 
  
RNASEL BC115697 
 
x 
  
RSAD2 BC017969 x 
   
SOCS1 AF132440 
 
x 
  
SP100 AF056322 x 
   
STAT1 BC002704 x x x 
 
STAT2 BC051284 x x 
  
TAP1 L21207 
 
x 
  
TRIM22 BC035582 x x 
  
TRIM5 BC021258 
 
x 
  
TYK2 BC014243 
 
x 
  
ZBP1 BC131706 
 
x 
  
 
The functions of most of these ISGs are unknown (Table 2). For some of them, notably 
APOBEC3G, Tetherin, and TRIM5α, their mechanism of action against HIV-1, other 
retroviruses and enveloped viruses has been discovered recently (see below).  
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IFN-α: good or bad in HIV-1 infection 
IFN-α plays an important antiviral role during acute HIV-1 infection. This is remarkable since 
there is an increase of IFN-α in the peripheral blood, immediately after the initial viremia is 
detectable[98]. Additionally, there is an upregulation of hundreds of ISGs, with antiviral 
effects (see below). Interestingly, IFN-α decreases viral replication of founder viruses during 
initial steps of transmission and only the most IFN-α-resistant viruses succeed to establish a 
productive infection[99]. Finally, in acute SIV infection there is a negative correlation 
between peak IFN-α levels and viral loads[100] or in African Green Monkeys, a strong and 
rapid IFN-α response contributes to the control of non-pathogenic SIVAGM[101].  
Moreover, CD8+ T cells, in elite controllers or asymptomatic infected people, produce IFN-α, 
which is thought to contribute to the protracted or absent progression rate and which might act 
by up-regulating ISGs in CD4+ T-cells and in an autocrine fashion by increasing the CD8+ T 
cell non-cytotoxic antiviral response[102]. Additionally, elite controllers have increased levels 
of a particular ISG, namely, the restriction factor Schlafen 11[103].  
Although the number of circulating pDCs decreases during HIV-1 infection, the pDCs that 
survive are hyperfunctional, producing large amounts of IFN-α[104], resulting in increased 
IFN-α concentrations as quantified in the peripheral blood[105, 106]. This increase is thought 
to be deleterious. For instance, in vitro, HIV-1 infection is responsible for IFN-α production, 
which in turn induces TLR7 activation. This TLR7 stimulation transforms pDCs into DCs 
expressing the TNF-related apoptosis-inducing ligand (TRAIL)[107, 108]. In vivo, TRAIL-
expressing DCs induce apoptosis of CD4+ T-cells in patients, leading to CD4+ T-cell 
loss[109]. Nevertheless, in elite controller patients, this TRAIL induction is useful to kill 
infected CD4+ T-cells[110], which in that case represents a protective effect of IFN-α. 
Moreover, sustained TLR7 stimulation by HIV-1 ssRNA itself may contribute to HIV-
associated immune activation[111].  
Although IFN-α plays an important antiviral role for the initial phase of immune defense, as 
mentioned above, it is controversial whether exogenous administration of IFN-α as an 
alternative or complementary treatment for HIV-1 infection is good or bad. In vitro treatment 
with IFN-α inhibits HIV-1 replication in T-cell lines like CEM-174[112] and MT4R5[113], as 
well as in primary CD4+ T-cells[94, 114, 115]. In macrophages (ex vivo), a high restriction of 
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HIV-1 by IFN-α was documented at early stages of viral infection[116]. Also, expression 
levels of several cellular factors, including TRIM5α, CypA, APOBEC3G, SAMHD-1, 
TRIM22, Tetherin and TREX-1, and different anti-HIV miRNAs, which were increased by 
IFN-α, were considered to be partially responsible for this inhibition[117]. 
In vivo, IFN-α treatment has been studied mainly in HIV-1/Hepatitis C virus co-infected 
patients with very prominent antiviral effects[118-120]. In mono-infected ART-naïve patients 
or patients which were off ART for at least 12 weeks, IFN-α decreased the viral load by a 
factor of approximately 10[121-123] and upregulated several host restriction factors with 
known activity against HIV-1[124] (see below). IFN-α treatment during acute HIV-1 
infection also enhances the production of anti-HIV-1 antibodies, improving control of viral 
replication[125], highlighting the importance of this cytokine during primary HIV-1 infection. 
In patients, it significantly enhanced CD8+ T cell activation, although no CD4+ T cell 
activation was detected[126]. 
The protective anti-HIV-1 effects of IFN-α have also been corroborated in humanized mice, 
with a complete suppression of viral load due to IFN-α treatment[127]. On the other hand, 
IFN-α appears also to have disadvantageous effects: for instance, IFN-α upregulates the 
CCR5 co-receptor in the T-cell precursors in the thymus of humanized mice[128] or human 
CD4+ T-cells in vitro[129], which increases the susceptibility of the cells to HIV-1 infection, 
leading to increased cell depletion. Additionally, in humanized mice, IFN-α treatment 
increased CD4+ and CD8+ T-cell activation[130]. 
In vitro, adding neutralizing antibodies against IFN-α enhanced viral replication but inhibited 
CD4+ T cell depletion[129], and TRAIL upregulation and immune activation were 
decreased[131], which indicates that IFN-α increases immune activation and CD4+ T-cell 
depletion. IFN type I treatment as studied ex vivo in PBMCs results in the death preferentially 
of effector memory CD4+ T-cells by increasing the expression of a pro-apoptotic protein 
called Bak[100]. Increased expression of Bak acts by activation of the CD95/Fas-mediated 
apoptosis pathway. In infected patients, there was a positive correlation between ISGs 
expression, Bak levels, apoptosis, viremia and a negative correlation with CD4+ T-cell 
counts[100].  
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One approach to counteract the IFN-induced immune activation is to block or decrease IFN-α 
production. In two previous clinical trials, 27 HIV-1 infected patients (16 ART naïve and 27 
ART-treated) and 122 HIV-1 patients (ART-naïve and ART-treated) were vaccinated against 
IFN-α, using an albumin-free preparation of recombinant human IFN-α-2b, chemically 
inactivated, as an immunogen, producing anti-IFN-α antibodies[132, 133]. These studies 
showed promising results, including stabilization of CD4+ T-cell counts, stable viremia over 
time and decrease of IFN-α titers, as compared to non-vaccinated patients.  
Finally, IFN-α plays a major antiviral role inhibiting the cross-species transmission of primate 
lentiviruses, which is more pronounced than the antiviral effect against lentiviruses adapted to 
their natural host[134]. Very interestingly, this effect was not due to the known restriction 
factors TRIM5α, APOBEC3, Tetherin, or SAMHD1 (described in details below), indicating 
the presence of undiscovered restriction factors which play a major role in blocking the cross-
species transmission of HIV-1 and other lentiviruses.  
Taken together, it appears that IFN-α  has two faces like Janus, the Roman god ; one face of 
IFN-α is its inhibition of HIV-1, especially during acute infection, and the other face is its 
detrimental effect on CD4+ T-cells, increasing their immune activation and depletion, during 
chronic infection. 
APOBEC3G/F and Vif 
Discovery of APOBEC3G/F 
The Vif protein of HIV-1 is a 23 kDa protein constituted by 192 residues[135]. It was from 
the beginning of its discovery postulated to have an important role on HIV-1 infectivity and to 
be essential for viral spread[6]. The reason for this was unclear, mainly because this protein 
was non-essential in some cell cultures but not in PBMCs[136, 137] or in vivo[138], but 
dispensable in some cell lines. This enigma was solved when a novel restriction factor 
initially called CEM15 was identified[139]. In that work, the researchers limited the numbers 
of potential factors by subtraction hybridization of PCR-amplified fragments from cells 
permissive or non-permissive for replication of Vif-deficient HIV-1.  The resulting PCR 
products were used for generating a cDNA library, which then served, as probes against 
RNAs extracted from permissive and non-permissive cell lines. By this approach, a transcript 
of 1.5 kb was identified only present in the non-permissive cell lines. This transcript, CEM15, 
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belongs to the family of deaminase enzymes of the apo-lipoprotein B editing complex 3 
(APOBEC3), and was subsequently renamed APOBEC3G (A3G)[140, 141]. Soon after its 
discovery, APOBEC3F (A3F), another protein of the same family, was found to have similar 
effects on HIV-1 and HIV-2[142, 143]. These proteins are constitutively expressed in several 
cell lines (CEM, MT2, PM1, etc.)[144, 145] and in primary cells like CD4+ T-cells, 
macrophages and DCs[146].  
APOBEC3G/F and IFN-α  
A3G/F are prototype ISGs. In vitro, they are upregulated by exogenous IFN-α, although the 
level of upregulation depends substantially on the cell type and the donor. For instance, A3G 
is upregulated in primary hepatocytes, MDMS and pDCs (where it is thought to exert anti-
HIV activity)[24] by IFN-α manifold in ex vivo samples from healthy donors[22], but not at 
all or very weakly in primary CD4+ T-cells, PBMCs or in the CD4+ T-cell line H9. Of note, 
all the latter cells express high basal levels of A3G[23]; in fact, downregulation of A3G in 
MDMS or MDDCs (monocyte-derived dendritic cells) with siRNAs goes along with loss of 
the antiviral effect[22, 24]. Likewise, A3G is also upregulated by IFN-β in MDMS[117], 
neuronal cells/astrocytes[147] and, very weakly, in PBMCs[148]. Similarly to A3G, A3F is 
upregulated by IFN-α in MDMS, MDDCs and hepatocytes but not induced in primary CD4+ 
T-cells[149, 150]. No data concerning A3F upregulation upon IFN-β treatment is available. 
Moreover, the IFN-α-mediated upregulation of A3G/A3F is associated with a blocking of 
viral replication and a decrease of the transmission from MDDCs to CD4+ T-cells[150]. 
Likewise, the upregulation of A3G is associated with the inhibition of HIV-1 replication[117]. 
However, there are also several other factors upregulated at the same time, such as TRIM5α, 
Tetherin, TRIM22, SAMHD1, TREX-1 and hundreds of other ISGs whose induction by IFN-
α was not determined in this study. Finally, all APOBEC3 deaminase family members are 
upregulated by IFN-α[150-152] 
APOBEC3 family members  
 The APOBEC3 family includes seven members, APOBEC3A (A3A), APOBEC3B (A3B), 
APOBEC3C (A3C), APOBEC3DE (A3DE), APOBEC3F (A3F), APOBEC3G (A3G) and 
APOBEC3H (A3H). These proteins are encoded by seven genes, all arranged in tandem on 
the chromosome 22, and all have the capacity to mutate cytosines to uracils[153, 154]. From 
these seven members all have anti-HIV activity, but the really relevant ones are A3F and A3G 
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due to their potent negative effect on HIV-1 infectivity and levels of expression, which is 
much higher than that of the other members. Table 3 summarizes the antiviral activity, 
expression levels and Vif sensitivity of each one of the seven APOBEC3 members. 
Table 3. APOBEC3 family members. 
APOBEC3 
family member 
Antiviral 
activity 
Expression  
level 
Vif sensitivity 
APOBEC3A 
Human 
parvovirus 
adeno-associated 
virus (AAV), 
HIV-1 in 
myeloid cells and 
retrotransposons 
High in 
monocytes, 
macrophages and 
neutrophils 
Resistant[155] 
APOBEC3B 
Low anti-HIV 
activity 
Low Resistant[152] 
APOBEC3C 
SIV, very low 
anti-HIV activity 
Middle 
Sensitive[152, 
156] 
APOBEC3DE 
Low anti-HIV 
activity 
Middle Sensitive[152] 
APOBEC3F 
Moderate anti-
HIV activity 
Middle Sensitive[152] 
APOBEC3G 
Strong anti-HIV 
activity 
High 
Sensitive[139, 
152, 157-159] 
APOBEC3H 
Low anti-HIV 
activity 
Low Resistant[152] 
 
 
APOBEC3G/F antiviral mechanism 
Production of viral particles goes along with the incorporation of A3G/F by its binding to the 
Gag protein and the HIV-1 RNA[160]. In the newly infected cell, A3G/F by virtue of their 
deaminase activity will mutate cytosines to uracils by removing the amino group present in 
the cytosine of the nascent negative HIV-1 DNA strand during reverse transcription[153, 
154]. Uracil, as a thymine analogue, will result in the incorporation of A into the plus strand 
leading to G-to-A mutation in the proviral DNA. For A3G, this occurs in a GG-to-GA context 
and for A3F in a GA-to-AA context[157-159, 161, 162]. The A3G/F editing effect generates 
several non-synonymous mutations in HIV-1 DNA, leading to diversity of the virus but also 
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to many stop codons[163, 164] and thus in several truncated proteins[165, 166], which in turn 
inhibits viral spread and drastically decreases viral infectivity. For instance, infectivity of Vif-
deficient viruses is reduced up to 97% and viral production up to 300 times in CEM cells, 
expressing basal levels of A3G[139].  
While an entirely unopposed deployment of the A3G/F editing system is detrimental to HIV-
1, a partially active A3G/F editing system may promote viral diversity, which is beneficial for 
viral evolution, immune escape and emergence of drug resistance[167-169]. Additionally, the 
truncated proteins, as a result of hypermutation or partial hypermutation, are an additional 
source of peptides which are potentially loaded onto MHC class I and II molecules, which 
links the innate and the adaptive immune system[165, 166].  
The effects of A3G/F-mediated hypermutation is mainly observed on integrated HIV-1 DNA 
and to a lesser extent on intracellular viral RNA, but only rarely on plasma viral RNA[170, 
171]. This might be explained by the fact that hypermutated viral genomes might code for 
many truncated proteins, resulting in no viral progeny (see above). Therefore, only infected 
cells with a non-hypermutated or partially hypermutated genome would be able to produce 
virions. The “hypermutation” phenomenon of A3G/F was also found for other 
retroviruses[159] and the hepatitis B virus (HBV)[172, 173]. Of note, A3G/F are highly 
expressed in hepatocytes (see above), where the HBV replicates and thus can be inhibited by 
these factors. 
A3G/F may interfere with viral replication independently of hyperamination by inhibiting the 
reverse transcription elongation; this was shown in cell-free assays where reverse transcripts 
were measured by qPCR and elongation was blocked[174] or using an artificial mutant of 
A3G on its catalytic domain (C291S) and again a blockage of transcription elongation was 
observed[175]. The mechanism remains unknown; thus, this non-editing effect of A3G/F 
impedes the synthesis and accumulation of viral cDNA[174, 175]. Of note, such catalytic 
domain-mutant is an artificial construction by site-directed mutagenesis and has not been 
reported in vivo. The same mechanism is also operative for HBV and human T cell leukemia 
virus type 1 (HTLV-1)[145, 176, 177]. 
It has been reported previously that the accessory protein Vpr activates the DNA damage 
stress-sensing response and promotes G2 cell-cycle arrest, which results in the upregulation of 
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several NK cell-activating ligands (ULBP1, ULBP2, ULBP3, etc.), which increase the lysis of 
infected cells by NK cells[178-180]. On the other hand, A3G might also contribute to this 
process. The hypermutation or partial hypermutation of HIV-1 by A3G results in a significant 
incorporation of uridine[181]. The HIV-1 Vpr accessory protein, together with a cellular 
uracil glycosylase, decreases the uridine accumulation[181]. However, this mechanism 
activates the DNA-damage-response pathway, which in turn upregulates NK cell-activating 
ligands (in this case, ULBP1)[181]. Although Vpr is produced in the infected cells, and the 
viral cDNA is deaminated just at the beginning of the viral replication cycle, partially 
hypermutated cDNA might still be able to produce viral progeny[168], including Vpr and 
several other viral proteins. However, the contribution of A3G in this process remains to be 
confirmed in more physiological studies such as in vivo studies.  
APOBEC3G/F neutralization by Vif 
HIV-1 Vif counteracts the A3G/F editing system by promoting their polyubiquitination and 
proteasomal degradation involving the cullin 5-containing E3 ubiquitin ligase, composed of 
cullin 5, elongin B, elongin C and a RING-box protein[182-184] (Fig. 1). Vif can directly 
bind A3G/F using its N-terminal region, thereby serving as an adaptor between A3G/F and 
the ubiquitin ligase complex (Fig. 1) [162, 182-185]. The transcription factor core binding 
factor β (CBF-β) is essential for the Vif-E3 ubiquitin ligase complex - without CBF-b there is 
no proteasomal degradation[186-188]. Vif binds the amino acids 126-132 in the N-terminal 
region of A3G, while it binds the residues 283-300 of the C-terminal region of A3F[189]. Of 
note, the anti-A3G/F effect of Vif is species-specific[190-193].  
 
Figure 1. Vif binds APOBEC3G for its proteasomal degradation. APOBEC3G possesses 
2 catalytic domains, necessary for its deaminase-dependent antiviral activity. Close to the first 
catalytic domain, there is a region where Vif recognizes and binds it (Vif-binding domain). 
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Vif, on the other hand, has an APOBEC3G-binding domain, used to bind APOBEC3G and 
target it to the proteasome. This is done by recruiting the Cul5 protein, which in turn is bound 
to Rbx1 and E2 and the SLQYA recruits the EloC and EloB. This results in a 
polyubiquitination of APOBEC3G and its proteasomal degradation. 
 
In vivo studies of APOBEC3G/F  
It is difficult to assign a specific anti-HIV-1 effect to the A3G/F system in HIV-1 infected 
patients since all studies rely on correlations; there are no compounds available which would 
permit to interfere with the A3G/F–Vif axis so far.  
For instance, in a clinical study with 30 HIV-infected patients, A3G and A3F mRNA levels 
increased after HIV-1 infection (between primary infection and chronic infection)[140]. When 
comparing the mRNA levels of A3G/F from PBMCs in HIV-infected patients with a low or a 
high viral set point as defined by 6-30 months after primary infection (in this study), the 
mRNA levels of A3G and A3F were higher in people with a lower viral set point 22 months 
post infection. Of note, the viral set point determines the HIV-1 progression rate[194]. To 
what extent the levels of A3G/F are a major determinant of the viral set point remains 
unknown. In ART-naïve HIV-Hepatitis C Virus (HCV) co-infected patients, anti-HCV 
treatment with IFN-α and Ribavirin led to an increase of A3G/F levels in PBMCs and an 
increase in viral hypermutation, mainly GG-to-AG mutations (A3G) but also GA-to-AA 
mutations (A3F) were observed, indicating an A3G/F-related editing effect in vivo[124]. In 
another clinical study involving long-term non progressors, a negative correlation between 
A3G gene expression level, extent of HIV hypermutation and control of viremia was 
observed, suggesting a protective effect of the A3G/F editing system[195]. Similarly, a 
negative correlation between the viral load and expression of A3G/F was observed in SIV-
infected rhesus macaques with long-term non-progression [196].   
However, other studies reported no obvious protective effects of the A3G/F editing system. 
For instance, in a clinical study in HIV-infected adults (ART naïve and chronically infected), 
the levels of potential A3G-mediated mutations found in integrated HIV DNA (vif, env and 
gag regions) did not correlate with the viral load[154] or in a similar study with ART-naïve or 
treated, chronically infected HIV-infected children the gene expression level (mRNA) of A3F 
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or A3G did not correlate with the editing effect (hypermutation events) and disease 
progression[197]. Interestingly, in this case the majority of hypermutations observed were in a 
GA-to-AA context (A3F). Thus, the clinical relevance of the A3G/F editing system remains to 
be shown. The highly polymorphic nature of A3G and A3H speaks in favor of the notion that 
there is a selective pressure on these genes and this in turn speaks in favor of an important 
role as a defense system against retroviruses or for a yet unknown function[198-200]. For 
instance, there is the H186R polymorphism in the A3G protein, whereby the 186R allele is 
associated with an increased CD4+ T cell-depletion and thus accelerated AIDS development 
in African Americans[201]. Puzzlingly, both polymorphisms displayed a preserved antiviral 
activity in cell cultures[201]. Also, different polymorphisms and splice variants of the A3H 
have been identified, which have variable antiretroviral activities and are mostly resistant to 
the neutralization by the Vif protein in vitro, for instance haplotype I (HapI), 
18R/105G/121K/178E; or haplotype II (HapII), 18R/105R/121D/E/178D[202, 203]. In 
particular, the polymorphism K121E is responsible for binding and susceptibility to Vif[204]. 
Data from humanized mice demonstrate the significance of the anti-viral mechanism of A3G 
in vivo[205]. HIV-1 strains deficient in Vif did not replicate, since there was no detectable 
viral load in the plasma of the infected animals. Subsequent sequencing of proviral DNA from 
splenocytes of infected animals with HIV-1 wildtype (WT) revealed the fingerprints of 
deamination by APOBEC3 members. There was a predominant accumulation of G-to-A 
mutations, which were induced by different APOBEC3 members and not only A3G/F. 
Moreover, the hypermutation created mainly stop codons and not non-synonymous mutations 
that could potentially increase viral diversity.  
Other functions of APOBEC3G/F 
Other functions than being a very important intrinsic immune defense system has not yet been 
attributed to the APOBEC3 system. We would like to emphasize that this APOBEC system 
also protects the host cell against endogenous retroviruses and retrotransposons by 
introducing non-synonymous mutations in their genome and by decreasing their cDNA 
levels[206-209].  
Tetherin and Vpu 
Discovery of Tetherin 
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Three observations were essential for the discovery of the restriction factor Tetherin/Bst-2. 
First, infection with HIV-1 strains deficient in the Vpu gene (ΔVpu) resulted in reduced viral 
particle release in epithelial cell lines such as HeLa cells as compared with the monkey cells 
COS-7[210]. Heterokaryons between those two cell lines resulted in a restrictive phenotype, 
which pointed to a dominant factor provided by the HeLa cells[210]. Second, IFN-α treatment 
decreased the release of viral particles in 293T cells infected with HIV-1-ΔVpu more than 
expected compared to HIV-1 WT, which suggested that an ISG is specifically neutralized by 
Vpu. Third, electron microscopy revealed that the virions were completely formed but 
remained tethered to the outer leaflet of the membrane, pointing to the existence of a protein 
tethering the virions to the cell surface; this mysterious protein at that time was named 
Tetherin[25]. 
Comparative microarray analyses eventually identified the mysterious factor to be Bst-2[211]. 
The IFN-α-mediated upregulation of this restriction factors was a key element for its 
identification: microarrays analysis were performed in HeLa, HOS, 293T, HT1080 or Jurkat 
cells treated or not with IFN-α. Less than 10 candidates were endogenously expressed in 
HeLa cells and upregulated by IFN-α in all the cell lines, but Bst-2 was the candidate that 
fulfilled all the requirements. Bst-2 is the acronym for bone marrow stromal cell antigen 2 
since it was first identified at the cell surface of bone marrow stromal cells[212].  
Tetherin and IFN-α 
Tetherin is an ISG with anti-HIV-1 activity. Its discovery was based on its IFN-α upregulation 
and subsequent inhibition of HIV-1 deficient for the Vpu protein[25]. For instance, in 293T 
and HT1080 cells, HIV-1 deficient for the Vpu protein can replicate as efficiently as the WT 
virus[25]. However, an IFN-α treatment blocks viral release on these cells[25]. In Jurkat cells 
and primary lymphocytes, the partial block of viral release is enhanced by IFN-α 
treatment[25]. Therefore the upregulation of Tetherin by IFN-α was one of the criteria for its 
selection and subsequent identification. Tetherin levels are upregulated in different degrees, 
depending on the cell type in which it is expressed: Tetherin was more than 20 times 
upregulated in 293T cells (mRNA levels) or 2 to 5 times in Jurkat cells[211]. Moreover, 
Tetherin seems to be completely dependent on IFN-α for its expression and efficient antiviral 
effect: Tetherin plays a role only when the infected cells are exposed to endogenous IFN-
α[213] or treated with IFN-α[124, 213, 214], not like A3G/F, which are expressed at high 
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basal levels in CD4+ T-cells, which are sufficient for their antiviral effect[23, 149] (see also 
section in vivo studies of Tetherin).  
Tetherins’ antiviral mechanism 
Bst-2/Tetherin is a membrane protein found in the cellular membranes of the endoplasmic 
reticulum and the plasma membrane, and there, more specifically in the lipid rafts[215] (Fig. 
2). It possesses a transmembrane domain on its N-terminus, required for the location of 
Tetherin in the lipid rafts, and a glycosyl-phosphatidylinositol (GPI) anchor at its C-terminal 
end. The GPI anchor has the same function as the transmembrane domain since it can be 
artificially replaced by another transmembrane domain without altering Tetherin’s 
function[216]. The extracellular domain, also named “ectodomain”, is located outside of the 
lipid rafts, accounts for the rest of the protein and contains a coiled-coil domain and several 
glycosylation sites[215, 217]. This ectodomain is required for microdomain localization and 
antiviral function[218]. 
 
Figure 2. The topology and structure of Tetherin determines its antiviral effect. Tetherin 
is localized in the cellular membrane and harbors a transmembrane domain in the N-terminal 
part, an extracellular domain and a GPI anchor in the C-terminal part. In this way, Tetherin is 
incorporated into the viral particles during budding and tethers them to the cellular membrane. 
 
Cell assays using protease treatment convincingly demonstrated the tethering mechanism of 
viral particles by Tetherin (see above)[25]. Bieniasz and co-workers[219] generated an 
artificial Tetherin, which completely differed from the WT sequence but with a similar 
tridimensional structure, size, post-translational modifications and topology. This artificial 
Tetherin displayed very potent anti-HIV activity and was insensitive to Vpu degradation.  Its 
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anti-HIV mechanism is thought to interfere with HIV-1 release and cell-cell transmission 
similar to the natural Tetherin by binding at the same time to the cell surface and to the 
budding HIV-1 particle [211, 220, 221]. The authors speculated that the artificial Tetherin’s 
mechanism(s) is indicative of the one of the natural Tetherin.  
HIV-1 viral production is decreased by Tetherin more than 100 times for Vpu-deficient 
viruses and only 2 times for HIV-1 WT in 293T cells stably transfected with Tetherin[211]. 
Tetherin, when overexpressed in 293T cells, also decreases the infectivity of Vpu-deficient 
strains by interfering with the activation of HIV-1’s own protease by an unknown mechanism, 
leading to an accumulation of pr55Gag and p40Gag precursors[222].   
Human Tetherin not only inhibits HIV-1, but also HIV-2 and its related simian Tetherin 
inhibits SIV, in humans and monkeys, respectively[223-225]. 
Tetherin neutralization by Vpu 
The Vpu protein is unique to HIV-1 and SIV from chimpanzees (SIVcpz)[226]. It is a 16 kDa 
phosphoprotein of 81 amino acids which harbors two principal domains: the transmembrane 
N-terminal domain of 27 amino acids, which is hydrophobic, and a cytoplasmic domain of 54 
residues[227, 228] (Fig. 2). It is a raft-associated membrane protein, which is generated in the 
ER, then transported to the Golgi apparatus, where it forms homo-oligomers and is finally 
translocated to the plasma membranes of the host cells. 
Vpu exerts its effect exclusively in the HIV-1 producer cell; Vpu is not incorporated in the 
newly produced HIV-1 particles, similar to Vif but dissimilar to Vpr and Nef, which are 
virion-associated proteins[229, 230]. The main function of Vpu is to facilitate the release of 
viral particles[231] by degrading the CD4 cell surface receptor and Tetherin. CD4, similar to 
Tetherin, blocks viral particles release by binding of the HIV-1 Envelope.  
Vpu co-localizes with and binds Tetherin at the cellular membranes[25, 220]. Overexpression 
of Vpu in HeLa cells leads to a significant reduction of Tetherin from the cell surface by the 
proteasomal/lysosomal degradation pathway[220, 232, 233]. The cytoplasmic domain of Vpu 
possesses a couple of serines (positions 52 and 56) which are constitutively phosphorylated by 
casein kinase II[234, 235], which allows the recognition and binding of the human protein β-
TrCP[234, 235]. Vpu-β-TrCP 2 in concert with an ATPase (p97) polyubiquitinate Tetherin 
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and CD4 on their cytosolic tail through the E3 ubiquitin ligase, resulting eventually in their 
proteasomal degradation[26, 236]. 
As mentioned above, SIV (except for SIVcpz and HIV-2) does not encode Vpu. Instead of 
Vpu, SIV uses Nef to downregulate monkey Tetherin from the cell surface, without apparent 
degradation[223, 224]; instead Tetherin is removed from the cell surface by clathrin-mediated 
endocytosis[237], HIV-2 uses Env to downregulate human Tetherin from the cell 
surface[225]. Intriguingly, HIV-1 Group P, which originates from gorilla, is unable to 
counteract human Tetherin even though all the known HIV-1 proteins, including Vpu, Nef or 
Env, are present[238]. This group of viruses seem less adapted to humans and suggests a 
protective role of human Tetherin against viral transmission.   
In vivo studies of Tetherin  
In humans, the antiviral role of Tetherin remains unclear. In a cohort of nine ART-naïve 
chronically HIV-infected patients, mRNA and protein levels of Tetherin were positively 
correlated with increased viral load, immune activation and lower CD4+ T-cell counts, 
suggesting that Tetherin is increased over time as an epiphenomenon of an advanced disease 
stage[239]. Thus, Tetherin loses its anti-HIV-1 function in advanced HIV-1 disease for 
whatever reason or its anti-HIV activity is outweighed by other factors promoting viral 
replication, confounding Tetherins’s anti-HIV-1 activity.  
However, different results were observed in a study where PBMCs from HIV-infected 
patients (acute and chronic infection with n=3 and n=10 samples, respectively) were analyzed 
for the plasma membrane levels of Tetherin, by flow cytometry[213]. There was an increase 
of Tetherin expression levels during acute HIV-infection and a decrease during the chronic 
phase, suggesting a role in the viral control from the beginning of the infection. IFN-α 
treatment of PBMCs from healthy volunteers substantially increased the Tetherin levels, 
similar to those found in infected patients in acute infection and more interestingly, these 
Tetherin levels were high enough to decrease viral release of HIV-1 in vitro, despite the 
presence of Vpu[213]. These results show the protective effect of IFN-α during acute 
infection through Tetherin upregulation and its antiviral effect.  
Additionally, exogenous IFN-α treatment lowers HIV RNA copy numbers in HIV-HCV co-
infected patients, which were treated for their HCV infection by pegylated IFN-α and 
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Ribavirin[124]. This decrease in viral load could be due to the antiviral effect of Tetherin, 
since its levels are increased and since Vpu presented several adaptive mutations as a 
counteracting strategy against Tetherin. However, only APOBEC3F, APOBEC3G and 
Tetherin mRNA levels were measured on clinical samples, therefore the effect could also be 
due to the upregulation of another factor. 
Concerning the polymorphisms of Tetherin, there is no data about genetic differences in 
human patients in the HIV-1-Tetherin context.  
In humanized mice, HIV-1 strains deficient in Vpu replicated less efficiently than WT HIV-
1[240]. Unlike WT HIV, Vpu-deficient virus did not downregulate CD4 and Tetherin in the 
spleen of infected mice. These results corroborate the in vitro data that Vpu facilitates viral 
production by degrading CD4 and Tetherin in vivo.  
Murine and feline Tetherin also have antiviral activities against Moloney murine leukemia 
virus (MoMLV) and feline immunodeficiency virus (FIV), respectively. In WT mice, the 
effect of Tetherin was only present when mice were treated with poly I:C (an IFN-α 
inducer)[214], indicating that basal levels of Tetherin were insufficient to have antiviral 
activity, and moreover, in Tetherin-knockout mice, this antiviral effect was not induced, 
indicating that the antiviral effect of IFN-α was specific for Tetherin. 
Nevertheless, in mice only one single nucleotide polymorphism (SNP) has been found so far, 
which induces the expression of higher amounts of murine Tetherin and thus increases its 
antiviral effect against the Friend retrovirus[241]. Therefore, it indicates that the amount of 
Tetherin present at the cell surface is an important factor for its antiviral role. In cats, the 
feline Tetherin decreased particle release of FIV, preventing FIV viremia[242]. Interestingly, 
FIV is not able to counteract feline Tetherin and FIV spreads by cell-to-cell associated 
replication[242]. 
Other functions of Tetherin 
Tetherin acts also as an innate immune sensor directly recognizing virions during the budding 
process, which in turn activates NF-κB in the infected cell and leads to the production of pro-
inflammatory cytokines(reviewed in[243]). The activation of NF-κB takes place using the 
NF-κB canonical pathway, in other words, by interacting with TRAF6 and other cellular 
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proteins resulting in the phosphorylation and proteasomal degradation of the NF-κB inhibitor 
IκB(reviewed in[243]). Additionally, the internalization and endocytosis of Tetherin and 
tethered viral particles for degradation exposes viral elements, such as viral RNA, to different 
membrane-associated TLRs, like TLR 3, 7 and 8[244].  
Tetherin is also present on the cell surface of bone marrow stromal cells and regulates the 
growth and development of B cells by supporting the microenvironment of the myeloid cell 
precursors, inducing their proliferation[212, 245-247].  
Additionally, Tetherin is upregulated in diverse myeloma cells[248, 249], laryngeal squamous 
cell carcinoma samples[250] and metastatic breast cancer[251]. Tetherin is the ligand for the 
immunoglobulin-like transcript 7 (ILT7) in pDCs which subsequent to its binding decreases 
their immune activation and IFN-α production[252]. Since IFN-α arrests the growth of 
primary tumors[253], Tetherin may have an immuno-tolerizing effect being induced by 
cancerous cells.   
TRIM5α and Capsid 
Discovery of TRIM5α  
Tripartite motif-containing 5 alpha (TRIM5α) is up-regulated by IFN type I or II[41]. The 
HIV inhibitory activity of TRIM5α from rhesus macaques (rhTRIM5α) was discovered when 
HeLa cells, which were transduced with a cDNA library from rhesus macaque, were infected 
with HIV-1[254]. rhTRIM5α inhibits HIV-1 approximately fivefold in HeLa cells, by binding 
the viral capsid[254-256].  
In contrast to rhTRIM5a, the human TRIM5α (huTRIM5α) does not restrict HIV-replication. 
However, it restricts the replication of other retroviruses, like MLV and Foamy Viruses[254, 
257, 258].  
Another host protein with a similar antiviral activity is CypA. CypA is a peptidyl prolyl 
cis/trans isomerase which catalyzes the isomerization of proline-imidic peptide bonds in 
oligopeptides and thus accelerates protein folding[259]. However, it has also an antiviral 
activity by binding capsids of some lentivirus[260]. In owl monkeys and some macaques, 
retrotransposition of CypA just in front of TRIM5 generated a TRIM-CypA fusion protein 
(TRIM5-CypA)[261-263] which inhibits HIV-1 to a similar extent as rhTRIM5α. 
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TRIM5α and IFN-α/β 
huTRIM5α  is expressed at basal levels in human cell lines, like HeLa, and rhTRIM5α in 
macaque cells like CMMT and they are upregulated by type I IFN (α and β) or type II IFN 
(γ)[264]. huTRIM5α is  also expressed at basal levels and upregulated by type I IFN in 
primary human cells such as MDMS, CD4+ T-cells, peripheral blood lymphocytes and 
DCs[265, 266]. However, this upregulation of huTRIM5α did not result in any HIV-1 
inhibition but in the inhibition of N-MLV[264, 267]. Moreover, type I IFN treatment of owl 
monkey cells (which express TRIM5-CypA)[264] or a rhesus monkey cell line (which 
express rhTRIM5α)[267] goes along with substantial upregulation of rhTRIM5α and a great 
increase of the anti-HIV-1 effect of TRIM5-CypA or rhTRIM5α, respectively.  
rhTRIM5α antiviral activity 
As the name implies, “tripartite motif containing 5 alpha”, TRIM5α has three domains, i) a 
ring finger domain with E3 ubiquitin ligase activity, ii) a B-box domain, and iii) a coiled-coil 
domain[41] (Fig. 3). The ring finger domain mediates ubiquityation of the viral capsid, which 
is thought to be important to block infection during capsid uncoating[268]. The B-box and the 
coiled-coil domain are important for multimerization of TRIM5α and antiviral activity, related 
to capsid binding[269-273]. In the C-terminal part of the coiled-coil domain is a PRY-SPRY 
sequence, important for binding of the capsid[257]. 
 
Figure 3. TRIM5α contains three motifs and a C-terminal PRY-SPRY region. TRIM5α 
is a tripartite motif protein; specifically, it harbors a ring finger, with E3 ubiquitin ligase 
activity, a B-box, and a coiled-coil domain. In the C-terminal part of the coiled-coil domain of 
TRIM5α, there is a PRY-SPRY sequence. SNPs modifying the antiviral activity of TRIM5α 
are depicted, such as the SNP H43Y in the ring finger, the G110R in the B-Box and the 
R136Q and G176 deletion in the coiled-coil domain.   
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The molecular mechanism of rhTRIM5α’s anti-HIV activity is not entirely clear: one model 
proposes that binding of the viral capsid by the PRY-SPRY induces capsid disruption and 
thus impedes the subsequent steps of the viral life cycle[274]. Another model suggests that the 
ring-finger domain viral capsid degradation by a proteasome-dependent mechanism[275]. 
Treatment with proteasome inhibitors or mutations in the ring finger, however, do not abolish 
the restrictive phenotype when HeLa cells encoding for rhTRIM5α were infected with HIV-
1[276], indicating that proteasome-independent mechanisms must also be operative in 
TRIM5α’s anti-HIV activity.  
As mentioned above, huTRIM5α has no anti-HIV activity[254]. A non-synonymous mutation 
in the PRY-SPRY domain (R332P), however, transforms huTRIM5α into a potent HIV-1 
restriction factor[277, 278]. This non-synonymous mutation was found by constructing 
chimeras between human and rhesus TRIM5α[277]. It remains unanswered whether there was 
a loss of function in humans and/or a gain in rhesus monkeys, respectively. In any case, the 
specific amino acid rendering huTRIM5α anti-HIV active has not been reported so far in 
HIV-1 elite controllers. 
In vivo studies of TRIM5α  
Although huTRIM5α has no obvious anti-HIV activity, some SNPs in different ethnicities 
appear to affect HIV-1 transmission rate. Comparing Japanese and Indian cohorts of HIV-
infected individuals with healthy volunteers, the SNP G110R was more frequent in HIV-
infected individuals whereas the SNP G176del was more frequent in the healthy volunteers; 
both mutations are located in the B-Box and the coiled-coil domain of TRIM5α, 
respectively[279]. In vitro tests showed that G110R decreases the anti-HIV-1 activity of a 
human/AGM chimeric TRIM5α (which possessed the SPRY domain of AGM TRIM5α), 
whereas the G176 deletion increased the chimeric TRIM5α activity against HIV-1. The 
ultimate mechanism underlying these effects is unknown.  
Two other SNPs, H43Y (located in the ring finger) and R136Q (located in the coiled-coil 
domain),  increase susceptibility to HIV-1[280, 281] or are enriched in HIV-resistant 
individuals, which are highly exposed to HIV-1[281, 282], respectively. The protective effect 
of R136Q was only observed against X4-tropic viruses, which infect naïve CD4+ T-cells, and 
with moderate-to-high viral loads[281]. The mechanistic explanation for this protective effect 
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would be that naïve CD4+ T-cells express higher levels of TRIM5α than memory CD4+ T-
cells, which are infected by R5-tropic viruses. In vitro, R136Q and H43Y variants were tested 
for their capability to restrict HIV-1[283]. Although the R136Q mutant restricted different 
capsid variants better than the H43Y mutant, it did not restrict HIV-1 better than WT 
TRIM5α. However, for some capsid variants tested there were different degrees of 
susceptibility to restriction by TRIM5α, indicating a selective pressure on the viral capsid. 
Together, these studies indicate that huTRIM5α has very limited anti-HIV effect but rather a 
potent antiviral effect against other non-human retroviruses, impeding zoonotic viral 
infections. 
Other functions of TRIM5α 
Besides its anti-HIV effect, TRIM5α acts also as a pathogen recognition receptor (PRR) of the 
retrovirus capsid lattice, by triggering  MAPK and NF-κB-dependent genes, leading to the 
activation of TAK1 and inflammatory transcription[284]. 
SAMHD1 and Vpx 
Discovery of SAMHD1  
Monocytes are rather resistant to HIV-1, while HeLa cells expressing CD4 are highly 
permissive. Heterokaryons made by monocytes and Hela cells display the same non-
permissiveness as monocytes, pointing to a dominant restriction factor present in monocytes 
but not in HeLa cells[285]. However, Vpx provided in trans renders cells of myeloid origin 
highly permissive to HIV-1[286-288]. The Vpx protein (acronym for viral protein X) is an 
accessory protein encoded by HIV-2, SIVsm  (sm: sootey mangabeys) or SIVmac (mac: 
rhesus macaques), which is incorporated into newly generated viral particles[289]. It is a 
small 112 amino acid protein[290] migrating at 16 kDa[291]. If HIV-1 was engineered to 
incorporate Vpx into the virions, cells of myeloid origin got highly permissive[292]. Thus, 
Vpx appears to counteract this restriction factor in cells of myeloid origin.  
Benkirane and co-workers identified SAMHD1 (sterile alpha motif and HD domain protein 1) 
as the restriction factor which is neutralized by Vpx using mass spectrometry and co-
immunoprecipitation studies, by comparing parental THP-1 cells with THP-1 cells genetically 
complemented by Vpx[293]. SAMHD1 is present in monocytes and MDDCs and absent in 
 42 
 
HIV-1 permissive cell lines. Monocytic cell lines silenced for SAMHD1, e.g., THP-1, are 16 
times more permissive to HIV-1 infection than parental cells[294].  
SAMHD1 and IFN-α 
Originally, SAMHD1 was previously identified as a factor induced by IFN type II in 
macrophages and dendritic cells in the context of differentially expressed genes in 
macrophages and DCs[37, 295]. It was thought that SAMHD1 is only upregulated by IFN 
type II, but it is also upregulated by IFN-α in MDMS[296] and by other cytokines such as IL-
12 and IL-18[297]. Of note, in MDMS treated with an anti-IFN-γ–neutralizing Ab, the effect 
of IL-12 and IL-18 was maintained[297]. Similarly to A3G/F (see above), SAMHD1 is highly 
expressed at basal levels in immune cells such as primary MDDCs or CD4+ T-cells, but is not 
upregulated at the protein level by IFN-α treatment[38, 298]. However, SAMHD1 protein 
levels can be significantly upregulated in cell lines such as 293T and HeLa.  
SAMHD1 antiviral mechanism 
SAMHD1 is a dGTP-stimulated triphosphohydrolase, i.e., it hydrolyses the deoxynucleoside 
triphosphates (dNTPs) into deoxynucleoside and inorganic triphosphate[299, 300]. This 
hydrolysis results in a depletion of the dNTP pool of the cell[88]. Reverse transcription of the 
HIV-1 single stranded RNA is dependent upon dNTP and thus depletion of the dNTP pool 
inhibits viral cDNA synthesis[299].  
SAMHD1 is phosphorylated in the position T592 in dividing cells, whereas in quiescent cells 
this phosphorylation is absent[301]. Phosphorylation results in the loss of SAMHD1’s 
hydrolase activity and thus in the bigger part of its antiviral activity. IFN type I treatment 
inhibits this phosphorylation on Thr592 residue without modifying the expression levels of 
SAMHD1, increasing the antiviral effect of SAMHD1 on activated CD4+ T cells, MDMS and 
MDDCs. This might explain why the antiviral effect of IFN-α takes place without an increase 
of the expression levels of SAMHD1 in different immune cells. 
Importantly, SAMHD1, as opposed to the previously mentioned restriction factors, is able to 
counteract WT HIV-1. Its expression is limited to the myeloid lineage (macrophages, 
monocytes, DCs)[286] and quiescent CD4+ T cells[89, 302]. In myeloid cells, SAMHD1 is 
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thought to impede a prompt immune response by blocking HIV-1 replication at early stages of 
infections and subsequently impeding IFN-α production. 
SAMHD1 not only restricts HIV-1 and other retroviruses, but also DNA viruses, like vaccinia 
and herpes simplex virus type 1 (HSV-1), by the same mechanism[303]. 
SAMHD1 neutralization by Vpx 
Vpx promotes the binding of SAMHD1 to the CRL4 (DCAF1-Vpx) E3 ubiquitin ligase 
complex by interacting with the DCAF1 substrate receptor subunit, leading to SAMHD1’s 
proteasomal degradation[90]. SAMHD1 is mainly a nuclear protein, and it harbors a nuclear 
localization signal (amino acids 11KRPR14) (Fig. 4). The Vpx-induced degradation takes 
place in the nucleus whereas the cytoplasmic fraction of SAMHD1 is resistant to Vpx and is 
thus able to deploy its activity[304, 305]. Furthermore, the binding of Vpx to SAMHD1 in the 
nucleus, prior to degradation, inhibits its catalytic activity[306]. Counteracting the intrinsic 
innate immune response appears to be a common strategy of the HIV-1 accessory proteins, 
including the HIV-1 Vif, Vpu and the HIV-2 Vpx. Counteracting SAMHD1 by Vpx provided 
in trans results in efficient HIV-1 infection of DCs or monocytes with ensuing high 
production of IFN-α and activation of the DCs[91]. Currently, it is speculated that HIV-2 is 
less pathogenic than HIV-1 due to its ability to productively infect cells of myeloid origin and 
in particular DCs which induce a prominent IFN-α response – the inability of HIV-1 to 
productively infect these cells will not lead to this first wave of IFN-α production.  
 
Figure 4. SAMHD1 has two different domains for its antiviral activity. The Sterile Alpha 
Motif (SAM) and the HD domain are depicted. Additionally, there is a region where Vpx 
binds SAMHD1 for its degradation. The nuclear localization signal (NLS) required for the 
nuclear localization of SAMHD1 is also depicted. 
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In vivo studies of SAMHD1 
The SNP rs1291142 was associated with lower mRNA levels of SAMHD1[307]. However, 
no association was observed for this SNP in cohorts of European and African-American HIV-
positive patients with distinct HIV-1 progression rates, i.e. elite controllers vs. progressors. 
Loss of function mutations in the SAMHD1 gene are responsible for the Aicardi-Goutières 
syndrome[308, 309] or familial chilblain lupus[310]. Aicardi-Goutières syndrome is a 
neurodegenerative disease which is characterized by a high level of IFN-α in the 
cerebrospinal fluid and a progressive encephalopathy (reviewed in[311]). The symptoms 
resemble those of viral infections and the disorder is due to a lack of suitable processing of 
cellular nucleic acid debris, triggering permanently innate and acquired immune 
responses[312]. These mutations alter the localization of SAMHD1, leading to its 
accumulation in the cytoplasm. As mentioned above, SAMHD1 is mainly present in the 
nucleus. Not surprisingly, without a functional SAMHD1, PBMCs from Aicardi-Goutières 
syndrome patients support HIV-1 replication without any exogenous activation and moreover, 
the monocytes of these patients are highly permissive to HIV-1[296].  
Other IFN-α/β/γ-stimulated restriction factors  
Several other anti-HIV-1 restriction factors, which are stimulated by IFN-α/β/γ, have been 
identified so far and are therefore mentioned here. However, their potency is less than that one 
of those reviewed above and their antiviral mechanisms remain largely unknown. 
Additionally, there are no publications studying the anti-HIV effect of these factors depending 
on IFN-α production. 
TRIM22  
TRIM22 (another tripartite motif protein) was identified in a screening with a cDNA library 
from the lymphoblastoid Daudi cell line treated with IFN-α/β and was initially named Staf-50 
for Stimulated Trans-Acting Factor of 50 kDa[313]. Similarly to TRIM5α, TRIM22 is also 
upregulated upon IFN type I or II treatment[313]. For instance, in monocyte-derived 
macrophages, this factor is upregulated upon IFN-α treatment[314]. An overexpression of 
TRIM22 efficiently inhibits HIV-1 replication by blockingHIV-1 transcription[314], directly 
at the LTR promoter region[315]. For this, it has been speculated that TRIM22 interferes with 
Tat- and NF-κB-independent LTR-driven transcription. Additionally, it was also reported that 
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TRIM22 could restrict HIV-1 replication by altering Gag trafficking[43]. In associative in 
vivo clinical studies, TRIM22 expression was positively correlated with endogenous levels of 
IFN-α in HIV-1-infected patients during acute infection, among other factors[316]. Moreover, 
there was a negative correlation between TRIM22 and viral load and a positive correlation 
with CD4+ T-cell counts, indicating a protective role of TRIM22. 
RNase L and 2-5A 
RNase L and 2, 5’-linked oligoadenylate (2-5A) were simultaneously discovered in Ehrlich 
ascites tumor cells (EAT), which were treated with IFN (not specified which type of IFN) and 
the enzymes were purified by different biochemical procedures. RNase L and 2-5A were 
highly upregulated in these cells and their protein levels were abundant enough to be 
purified[317]. Later on, it was discovered that HIV-1 can be inhibited by an overexpression of 
RNase L[35]. This RNAse is dependent on 2-5A, which is also inducible by IFN-α. RNase L 
acts by degrading viral and cellular RNAs. However, HIV-1 appears to induce an RNase L 
inhibitor (RLI) resulting in productive HIV-1 replication.  
PKR 
The Protein kinase RNA activated (PKR) was discovered for its ability to inhibit protein 
synthesis in rabbit cell’s lysates exposed to double-stranded RNA[318]. Later on, looking for 
partners of the HIV-1 Tat protein, with GST fusion chromatography, it was shown that Tat 
binds the PKR protein. PKR is another IFN-α-stimulated protein that can inhibit viral 
replication[319]. This kinase can be activated by different means, such as sensing dsRNA, pro-
inflammatory stimuli, or cytokines[34]. Activation and over-expression of this protein highly 
blocks HIV-1 expression and replication, by inhibiting protein translation. However, HIV-1 
has developed different strategies to counteract this barrier. Among them, the viral Tat 
protein[34] or the expression of cellular dsRNA binding proteins (e.g. trans-activation 
response RNA-binding protein and ADAR1), inhibit PKR activation and thus its antiviral 
activity[320-322].  
ISG15 
ISG15 was discovered in experiments where the researchers were looking for ISGs[323]. This 
was done by loading protein gels with cell lysates of cells stimulated or not with IFN type I. 
Subsequently, ISG15 was tested against HIV-1 and it was observed that ISG15 inhibits viral 
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budding and release, by impeding Gag and Tsg101 ubiquitination and their interaction, 
necessary for viral release[324]. Tsg101 is a protein implicated in endosomal sorting[325]. 
Moreover, ISG15 inhibits viral budding by decreasing Vps4 ATPase activity through 
targeting the CHMP5-LIP5 complex[326]. Of note, the cellular ATPase Vps4 is involved in 
endosomal sorting[327].  
IFITM protein family 
The interferon-induced transmembrane (IFITM) proteins were identified as ISGs with anti-
HIV activity by using short hairpin RNA (shRNA) against ISGs present in SupT1 cells[328]. 
IFITM protein members 1, 2 and 3 are induced by IFN type I. These proteins restrict HIV-1 at 
the level of viral entry, at the endocytosis pathway (IFITM 2 and 3), and also by decreasing 
Gag expression (IFITM 1, 2 and 3). Moreover, the C-terminal part of IFITM proteins is 
responsible for the viral restriction.  
HERC5 
HECT domain and RCC1-like domain-containing protein 5 (HERC5) was discovered by a 
cDNA screening of endothelial cells stimulated with LPS or TNF-α[329]. Subsequently, in 
another study, the authors tested IFN-β-induced factors previously identified for their anti-
HIV activity. Since HERC5 is also IFN-β-inducible, it was identified as a new restriction 
factor among the upregulated proteins[29]. HERC5 inhibits HIV-1 replication at a late stage 
of particle production, specifically, by arresting Gag particles at the assembly site on the 
plasma membrane. It was recently documented that HERC5 blocks HIV-1 replication by 
inhibiting the nuclear export of Rev/RRE-dependent RNA by altering Rev localization[330].  
CNP 
2',3'-cyclic-nucleotide 3'-phosphodiesterase (CNP) was discovered by screening for ~50 ISGs 
transduced in 293T together with an HIV-based lentiviral[27]. CNP was responsible for a 
decreased viral protein production. CNP is a membrane-associated protein, which counteracts 
HIV-1 by binding to the structural retroviral protein Gag[27]. In this way, it blocks viral 
particle assembly once both Gag and the viral RNA have associated at the plasma membrane. 
Sensitivity or resistance to CNP is determined by a single codon (E/K40) in the matrix 
domain of Gag. Finally, CNP presents a spectrum of interspecies variation in antiviral 
activity.  
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SLFN 11 
Schlafen 11 (SLFN 11) belongs to the protein family Schlafen, which is involved in 
thymocyte maturation and is expressed in lymphoid cells[331]. Interestingly, 293 cells 
produced less HIV-based lentiviral particles as compared to 293T cells[39]. The researchers 
discovered that SLFN 11 is expressed in 293 cells but not in 293T cells and thus was 
postulated to be responsible for the phenotype observed. Additionally, other restriction factors 
such as APOBEC3G or ISG15 were discarded since there was no difference in their 
expression in the two cell lines 293 and 293T.  SLFN 11 is highly upregulated in murine 
macrophages and human fibroblasts by poly-IC or IFN-α/β treatment. SLFN 11 acts at the 
level of production of viral proteins in a “codon-usage-dependent manner”[39]. To do so, 
SLFN 11 binds transfer RNA (tRNA) and inhibits changes in the tRNA pool that HIV would 
otherwise induce. It is important to mention that the inhibitory activity of this factor is only 
against viral proteins but not cellular proteins. As mentioned above, in the previous section 
“IFN-α: good or bad in HIV-1 infection”, this factor is significantly upregulated in HIV-1 
elite controllers.  
MX2 
Myxovirus resistance 2 (MX2) is an interferon-induced protein which was discovered by 
comparing the transcription profiles of monocytic cell lines (THP-1), primary CD4+ T-cells 
and several CD4+ T-cells lines (HT1080 and U87-MG cells), which present an inhibitory 
phenotype against HIV-1 when stimulated with IFN-α, as compared to other cell lines which 
do not exhibit this restrictive effect such as Jurkat, CEM, CEM-SS, K562 and U937 cells[32, 
33]. MX2 inhibits early steps of the HIV-1 replication cycle, in particular HIV-1 nuclear 
import or integration. The Capsid region of the viral Gag protein is responsible for the 
susceptibility of HIV-1 to this factor, as shown by mutations in the Capsid, which abolished 
the antiviral effect. It is not known yet how HIV-1 manages to escape this factor, but one can 
speculate that HIV-1 mutates its capsid when this factor is upregulated upon IFN-α 
stimulation or exogenous IFN-α treatment.  
Conclusions and perspectives 
Since the unrestricted activity of APOBEC3 in Vif-deficient HIV-1 infections results in 
abortive HIV-1 infection, interfering with Vif neutralization of APOBEC3 enzymes may 
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provide a very attractive therapeutic strategy. Similarly, for Tetherin, one may envision to 
inhibit either the Vpu/Tetherin interaction or the degradation of Tetherin by Vpu. Or for 
TRIM5α, a drug that is able to mimic the molecular effects of TRIM5α could be designed, by 
binding the viral capsid and sending it for its proteasomal degradation. 
Alternatively, given that the mutation R332P renders huTRIM5α completely effective against 
HIV-1 and the SNP R136Q and the G174 deletion seem to increase HIV-resistance, one can 
think about a gene therapy approach based on a modified huTRIM5α harboring these three 
mutations. The R136Q mutation would protect the naive CD4+ T-cells against infection by 
X4-tropic viruses, which would decrease the chances of developing AIDS. However, this 
huTRIM5α harboring these three mutations has not been tested in vitro against HIV-1 yet.  
Similarly, since SAMHD1 is able to counteract HIV-1 WT in different myeloid and lymphoid 
cells, therapies targeting the upregulation of SAMHD1 should be considered, in order to 
develop alternative anti-HIV-1 treatments. Additionally, learning about how the restriction 
factor works and how HIV-1 is able to counteract it or escape its action can provide the 
researchers with new ideas how to develop new antiviral drugs and new vaccine and cure 
strategies. 
Although called “accessory proteins”, these viral factors can be essential for the virus through 
inhibition of several restriction factors, as shown for Vif, Vpu and Vpx against 
APOBEC3G/F, Tetherin and SAMHD1 respectively. It is likely that more restriction factors 
exist which might be counteracted by the accessory proteins. There might also be other IFN-
stimulated restriction factors, which HIV-1 is able to escape from. It was recently shown that 
a chimeric HIV-1/SIVmac, which is able to counteract the known restriction factors 
APOBEC3, Tetherin, SAMHD1 and TRIM5α, is highly inhibited upon IFN-stimulation, 
indicating existence of more restriction factors upregulated by IFN-α[134, 332].  
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1.3 Modelling HIV infection and therapies in humanized mice 
 
Since HIV-1 only replicates in humans and chimpanzees, it is necessary to develop a murine 
model that supports HIV-1 replication for in vivo studies. Different immunodeficient murine 
strains have been created in order to provide a human immune system that allows HIV-1 
replication, called humanized mice. In order to describe the different humanized mice used 
today for HIV-1 in vivo studies, the next review was written. 
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Summary
The human immunodeficiency virus (HIV) type-1 is a
human-specific virus. The lack of a widely available small-
animal model has seriously hampered HIV research. In
2004, a new humanised mouse model was reported. It was
based on the intrahepatic injection of human CD34+ cord
blood cells into newborn, highly immunodeficient mice.
These mice develop a lymphoid system of human origin
and are highly susceptible to HIV infection and showed
disseminated infection, persistent viraemia and character-
istic helper CD4+ T-cell loss. Here, we will briefly review
the various existing humanised mouse models and high-
light their value to the study of HIV infection.
Key words: HIV-1 infection; HIV pathogenesis;
humanised mice; BLT mice; SCID; human CD34+ cells;
gene therapy; CCR5; antiretroviral treatment;
microbicides; HIV pre-exposure prophylaxis (PrEP)
The HIV situation globally
The UNAIDS report on the Global AIDS Epidemic 2010
optimistically announced that the HIV pandemic had
peaked in the preceding two years. Nevertheless, the num-
bers are shocking: an estimated 33.3 million humans –
0.8% of all adults 15–49 years old – are infected, and
more than 1.8 million people died in 2009 (ht-
tp://www.unaids.org/globalreport/Global_report.htm).
More hopefully, the number of people newly infected with
HIV declined by nearly one-fifth over the last decade
(1999, 3.1 million; 2009, 2.6 million). This decline is based
on more widely applied “safer sexual practices” and reduc-
tions in mother-child transmission. The UNAIDS vision is
Zero New Infections, Zero Discrimination, Zero HIV-asso-
ciated Deaths. The goal is to halt and reverse the spread of
HIV.
A human-specific virus: a challenge
for in vivo studies
HIV specifically infects human cells. Even cells from
chimpanzee, a very close relative of humans, are only
somewhat permissive to HIV infection [1]. Human host
factors are critical for the virus throughout its entire replic-
ation cycle (fig. 1). For example, to enter a cell and begin
its replication cycle, HIV engages a receptor complex of
CD4 and a chemokine receptor, either CCR5 or CXCR4
[2, 3]. However, expressing human CD4 on murine cells
does not make them permissive to HIV. Other human-spe-
cific factors, such as the human chemokine receptors, are
needed.
Over the last three decades, human transgenes essential for
HIV replication were expressed together in rodent cells, but
the cells were still not permissive [4]. Furthermore, human
transgenes were expressed in rodents in an attempt to gen-
erate HIV small-animal models. These models confirmed
the human-specific nature of HIV and the in vitro data. No
replication was observed in mice expressing human CD4
[5], CD4 and CCR5 [6] and Cyclin CDK9 [7], and rats
transgenic for human CD4 and CCR5 replicated HIV only
at very low levels for limited times [8, 9].
Other in vivo studies attempted to create models based on
creating chimeric HIV strains. This approach relies on en-
gineering a distinct HIV gene in a species-specific retrovir-
us, which despite the HIV transgene, replicates vigorously
in the original species (e.g., simian-immunodeficiency vir-
us [SIV] engineered to express the HIV envelope [SHIV])
[10]. The use of SHIV in monkeys allowed key questions
about immune responses to vaccine constructs expressing
various HIV gene encoded proteins to be addressed [10].
However, use of monkeys as animal models is restricted to
specific questions with a narrow focus and cannot recapit-
ulate the overall complexity of HIV, since the biological
properties between SHIV, SIV and HIV are quite distinct.
Finally, HIV-encoded gene products were expressed en-
tirely as transgenes in mice [11–15]. These studies
provided insight into the pathogenic potential of HIV gene
products. However, they were expressed universally at high
levels, and it is difficult to assess the significance of the res-
ulting data since the dynamic nature of true HIV replication
is lacking.
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The requirements for a mouse model
to study HIV infection
Faithfully modelling any human disease in an animal is dif-
ficult. Does the model replicate enough key features of the
disease to allow us to conduct experiments?
Many of the key features of HIV infection are known. The
main route of HIV transmission is vaginal or rectal inter-
course. In acute HIV infection, a massive productive infec-
tion causes cell death in the lymphatic system, most prom-
inently in the gastrointestinal tract. About 3–5 weeks after
acute HIV infection, the levels of HIV RNA decline and
the specific anti-HIV CD8+ T-cell response begins. Un-
like in acute infection, fewer than 1% of CD4+ T cells
are productively infected in the chronic phase [16], a num-
ber that cannot fully explain the progressive immunodefi-
ciency. Poorly understood bystander effects seem to con-
tribute to the overall cell loss [17], and sustained immune
activation triggers it [18]. Combined antiretroviral treat-
ment (cART) has been very successful in suppressing HIV
RNA levels to below the limit of detection in about 90% of
treated patients [19] and has resulted in a marked reduction
of morbidity and mortality [20]. However, cART does not
cure HIV. A small portion of HIV remains silent in long-
lived cells, such as the quiescent memory CD4+ T-cells
[21]; these cells form a latent reservoir of HIV. Besides
finding simpler and more efficient treatment strategies, ma-
jor efforts are now aimed at eradicating the latently infected
cells to eventual cure HIV, and to develop novel gene ther-
apy approaches and vaccination strategies. Other efforts are
focused on orally administered pre-exposure prophylactic
measures using anti-retroviral drugs and finding effective
topical microbicides that can prevent sexual transmission.
Thus, the requirements for a HIV mouse model include the
following:
– Permissiveness to replication-competent HIV with
distinct co-receptor usage (i.e., CCR5- or
CXCR4-tropic HIV strains), resulting in high-level
viraemia, systemic viral dissemination and
histopathology reminiscent of HIV disease in humans.
– Supporting long-term chronic infection, allowing
monitoring of HIV infection over time.
– Susceptibility to natural transmission modes of HIV,
including vaginal and rectal routes.
– Displaying gradual depletion of CD4+ T-cell numbers
during HIV infection.
– Activation of the immune system to lead to HIV-
specific immune responses.
– Establishment and maintenance of an HIV latent
reservoir.
– Allow development and testing of anti-HIV therapeutic
and prevention strategies.
Humanised mice in general
The generation of humanised mice involves either the ex-
pression of human transgenes or the transplantation of hu-
man tissue into immunodeficient mice. However, as men-
tioned above, even constitutive expression of multiple hu-
man transgenes has not rendered mice fully permissive to
HIV infection.
The human-PBL-SCID and foetal thy/liv SCID mouse
model
Transplantation of human tissue into immunodeficient
mice without rejection was first reported in the early 1980s.
This became possible with the identification of a spontan-
eous mutation of the Prkdc gene in mice, which results in
the complete lack of T and B cells and consequently in
severe combined immunodeficiency (C.B.-17 SCID/SCID
[SCID]; descriptions of the various mouse strains, see box)
[22]. The Prkdc gene encodes for the catalytic subunit of
a DNA-dependent protein kinase that is needed for V(D)J
recombination in developing T and B lymphocytes. The
two early humanised (Hu) mouse models were the foetal
thymus/liver (thy/liv) SCID-hu mouse [23, 24] and the hu-
PBL-SCID (PBL, peripheral blood leucocytes) mouse [25].
The foetal thy/liv SCID-hu mouse model is based on sur-
gical placement of foetal thymus/liver tissue under the ren-
al capsule. At 4–6 months post-implantation, foetal
thymus/liver tissue forms a conjoint organoid that re-
sembles human thymus and sustains T-cell lymphopoiesis
for over a year [23]. The system is susceptible to HIV in-
fection, but in the absence of robust peripheral human leuk-
ocyte reconstitution, samplings to analyse the infected hu-
man cells are mainly restricted to the engrafted conjoint or-
ganoid. Also there is no multilineage human haematopoies-
is in this model (table 1).
Figure 1
HIV-1 needs critical host factors for efficient replication. HIV binds to the HIV receptor
complex of the human CD4 cell-surface molecule and a co-receptor, either CCR5 or
CXCR4, via the HIV envelope glycoprotein 120 (HIV env gp120). After conformational
changes in the HIV env gp41, viral host cell membrane fusion occurs (2). The next steps
are the decapsidation (3) and release of the HIV RNA from the virus particle. Reverse
transcription generates a viral complementary DNA (cDNA) based on the viral RNA
template and using HIV’s own reverse transcriptase (4). Once the cDNA is generated, the
preintegration complex (PIC) is assembled, nuclear trafficking and integration of the viral
cDNA into the host genomic DNA follow (5). Efficient transcription and elongation require
formation of P-TEFb (positive transcription elongation factor b) consisting of Tat (6A),
human cyclin-dependent kinase 9 (CDK-9) (6B) and cyclin T1 (6C), which binds to the
nascent HIV transcripts. Fully or partially spliced HIV mRNA (7) is used to translate viral proteins. Unspliced HIV RNA is packaged into newly
generated virions. Assembly of HIV proteins and RNA and budding takes place at the cellular membrane (9). HIV release is inhibited by murine
tetherin at the cellular membrane because murine tetherin is insensitive to the viral protein Vpu, which inhibits human tetherin by directing its
proteasomal degradation (blue frame). Human host factors critical for HIV replication are CD4, CCR5, CXCR4 and cyclin T1 (red frame).
Additional human specific factors probably exist.
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The hu-PBL-SCID mouse model is based on the intraperi-
toneal injection of human PBL [25] and is susceptible to
HIV infection [26]. However, within days, human PBL in-
jected into mice react against the murine disparity with a
vigorous activation: their proliferation rate increases, and
the CCR5 chemokine receptor and HLA-DR are upregu-
lated [27–29], resulting in xeno-reactive T-cells [30]. Mice
with significant blood T-lymphocyte chimerism suffer from
high levels of graft-versus-host disease (GVHD) and mor-
tality. Mice with no or transient T-cell chimerism have a
low incidence [31]. Use of this model is limited mostly by
the lack of de novo development of continuously differen-
tiating human cells, activation status of the xenoreactive T
cells and the GVHD (table 1).
New approaches for generating humanised mice
In 2004, a novel humanised mouse model was reported. It
was based on transplanting human CD34+ haematopoiet-
ic progenitor cells (CD34+ cells) directly into the liver of
newborn immunodeficient mice (Rag2-/- γc-/-) [32]. By 10
weeks after transplantation, the mice develop a lymphoid
system of human origin with T cells, B cells, NK cells,
monocytes and dendritic cells. Notably, the T cells display
a pattern of naive and memory cells and a Vβ repertoire
similar to that of humans. The mouse mounts a specific an-
tibody response against model antigens, such as pneumo-
coccal and tetanus toxoid antigens, but the response is
much weaker than that in humans (table 1).
This model is a significant step toward humanisation. Im-
portantly, the mice lack the γc chain, which results in even
more drastic immunodeficiency as compared with SCID
mice. The γc chain is an essential component of the IL-2,
-4, -7, -9, - 15 and -21 receptors. Its absence severely com-
promises the development of immune cells, including NK-
cell development, and thus their rejection potential against
transplanted xenogeneic tissue. It also makes the mice less
susceptible to lymphoma development. Indeed, the NOD-
SCID IL-2Rγ-null mice are much more useful than the
NOD-SCID mice for transplanting human tissue [33]. Not-
ably, NOD-SCID IL-2Rγ-null mice show a similar degree
of immunodeficiency as Rag1 or 2-/- γc -/- knock-out mice;
they have been developed by crossing of SCID mice with
non-obese diabetic (NOD) mice and mice deficient in the
gamma c (γc) chain of the IL-2 receptor [34].
Table 1: Compilation of the various humanised mouse models.
Humanised mouse
model
Engraftment Cellular composition in
reconstituted hu mice
Supports HIV
infection with
Advantages Disadvantages
hu-PBL SCID [25] N/A • T and B cells • CCR5 and
CXCR4-tropic
strains§ [26, 28,
62]
• Easy to generate (i.e. good access to
PBLs)
• Can immediately be used after transfer of
PBLs
• No multilineage haematopoiesis
• Limited time frame for experi-
ments [62]
• Strong activation of T-cells [27,
28]
• Emergence of xeno-reactive T-
cells (GvHD) [30]
Thy/Liv SCID hu [23] N/A • T cells
• Single positive
double positive
and double negat-
ive Thymocytes
• CCR5-* and
CXCR4-tropic
strains [24, 58,
59]
• Organoid of foetal thymus/liver tissue with
sustained T-cell lymphopoiesis
• Valuable to study certain pathogenic as-
pects (see text)
• Surgical skills needed
• Human foetal tissue needed
• No multilineage haematopoiesis
• Sampling mainly restricted to the
organoid since lack of solid peri-
pheral reconstitution
• Lack of CCR5 expression on in-
trathymic T progenitor cells
Rag2-/- γc -/-[32] ++ • T and B cells
• Monocytes
• Macrophages
• NK cells
• DCs
• CCR5- and
CXCR4-tropic
strains [68, 69,
71]
• Long-term multilineage haematopoiesis
• Specific antibody response to recall anti-
gens [32]
• Suited to study HIV pathogenesis [118,
131, 132], HIV latency [90], gene therapy
and novel anti-HIV treatment approaches
[90]
• Delay between transplantation of
human CD34+ cells and develop-
ment of lymphoid system of ~15
weeks.
NOG [38] or NSG [33] +++ • T and B cells
• Monocytes
• Macrophage
• NK cells
• DCs
• CCR5- and
CXCR4-tropic
strains [40, 70,
131, 132]
• Higher reconstitution levels as compared
to Rag mice [39, 41]
• Suited for studying HIV pathogenesis
[119, 123], HIV treatment [95, 98] and
latency and gene therapy approaches
[102, 107]
• Sensitive to irradiation
NOD/SCID ¶
-hu BLT [42]
And
NOD/SCID γc -/- (NSG)
BLT [133]
+++ • T and B cells
• Monocytes
• Macrophages
• NK cells
• DCs
• CCR5- and
CXCR4-tropic
strains [43, 77,
80, 88, 108, 115]
• Generation of adaptive immune re-
sponses [115]
• Suited for studying HIV pathogenesis [43,
115], anti-HIV treatment [77, 80, 108], HIV
latency [88] as well as novel gene ther-
apies
• Two step procedure for generat-
ing BLT mice
• Surgical skills needed
• Human foetal tissue needed
N/A = not applicable
+ = good engraftment
++ = high engraftment
+++ = very high engraftment
§ Infection using CXCR4 tropic HIV-1 strains only successful shortly after transfer of human PBLs.
* Controversial data concerning the permissiveness of foetal thy/liv SCID mice to infection with CCR5 tropic HIV-1 strains.
¶ For simplicity reasons, we put together these two subtly different models; in fact, BLT mouse using NSG background show a superior engraftment as compared to NOD/
SCID BLT mice.
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Modifications for improving the engraftment of human
haemato-lymphopoietic tissue have been investigated, in-
cluding the use of human foetal liver derived CD34+ cells,
cultivating the CD34+ cells with a cytokine cocktail before
transplantation [35], pre-conditioning the mice with bu-
sulfan instead of irradiation [36, 37], the use of different
mouse strains, such as NOD/shi-scid/γcnull (NOG) [38] or
NOD/SCID/γc -/- (NSG) mice [39], the transplantation of
CD34+ cells intravenously or into the bone marrow or the
transplantation of CD34+ cells at older age of the mice
[39]. (NSG and NOG mice are nearly identical except for
the modification of the γc chain receptor; in both strains,
triggering through the γc chain receptor is disabled: in NSG
mice the receptor is completely knocked down, and in
NOG mice the intracytoplasmic tail is truncated). NOG
mice are especially vulnerable to developing lymphomas
after irradiation; however, they yield similar engraftment
results even when not irradiated [40]. Very importantly,
the lifespans of humanised mice, except of irradiated NOG
mice, appear to be similar to those of wildtype mice; the
mice eventually die due to infirmity. NSG mice trans-
planted at birth with haematopoietic progenitor cells either
from human foetal liver or from human cord blood gave
the better engraftment than the Balb/c-Rag1-/- and
C.B-17-scid/bg mice [41]. Similar data have been reported
by Brehm et al. [39].
The BLT mouse deserves special mention [42]. BLT is
an acronym for bone marrow liver thymic. In this model,
foetal liver/thymus is placed under the renal capsule in
6–8-week-old immunodeficient mice as with standard
SCID-hu mice. However, after 3 weeks, the mice are sub-
lethally irradiated, and autologous human CD34+ cells are
transplanted into the mice. These cells home to the bone
marrow and also migrate to the scaffold generated by the
initial transplantation of the human foetal liver/thymus tis-
sue. In the BLT mice, engraftment of human lymphoid tis-
sue is highly efficient, even to the gastro-intestinal tract
[43]. The innate and adaptive immune responses appear to
be generally more complete in the BLT mice than in hu-
manised mice generated by transplanting human CD34+
cells alone [42]: BLT mice generate a human MHC-restric-
ted T-cell response to Epstein Barr virus (EBV) and ac-
tivated Vβ2-TCR+ T-cells when dendritic cells present the
superantigen toxic shock syndrome toxin 1 (TSST-1). Not-
ably, TSST-1 specifically activates and induces the TCR
Vβ2+ cells to proliferate. Generating an adaptive immune
response is facilitated by educating the human T-cells in
an autologous thymic microenvironment. This is not the
case in the other humanised mouse models, which have
xenogeneic mouse thymic environments. To overcome this
limitation, immunodeficient mice were generated express-
ing the human HLA class I genes [44]. Here, mice trans-
planted with HLA-matched cord blood cells supported the
in vivo differentiation of functionally mature human cyto-
toxic lymphocytes associated with a wide spectrum of
functional human T-cell subsets. The mice mounted an
EBV-specific immune response upon challenge as quanti-
fied by tetramer staining and enzyme-linked immunospot
(ELISPOT) assay.
Thus, introducing human HLA-class I transgenes signific-
antly improved the humanisation of the mice. Similarly, a
new report demonstrated expression of class II (HLA-DR4)
in NOD- Rag1 -/- /γc -/- mice and consequent improvement
in T- and B-cell development and function [45]. Additional
human transgenes critical for haematopoiesis have been in-
troduced into the mouse strain backgrounds, and this action
should result in a lymphoid system that even more closely
approximates the human lymphoid system.
Humanised mice have also been used to study (1.) haema-
topoietic development, (2.) a variety of microorganisms,
including EBV [42, 46], herpes simplex virus [47], Dengue
fever [48, 49], influenza [50] and Salmonella typhi [51, 52],
(3.) sepsis [53] and iv) virus-induced tumours [54, 55].
Irrespective of the strain, immunodeficient mice are prone
to opportunistic infections and must be kept in optimized
hygienic animal care facilities. Whether the humanisation
protects mice from infections is not known.
Humanised mice for studying HIV
infections
The hu-PBL SCID and foetal liv/thy SCID hu mouse mod-
els have been valuable for the study of HIV infection, in-
cluding immune responses (e.g., the effect of vaccination
with vaccinia gp160 and recombinant gp160 [56]), in vivo
drug testing [57–59], anti-HIV effects of CD8+ cytotoxic
T-cells [60] and neutralising antibodies [61], virulence of
HIV isolates [62], and the significance of distinct HIV ac-
cessory proteins on virulence [63, 64], and viral latency
[65]. However, these models have several limitations. Most
importantly, they lack multilineage haematopoiesis and the
capacity to generate an effective human immune response
(table 1).
The “new generation” of humanised mice has a number
of positive aspects, such as multilineage haematopoiesis,
no or very rarely graft-vs-host disease, a longer lifespan of
the mice, and the generation of some immune responses
(table 1). In the next sections, we will focus exclusively
on these new humanised mouse models. Reviews compar-
ing the properties of the various humanised mouse models
based on the use of either Rag, NSG or NOG mouse strains
have recently been published [66, 67]. In this review, we
focused primarily on the overall value of humanised mice
for studying HIV infection and specified only the mouse
strain used when clear differences were described as related
to HIV infection or pathogenesis.
Humanised mice support high-level viraemia
The new humanised mice support high levels of HIV in-
fection with either CCR5- or CXCR4-tropic strains [36,
68–71]. Plasma HIV RNA copy numbers of 104–105/ml in
those mice are similar to the levels found in HIV-infected
humans (note, that HIV replication can be easily monitored
by repetitive sampling of peripheral blood). HIV-infected
cells were detected in the spleen, lymph nodes, thymus
and lungs, indicating dissemination of the virus. Unlike hu-
PBL SCID mice, humanised mice sustain high-level viral
replication for more than a year [35]. Depending on the vir-
ulence of the HIV strain used, the mice show distinct CD4+
T-cell depletion rates over time. Initial reports noted either
very limited or no HIV-specific humoral immune responses
[68, 70]. Importantly, expression of the HIV co-receptors
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CXCR4 and CCR5 on engrafted and differentiated human
immune cells was similar to that seen in humans [68, 70,
71]. Co-receptor expression in human CD4+ T cells is the
major determinant of HIV tropism in vivo [72]. Indeed, as
seen in HIV-infected human, disseminated infection in hu-
manised mice with CCR5-tropic stains leads preferentially
to infection and depletion of CD4+ memory T lymphocytes
[73]. CCR5 is expressed mainly on memory T lymphocytes
and is absent from naive T cells.
Humanised mice for studying sexual transmission and
its prevention
A prerequisite for studying HIV sexual transmission in hu-
manised mice is the engraftment of the female reproductive
tract and/or the gastro-intestinal tract with virus suscept-
ible human cells. Both humanised Rag1-/-γc-/- mice and
Rag2-/-γc -/- mice, as well as BLT mice, are well engraf-
ted with human cells in the vagina [74–77], and vaginal
HIV transmission is efficient in all these three new mouse
models. Like the human gut, the mouse small intestines
include abundant Peyer’s patches and the large intestines
are populated with lymphoid follicular aggregates with hu-
man T and B lymphocytes, macrophages and DC [43, 74].
Here, memory T cells with prominent expression of CCR5
are permissive to CCR5-tropic strains. BLT mice also show
human CD4CD8αα cells, a T-cell subset present only in the
gut-associated lymphoid tissue [77]. These mice respond
with disseminated HIV infection subsequent to either rectal
or vaginal infection with cell-free HIV [43, 74, 75, 77].
However, efficient engraftment of the gastrointestinal tract
of Rag2-/-γc-/- mice with human cells appears to depend on
the protocol used: mice transplanted with CD34+ cells de-
rived from human foetal liver and cultured overnight with
IL-3, IL-6 and stem cell factor showed human cell engraft-
ment in the gut [74]. This is not the case in mice trans-
planted with uncultured CD34+ cells derived from cord
blood [78]. The latter also differed in their susceptibility to
rectal HIV challenge [74, 78].
Humanised mice represent a very significant advancement
for evaluating novel microbicides for preventing HIV in-
fection and very nicely complement the much more ex-
pensive monkey models. Indeed, several recent studies
demonstrated the utility of these models for testing oral and
topical pre-exposure prophylaxis strategies with different
anti-HIV drugs (e.g., Tenofovir, Maraviroc, Raltegravir)
currently on the market [77, 79–82] or with compounds
in development [83]. In particular, topical application of
the CCR5 antagonist Maraviroc formulated as a gel pre-
vented HIV vaginal transmission [81], and the novel CD4
aptamer-siRNA chimeras [83] showed partial protection.
Studies of anti-retroviral treatment strategies
A few reports have noted the utility of the new humanised
mice for evaluating antiretroviral therapies [84–89]. We
made a major effort for defining a gold standard for ART
in humanised mice by first examining the pharmacokinetic
of a number of anti-retroviral compounds [90]. In this work
we showed efficacious anti-retroviral treatment when the
anti-retroviral compounds were added to food pellets or
when long-acting drugs were used [90]. We also demon-
strated emergence of resistance in insufficiently treated
mice, and viral rebound from previously undetectable
levels after cART interruption, confirming a latent reser-
voir as reported recently [85, 86, 88, 91]. Thus, humanised
mice represent a highly valuable model for pre-clinical
proof-of-concept studies to evaluate novel anti-retroviral
compounds and to study latency that closely approximates
the status of HIV-infected humans treated with cART.
Several studies also evaluated novel molecules for sup-
pressing HIV in vivo in these new mouse models [89,
92–98]. They involved studies investigating the potential of
Tat peptide analogues for inhibiting HIV replication (89) as
Box
Human host
factors
Definition Function
CD4 Cluster of differentiation 4 HIV binding-entry receptor, expressed in T-helper cells, macrophages/
monocytes and dendritic cells
CCR5 C-C motif-chemokine receptor 5 Transmembrane chemokine receptor, important for cytoskeletal reorganisation
and cell motility, HIV co-receptor
CXCR4 CXC motif-chemokine receptor 4 Transmembrane chemokine receptor, chemotactic activity for lymphocytes, HIV
co-receptor
Cyclin CDK9 Cyclin dependent kinase 9 Cell-cycle regulator, binds Tat and cyclin T1, required for RNA polymerase II
transcriptional elongation of HIV
Mouse strains Definition Description
C.B.-17 SCID/
SCID
Severe combined immunodeficiency (SCID) Mutation in the Prkd gene (lack of B and T cells)
human-PBL-
SCID
PBL: peripheral blood leucocytes Intraperitoneal injection of human PBL into SCID mouse
Rag1-/- γc-/-
Rag2-/- γc-/-
Deficiency in the recombinase activating gene 1 or 2 and the common
γ chain of the IL-2 receptor
Lack of B, T and NK cells
NOD Non-obese diabetic mouse Reduction of NK cell activity
NOD/SCID NOD and SCID mouse Lack of B and T cells and NK cell activity
NSG (NOD/
SCID/γc-/-)
NOD/SCID mice with entire knock-out of the common γc chain
receptor
Lack of B, T and NK cells and block of the maturation and activity of these cells
NOG (NOD/
SCID/γc-/-)
NOD/SCID mice with knockout of the intracytoplasmatic tail of the
common γc receptor
Lack of B, T and NK cells and block of the maturation and activity of these cells
BLT Bone marrow, liver, thymus NOD/SCID or NOD/SCID/γc-/- mice transplanted with foetal liver, thymus and
CD34+ cells
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well as the effects of silencing (si)RNAs directed against
viral proteins (e.g., Tat, Rev, Vif) or CCR5 that were de-
livered either by aptamers binding to the HIV envelope gly-
coprotein [92], dendrimer nanoparticles [93], single-chain
antibodies binding to CD7 [95] or by immunoliposomes
targeting the lymphocyte function-associated antigen-1
(LFA-1) [94]. The gp-120-binding aptamers targeted pro-
ductively infected T cells specifically, and the single-chain
antibodies and immunoliposomes targeted the white blood
cells independently of HIV infection. In all of these in vivo
studies, HIV replication was significantly suppressed. The
humanised mice are also useful for studying the protect-
ive effect of distinct broadly neutralising antibodies de-
livered either by antibody-expressing cells administered as
“backpacks” [96] or by adeno-associated virus-based vec-
tors [97].
Studying gene therapeutic approaches for HIV/AIDS
Humanised mice represent a unique option to explore
haematopoietic stem cell–based gene therapy strategies.
Gene manipulation of human CD34+ cells to modulate host
factors is also very attractive for HIV pathogenesis studies.
Immunodeficient mice have long been used to assess the
ability of gene-transduced human CD34+ cells to differen-
tiate into various cellular subsets. In 1994, retroviral vec-
tor–transduced human CD34 cells were shown to differ-
entiate into mature T-cell subsets in SCID-hu grafts [99].
Later, long-term engraftment of human CD34+ cells trans-
duced with an HIV vector was demonstrated in NOD/SCID
mice; 4–10% of the human cells were transduced [100].
NOD/SCID and the NSG mice seem to engraft similar
numbers of transduced human CD34+ cells [101].
However, when using bone marrow from those mice for
secondary reconstitutions in mice on the same background,
human tissue from NSG mice engrafted far better than that
from NOD/SCID mice, pointing to increased numbers of
long-term SCID repopulating cells. These features are fa-
vourable for studying long-term transgene expression and
the analysis of retroviral-insertion sites in primary and sec-
ondary transplanted NSG mice.
These findings, along with the higher levels of human tis-
sue engraftment, suggest that the “novel generation” of hu-
manised mice will be very useful for studying gene therapy
approaches and examining distinct genes for their patho-
genic effects in various settings. In addition, zinc-finger
nuclease–mediated gene engineering is another very prom-
ising gene-engineering technology that has been explored
in these mouse models [102].
A vast body of literature describes various approaches to
control HIV by ex vivo gene therapy [103, 104]. Gene ther-
apy approaches for HIV/AIDS i) target host factors critic-
al for HIV replication or ii) HIV genes mandatory for HIV
replication (e.g., Nef) [105], iii) introduce novel gene con-
structs (e.g., Trim5-cyclophilin fusion protein that inhib-
its HIV replication) [106], or iv) employ a broadly neut-
ralising anti-HIV antibody [107]. The value of humanised
mice for studying genetically altered human CD34+ cells
to treat HIV is nicely illustrated by several studies, such
as those targeting CCR5 with siRNA- or shRNA-mediated
silencing [108, 109] or by zinc finger–mediated excision
[102]. Notably, the HIV receptor complex consists of CD4
and either the HIV co-receptor, CCR5 or CXCR4 [72].
CCR5-tropic strains are transmitted and predominate un-
til late-stage disease [110]. CXCR4-tropic strains emerge
in advanced stages of HIV disease in about 50% of HIV-
infected patients and seem to accelerate the immune de-
ficiency [111]. Silencing CCR5 has been mentioned as a
potential “cure” for HIV. A recent report described an HIV-
infected patient who suffered from acute myeloid leuk-
aemia and who was transplanted with human CD34+ stem
cells lacking CCR5. Strikingly, the patient appears to be
fully cured since HIV did not rebound subsequent to inter-
ruption of cART [112]. While it involved only a single pa-
tient, this report gives credence to genetic approaches tar-
geting CCR5.
Introducing a lentiviral construct silencing CCR5 into hu-
man CD34+ cells resulted in a clear reduction of CCR5 on
the target cells of HIV in vivo [108]. The engineered pro-
genitor cells showed long-term haematopoietic repopulat-
ing capacity by secondary transplantation. Notably, the ge-
netically engineered progeny cells behaved identically as
the controls. In vitro the engineered cells were resistant
to HIV infection with CCR5-tropic strains. Zinc fin-
ger–mediated excision of CCR5 in CD34+ cells resulted in
progeny cells lacking CCR5, and the mice showed lower
HIV replication and prevention of CD4+ T-cell loss in vivo,
as compared to control mice [102]. Very importantly, HIV
infection resulted in a selection of cells resistant to HIV
over time. This technology demonstrated cells with long-
term haematopoietic repopulation capacity. Other genetic
approaches have focused on T cells and engineered HIV-
resistant CD4+ T cells with CXCR4-specific zinc finger
nucleases [113].
These studies clearly indicate that humanised mice are a
very promising tool for exploring gene engineering ap-
proaches to treat and/or cure HIV. The major hurdles will
not be the identification of targets rendering cells resistant
to HIV but to achieve sufficiently high numbers of genet-
ically engineered CD34+ cells, the migration of transduced
cells to the niches of haematopoietic stem cells, preventing
the insertional risk favouring neoplastic transformation or
off-target effects (e.g., activation of the innate immune re-
sponse). Here, too, the humanised mouse model will be a
versatile tool for exploring these questions.
Humanised mice for generating an HIV-specific
immune response
Inducing a robust HIV-specific immune response was re-
ported in NSG mice reconstituted with human CD34+ cells
from newborns [114] and in the BLT mouse model [115].
Both papers reported HIV-specific CD4+ and CD8+ T-cell
responses with overlapping HIV peptide pools [114, 115]
or ELISPOT assays [115]. The relevance of the CD8+ T
cells in constraining HIV replication in humanised mice
was illustrated by a significantly higher replication rate
when CD8+ T cells were depleted [114]. The humanised
mice also developed humoral immune responses against
HIV [115]. However, antigen-specific immune responses
in humanised mice seem to take longer to develop than
in adult humans infected with HIV, possibly reflecting the
lack of full maturity of the human immune systems of these
mice after reconstitution [115]. In previous work, such sol-
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id HIV-specific antibody immune responses were not re-
ported. The analysis might have been performed too soon
after HIV infection. In view of limited number of studies,
we still do not know if the current generation of human-
ised mice is suited for studying antigen-specific immune
responses and, in particular, vaccine approaches. In mice
reconstituted directly with human CD34+ cells the selec-
tion of T cells is done by murine thymic stromal cells. The
subsequent generation of an antigen-specific immune re-
sponse, however, is based on the processing of antigens
by human antigen-presenting cells in the humanised mouse
model and therefore might be suboptimal.
HIV evolution over time
HIV’s diversity is one of its main features. It is also a key
element for immune escape and emergence of resistance
to ART. HIV’s diversity is due to the inaccuracy of the
HIV reverse transcriptase, hyperamination of the nascent
DNA strand during reverse transcription by the members
of the APOBEC family, and recombination events between
distinct HIV strains. Indeed, the genotypic and phenotypic
changes in the viral envelope gene in humanised mice in-
fected with a distinct HIV strain, JR-CSF, showed the mean
rate of divergence of viral populations over 44 weeks sim-
ilar to that in humans [116]. They noted a disproportionate
number of guanosine-to-adenosine transitions in the HIV
envelope, indicating that APOBEC3G is active in this mod-
el. Furthermore, a number of substitutions in the envelope
gene were identified.
HIV immune activation and dysfunction
Sustained immune activation is the major trigger of HIV-
associated immunodeficiency. Various mechanisms, such
as disruption of the gastrointestinal tract barrier during
acute HIV infection [117] or various HIV accessory gene
products, may contribute to the HIV-associated immune ac-
tivation [18]. Immune activation is also observed on the
CD4+ and CD8+ T cells in HIV-infected humanised mice
[115, 118]. We used the humanised mice to study the role
of macrophages in immune activation [118]. We found that
HIV infection results in a disturbed phagocytosis by mac-
rophages. Notably, macrophages are essential for clearing
bacterial products. We concluded that disruptions of the
gastrointestinal tract barrier, together with the macrophage
dysfunction, are a main element of higher blood levels of
bacterial products and thus in HIV-associated immune ac-
tivation.
Immune activation affects also the PDL1-PD1 axis (PDL =
programmed death ligand). The inhibitory receptor PD-1,
which indicates exhaustion of T cells, was increased on the
T cells in HIV-infected humanised mice, reminiscent of the
findings in humans [115]. Ongoing studies are examining
the benefits of blocking the PD-1 pathway.
The presence of various immune cells, such as plasmacyt-
oid dendritic cells (pDC) and T-regulatory cells, in human-
ised mice presents a unique opportunity to assess their ef-
fects on HIV infection and vice-versa (i.e., HIV’s effect
on them). For example, rapid infection and activation of
pDCs were seen in HIV-challenged humanised mice [119].
Their activation correlated with activation of CD4+ T cells
and their apoptosis. While CD4+ T cells were depleted,
pDCs were maintained but functionally impaired. The pres-
ence of T-regulatory cells in these mice may help to dissect
their role in HIV infection. These cells are preferentially
targeted by HIV during acute HIV infection in these mice
[120].
CNS invasion by HIV
AIDS-related dementia occurs in about 30% of HIV-infec-
ted patients with advanced immunodeficiency [121]. AIDS
dementia is characterised by the immigration of macro-
phages, formation of microglial nodules, and generation of
multi-nucleated giant cells, most likely due to viral induced
fusion between microglial cells and/or macrophages. HIV-
infected humanised mice show pathologic anomalies in the
brain reminiscent of those in HIV-infected patients with
AIDS dementia. In particular, activated human blood-borne
macrophages migrate into the brain. Human cells enter into
the brains more quickly in HIV-infected mice than in con-
trol mice. Productively infected macrophages and cells of
lymphocyte morphology are found in the meninges and
perivascular spaces [122]. Strikingly, CD8+ T-cell deple-
tion aggravated the pathological findings, suggesting that
CD8+ T cells could subdue HIV infection to some extent.
Using advanced neuroimaging and post-mortem examin-
ation, HIV-infected mice show a loss of neuronal integ-
rity [123]. These data are encouraging: humanised mice
represent a valuable tool for examining mechanistic and
therapeutic aspects of HIV-associated dementia. However,
as reiterated by the study authors, additional studies are
needed for a more detailed characterisation and validation
of the neuronal damage associated with HIV infection in
this mouse model [124].
Future generations of humanised mice
Despite the advances made in humanised murine models,
the reconstituted lymphoid system still lacks a well-elab-
orated lymphoid architecture. This is partially explained
by the lack of human cytokines critical for haematopoiesis
and/or by insufficient interactions between cells of the mur-
ine stroma and human haematopoietic cells. The less than
optimal lymphoid architecture and the education/selection
of T-cells on a murine thymic scaffold result in a rather
modest adaptive immune response. As outlined above,
transplantation of HLA-matched cord blood into a mouse
strain transgenic for human HLA gives more robust specif-
ic T-cell response. To improve the humanisation of mice,
additional human transgenes critical for haematopoiesis are
introduced into mice.
The knock-in of human thrombopoietin (TPO) into Rag2-/-
γ c-/-, which is essential for the expansion and maintenance
of HSC [125], resulted in a higher level of engraftment and
an increase in the breadth of multilineage haematopoiesis
with higher number of myeloid cells than in control mice
expressing the murine TPO [126].
Other knock-in (KI) genes examined for improving the
humanisation were human IL-3 in concert with human
granulocyte macrophage cytokine stimulating factor (GM-
CSF) [127] and colony stimulating factor-1 (CSF-1) [128].
In IL-3/GM-CSF KI mice, transplantation of human pre-
genitor cells resulted in a more pronounced inflammatory
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reaction in response to intraperitoneal administration of
lipopolysaccharide than in controls. In addition, IL-3/GM-
CSF KI mice had improved human myeloid immune re-
constitution in the lung as exemplified by the presence
of alveolar macrophages; the human alveolar macrophages
mounted an innate immune response when challenged with
influenza virus but could not control it. This model might
be especially good for studying pulmonary diseases [127].
The knock-in of CFS-1 enhanced the differentiation of my-
eloid cells into monocytes and macrophages [128].
As outlined above, differences in the extent the various
mouse backgrounds support human cell engraftment exist.
Positional cloning identified alleles of the inhibitory re-
ceptor signal regulatory protein alpha (SIRPα) as a reason
for the difference of engraftment levels between mouse
strains [129]. In NOD mice, which have higher engraft-
ment levels than other mice, SIRPα on murine macro-
phages showed enhanced binding to the human CD47 lig-
and. This enhanced binding inhibits phagocytosis of the
xenograft and secretion of TNF-α by macrophages. Trans-
genic expression of SIRPα in Rag2-/-γc-/- increased the en-
graftment level of HSC to a level similar to NSG mice and
improved the functionality of the immune system [130].
These next-generation mice will most likely become im-
portant assets for the research community. Furthermore,
the step-wise progress made in humanisation methods will
continue and will create an array of humanised mouse mod-
els appropriately suited to address specific research ques-
tions.
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Figure 1
HIV-1 needs critical host factors for efficient replication. HIV binds to the HIV receptor complex of the human CD4 cell-surface molecule and a
co-receptor, either CCR5 or CXCR4, via the HIV envelope glycoprotein 120 (HIV env gp120). After conformational changes in the HIV env gp41,
viral host cell membrane fusion occurs (2). The next steps are the decapsidation (3) and release of the HIV RNA from the virus particle. Reverse
transcription generates a viral complementary DNA (cDNA) based on the viral RNA template and using HIV’s own reverse transcriptase (4).
Once the cDNA is generated, the preintegration complex (PIC) is assembled, nuclear trafficking and integration of the viral cDNA into the host
genomic DNA follow (5). Efficient transcription and elongation require formation of P-TEFb (positive transcription elongation factor b) consisting
of Tat (6A), human cyclin-dependent kinase 9 (CDK-9) (6B) and cyclin T1 (6C), which binds to the nascent HIV transcripts. Fully or partially
spliced HIV mRNA (7) is used to translate viral proteins. Unspliced HIV RNA is packaged into newly generated virions. Assembly of HIV proteins
and RNA and budding take place at the cellular membrane (9). HIV release is inhibited by murine tetherin at the cellular membrane because
murine tetherin is insensitive to the viral protein Vpu, which inhibits human tetherin by directing its proteasomal degradation (blue frame).
Human host factors critical for HIV replication are CD4, CCR5, CXCR4 and cyclin T1 (red frame). Additional human specific factors probably
exist.
Review article: Medical intelligence Swiss Med Wkly. 2012;142:w13618
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 12 of 12
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Aims 
 
 
 
 81 
 
2.1 Specific Aims 
1. To identify novel IFN-α dependent cellular host anti-HIV restriction factor(s) and 
characterize its/their molecular mechanism(s) of action. 
 
a) To determine the permissiveness to HIV-1 infection of CD4+ T cell lines when treated 
with IFN-α. 
b) To identify a potential IFN-α-stimulated restriction factor reducing HIV-1 
permissiveness in at least one CD4+ T cell line. 
c) To determine the step of the HIV viral cycle affected by the cellular factor. 
  
2. To determine the role of the Vif-APOBEC3 axis for HIV-1 evolution in vivo. 
 
a) To assess fitness, diversity and pathogenicity of HIV-1 encoding partially active Vif 
variants in a humanized mouse model. 
b) To determine the virological and clinical relevance of APOBEC3-driven mutagenesis 
in vivo. 
 
2.2 Rationale of this thesis  
In view of the ongoing HIV-1 pandemic, the lack of a cure or a vaccine and the limitations of 
the currently available treatments, there is a clear need for new treatment strategies for 
combating HIV-1 replication. This in turn requires a deepened understanding of the HIV-1 
biology.  
The identification of cellular restriction factors, part of the innate immune system and critical 
to inhibit HIV-1 replication, may pave the way for novel treatment approaches. However, 
HIV-1 has acquired countermeasures, in particular by its HIV-1 accessory genes.  Thus, it is 
important to discover new restriction factors which are able to counteract HIV-1 despite the 
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presence of its accessory proteins. We hypothesize that these as yet unidentified cellular 
factors are IFN-α-inducible. Subsequent studies may use the data from my work to generate 
novel therapeutic intervention strategies. 
On the other hand, we hypothesize that biological properties of the Vif-APOBEC3 axis, in 
particular the spectrum of APOBEC3 proteins, which hypermutate the HIV-1 genome, which 
are neutralized by Vif, determine whether or not HIV subtypes spread rapidly in a given 
human population. The APOBEC3-Vif axis may be critical for therapeutic failure: HIV-1 
drug resistance limits treatment options and is of great public health concern. In countries 
with wide access to ART, viral variants with reduced susceptibility to at least one 
antiretroviral drug are found in as many as 20% of newly infected patients. Thus, a narrow 
spectrum of APOBEC3 neutralization ability by Vif could be a risk factor for failing HAART. 
We consider the humanized mouse to be a very useful tool to study the role of the Vif-
APOBEC3 axis for HIV-1 evolution in vivo. 
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3.1 Analysis of the IFN-α signature by Next-Generation Sequencing in 
MT4 and SupT1 cells allows the identification of candidate genes for 
restriction factors against HIV-1 
Authorship contributions 
I performed all the experiments; I did all the tables, figures 1, 2, 3, 4 and 7 and supplementary 
figures and tables. With Annette Audigé and Roberto Speck, I designed the experiments and 
wrote the manuscript. Hubert Rehrauer performed the NGS data analysis and created the 
figures 5 and 6. This work is still a manuscript in preparation. 
Introduction 
Interferon-alpha (IFN-α) after binding to its cognate receptor triggers the Jak/STAT pathway, 
which results in a myriad of upregulated IFN-stimulated genes (ISGs)
1
. Some of these ISGs 
are key players in interfering with particular virus, such as MX1 with influenza
2
 and other 
RNA viruses
3,4
, but for the majority of them their biological relevance is unknown.  
HIV-1 results in a prominent IFN-α response: peak viremia during acute HIV-1 infection goes 
along with a ~8-fold increase of IFN-α secretion5 and subsequent upregulation of hundreds of 
ISGs
6
. Strikingly, the ISG signature in CD4+ T-cells from patients with acute HIV-1 infection 
does not differ from those with chronic HIV-1 infection
6
, indicating that the ISG signature 
gets imprinted in the acute setting and persist thereafter, or it will be maintained by 
continuous IFN-α production. A very similar ISG signature also occurs in ex vivo HIV-1 
infected primary lymphoid cultures
7,8
. Among the most common ISGs which are up-regulated 
in HIV-1 infection are the OAS family members (OAS1, OAS2, OAS3, OASL), the IFIT 
genes (IFIT1, IFIT2, IFIT3), RSAD2, the IFITM family members (IFITM1, IFITM2, 
IFITM3), MX1 and MX2
7,8
. The ISGs are upregulated to a different degree: for example in ex 
vivo infected lymphoid tissue, IFIT1 was upregulated 50fold, RSAD2 30fold, or 
APOBEC3G/F as little as 1.6 fold
7
. Notably, IFN-α released subsequent to HIV-1 challenge 
interferes with HIV-1 in vivo
9,10
, ex vivo
11
 and in vitro
12-14
.  
A limited number of the ISGs results in reduced or even abortive HIV-1 replication, 
especially when challenged with HIV-1 strains deficient in distinct HIV-1 accessory genes – 
these ISGs are called restriction factors (RFs) (reviewed in
15
). Best known examples are the 
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RFs APOBEC3G/F, SAMHD1 and Bst-2/Tetherin – each of those RFs act by a different 
mechanism (reviewed in
15
).  
All the RFs identified so far are IFN-inducible. In order to develop novel treatment strategies 
the search for additional RFs goes on, which blocks HIV-1 despite the presence of accessory 
proteins and which may be exploited as anti-HIV moiety.   
We hypothesized that there are additional yet unidentified IFN-α-dependent RFs and that the 
likelihood of ISGs to be RFs is much higher when they are present in more than one cell line 
where IFN-α inhibits HIV-1. Here we defined ISGs which were upregulated in two CD4+ T-
cells lines where HIV-1 infection was suppressed by exogenous IFN-α treatment for defining 
key pathways implicated in HIV-1 suppression. We also wondered whether we are able to 
narrow down potential RFs/pathways by comparing the IFN-triggered signature with the HIV-
triggered one assuming that the ones triggered by HIV-1 have no role as RFs as HIV-1 
replicates irrespective of their presence. This work should serve as a rational basis to identify 
the best possible candidate genes acting as RFs in HIV-1 for their further exploration.  
Materials and methods 
Cell lines  
MT4R5, SupT1and CEM-SS R5 cells were cultured in RPMI 1640 medium and 293 T-cells 
in DMEM (Sigma-Aldrich). Media were supplemented with 10% fetal bovine serum (FBS) 
(LONZA), 1% L-Glutamine (Life Technologies) and 1% penicillin/streptomycin (Life 
Technologies). SupT1 cells were transduced with the retroviral pE vector encoding CCR5 to 
render them permissive to CCR5 (R5)-tropic strains
16
; transduced (SupT1R5) cells were 
selected using  a medium containing 1 μg/mL of G418 (Sigma-Aldrich).  
Plasmids and viruses 
Replication competent stocks of NL4-3 and YU-2 were produced by polyethylenimine 
(Poylsciences, Inc.) based transfection of 293T-cells with the corresponding plasmids, their 
subsequent precipitation with PEG-it (System Biosciences) according to the manufacturer’s 
instructions, and their further storage at -80°C until use. The HIV-1 luciferase reporter virus 
pseudotyped with the envelope (env) of the ADA HIV-1 strain (ADA Env) was generated by 
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co-transfecting an HIV-1 proviral construct encoding a luciferase reporter gene (pNL4-
3.Luc.R−E−) with an ADA Env expression vector 17 in 293T-cells. 
For the generation of viral stocks free of contaminating plasmid DNA, viral stocks were 
produced by amplifying the NL4-3 virus in 3-way-stimulated peripheral blood mononuclear 
cells for 5 days
18
, filtered (0.22 µm), and stored at -80°C. Virus-like particles (VLPs) 
consisting of the HIV-1 capsid containing Vpx protein and VSV-G envelope were produced 
as described in
19
. 
shRNAs 
Custom shRNAs in the pLKO.1 vector were purchased to silence MX2 (Thermo Scientific). 
The non-target shRNA vector pLKO.1 was used as a negative control (Sigma-Aldrich). VLP 
encoding shRNAs were produced by co-transfecting the shRNA-coding plasmids in 293T 
with the plasmid psPAX2 encoding gag/pol and pCAG-VSVG encoding the VSV-G envelope 
as previously described
20
. Two days post-transfection, the supernatant was collected and viral 
particles were precipitated with PEG-it (see above). MT4R5 and SupT1R5 cells were 
transduced with the shRNAs against MX2 or non-targeted shRNA control and selected with 
puromycin (Sigma-Aldrich 0.3 μg/mL) for two weeks.  
IFN-α treatment 
For the analysis of mRNA expression of distinct ISGs, cells were treated with 1000 U/mL of 
interferon-alpha A/D (IFN-α) (PBL Interferon source) for 24 hours. In infection experiments, 
cells were pre-treated with different concentrations (0, 100 or 1000 U/mL) of IFN-α for 24 
hours. IFN-α concentration was maintained in the cell culture medium. For next-generation 
sequencing, MT4R5 and SupT1R5 cells were pre-treated with 100 U/mL of IFN-α for 6 
hours.  
HIV-1 infection 
YU-2 or NL4-3 was added overnight (5.7 ng of p24) to 2x10
5
 cells per well of a 96-well plate. 
p24 antigen concentrations were quantified using an “in-house” ELISA assay (described in21). 
3TC (50 μM), EFV (1 μM) and T-20 (10 µg/mL) were added ~12 hours prior to infection and 
maintained throughout the experiment.   
RNA/DNA extractions and qPCRs 
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RNA extractions were performed using the RNeasy Mini Kit and DNA extractions with the 
DNeasy Blood & Tissue Kit (both from QIAGEN). QPCRs were performed using the 
commercially available primers and probes for APOBEC3G, Bst-2, IFIT-1, RSAD2 and 
GAPDH (Hs00222415_m1, Hs00171632_m1, Hs01675197_m1, Hs00369813_m1, and 
Hs99999905_m1, respectively; Applied Biosystems). QPCR conditions were as follows: 
95°C for 5 min, 95°C 15 sec and 60°C for 1 min (50 cycles). 
For intermediate reverse transcripts, we used primers/probes for Gag regions and qPCR 
conditions as described previously
22
. The mean normalized gene expression was determined 
with the software qBase Plus 2.0 (Biogazelle). 
Alu PCR 
Alu PCR was performed in two steps, using a modified protocol previously described
23
. 
Notably, in the second round PCR, the amplification product was split in two parts for RU5- 
and GAPDH quantification, using the primer/probes for RU5 as previously described
22
 and 
the primers/probes from Applied Biosystems for GAPDH detection to normalize the DNA 
input. As a negative control, cells were treated with the integrase inhibitor Raltegravir 
(Isentress, MSD MERCK SHARP & DOHME AG, 30 μM). 
Western blots and antibodies 
Western blot analysis was performed as previously described
24
. In order to determine the level 
of silencing of MX2, MT4R5 and SupT1R5 cells transduced with the shRNAs against MX2 
or non-targeted shRNA control were treated with IFN-α (1000 U/mL) for 24 hours, cells were 
then collected and western blots performed as mentioned above.  
Next-generation sequencing of total RNAs 
Total RNAs were extracted from MT4R5 and SupT1R5R5 cells, in triplicates, pre-treated or 
not with IFN-α (100 U/mL). The RNAs were sequenced at the Functional Genomics Center 
Zürich (FGCZ) using the Illumina HiSeq 2000 sequencer, using two lanes of a flow cell with 
sample barcoding. The sequencing library was prepared as single stranded using the TruSeq 
protocol (Illumina), which includes poly-A selection. Reads were sequenced as paired-end 
100+100. Expression values were computed with RSEM
25
. As reference the human genome 
build GRCh37 from Ensembl was used as a reference. A list of differentially expressed genes 
which are potential RFs was obtained by comparing the IFN-α treated samples with the 
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corresponding untreated samples for each cell line. The statistical test was conducted with the 
DESeq2 
26
 package in Bioconductor.  
Gene ontology and enrichment analysis 
Enrichment analysis consists of matching genes in functional ontologies by GeneGo Meta- 
Core version 6.19. The 162 common upregulated genes there uploaded to MetaCore for 
pathway and network analysis. MetaCore was used to build a network from the 162 genes by 
using a shortest path approach and by adding at most two nodes to link two of the genes. 
Statistics 
For statistical analysis, the statistical software provided by GraphPad Prism (Version 5.04) 
was used. The significance level of p < 0.05 was considered as relevant. In the figures, p-
values are presented for comparisons between treatment groups and controls and are denoted 
by asterisks. 
Results 
MT4R5 and SupT1R5 but not CEM-SS cells are highly responsive to IFN-α  
We explored IFN-α responsiveness in MT4R5, SupT1R5 and CEM-SS cell lines by 
quantifying the prototype ISGs IFIT-1 and RSAD2 (Viperin) as well as APOBEC3G and Bst-
2. We observed a vigorous up-regulation already 6 hours after adding IFN-α in MT4R5 and 
SupT1R5 cell lines which persisted over the next 24 hours (Suppl. Fig. 1 and 2). In contrast, 
CEM-SS reacted only poorly. Thus, MT4R5 and SupT1R5 cell lines had the prerequisites for 
studying ISGs.  
IFN-α inhibits HIV-1 replication in MT4R5 and SupT1R5 cells 
We observed a clear dose-dependent anti-HIV effect of IFN-α with nearly complete inhibition 
at 100 and 1000 U/ml in MT4R5 cells while a less prominent one in SupT1R5 cells (Fig. 1a 
and b). At 3 days of HIV-1 infection, the inhibitory concentration (IC) 50 was 10 U/mL for 
both cell lines.  
 
 
 89 
 
A 
MT4R5
Days post infection
p
2
4
 p
ro
d
u
c
ti
o
n
 (
p
g
/m
L
)
100
101
102
103
104
105
3 6 9
SupT1R5
Days post infection
100
101
102
103
104
3 6 9
0
10
50
100
500
1000
 
B 
 MT4R5
IFN concentration (Units)
1 10 100 1000
0
20
40
60
80
100
V
ir
a
l 
re
p
li
c
a
ti
o
n
 (
%
)
 SupT1R5
IFN concentration (Units)
1 10 100 1000
0
20
40
60
80
100
 
C 
MT4R5
L
u
c
if
e
ra
s
e
 a
c
ti
v
it
y
 (
a
rb
it
ra
ry
 u
n
it
s
)
100
101
102
103
0 100 1000
***
***
SupT1R5
100
101
102
103
0 100 1000 IFN- (U/mL)
***
***
 
Figure 1: HIV-1 replication is strongly inhibited by IFN-α in MT4R5 and SupT1R5 cells. (A) 
Viral replication in MT4R5 cells (left panel) and SupT1R5 cells (right panel) over time. Cells 
were pre-treated with different concentrations of IFN-α (ranging from 0 to 1000 U/mL) for 24 
hours and infected with the CCR5-tropic HIV-1 strain YU-2. IFN-α was replenished every 
three days. HIV-1 replication was monitored by measuring the p24 antigen concentration 
(pg/mL) in the culture supernatant on days 0, 3, 6 and 9 post-infection. Each dot corresponds 
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to the average of three experiments performed in triplicates and the bars indicate the standard 
deviation (SD). (B) Dose-response curve to define the IC50 of IFN-α in HIV-infected MT4R5 
cells (left panel) and SupT1R5 cells (right panel). HIV replication between days 0 and 3 from 
(A) was used to calculate the area under the curve as an indication of viral replication. (C) 
Luciferase activity in MT4R5 cells (left panel) and SupT1R5 cells (right panel) pre-treated 
with IFN-α after challenge with a luciferase reporter virus (n=3; average and SEM shown). 
Statistics were performed using a one-way analysis of variance test and a Dunnett’s post test. 
*** represents p<0.001 
 
We corroborated these results with replication incompetent viral particles encoding the firefly 
luciferase gene and pseudotyped by the R5-tropic ADA envelope. We observed on average a 
26- and 86-fold decrease of luciferase activity in MT4R5 cells and a 7- and 15-fold decrease 
in SupT1R5 cells at 100 and 1000U/ml of IFN-α respectively (Fig. 1c).  
IFN-α interferes mainly after reverse transcription but prior to integration 
To further dissect at what step IFN-α interferes with HIV-1 replication, we measured 
intermediate reverse transcripts as well as integrated HIV-1 DNA. We used here the parental 
cell lines instead the R5 complemented ones since CCR5 was introduced into the cells using 
lentiviral based transduction and their remnants might confound the PCR assays used. IFN-α 
inhibited the CXCR4-tropic strain NL4-3 in MT4 cells similarly as it inhibited YU-2 in the 
MT4R5 ones which justified and validated the use of the parental cell lines for that purpose 
(Suppl. Fig. 3). IFN-α decreased proviral DNA in MT4 cells dose-dependently by 11-fold at 
100 U/mL, and 343-fold at 1000 U/mL (Suppl. Fig. 4a). The effect was less pronounced for 
SupT1 cells with a 1.3-fold reduction at 100 U/mL and 2.3-fold reduction at 1000 U/mL 
respectively (Suppl. Fig. 4b). We also observed a significant decrease for intermediate reverse 
transcripts (Gag) for the IFN-treated MT4R5 cells (Suppl. Fig.. 4c) and SupT1 cells (Suppl. 
Fig. 4d).  
The rather complete inhibition of HIV-1 particle production at higher dosage of IFN-α while 
the less than complete inhibition of RT products points to IFN’s activity at various stages in 
the HIV-1 replication cycle.  Since we infected the cells with wild-type HIV-1, budding will 
most likely not be due to Tetherin, which is counteracted by Vpu
27
.  
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Functional characterization of the ISGs 
To identify genes potentially implicated in the IFN-mediated block in MTR54 and SupT1R5 
cells, we did NGS of mRNA from cells treated with IFN-α for 6 hours. We considered genes 
as significantly changed if p < 0.01. For the subsequent functional analysis we required 
additionally 2-fold expression change. We found 396 genes up- and 15 genes downregulated 
in MT4R5 and 304 genes up- and 15 genes downregulated in SupT1R5 using the Illumina 
NGS platform. We identified 162 genes, which were upregulated in both cell lines 
simultaneously and none which was downregulated according to these criteria (Fig. 2, left 
panel and Suppl. Table 1). In comparison to previous analysis done in IFN-α exposed MT4 
cells using microarray
28
, we observed a high correlation but generally larger fold-changes and 
higher significances for the upregulation which indicates a higher sensitivity of our NGS 
based expression assay.  
 
Figure 2. IFN-α treatment results in a prominent ISG signature in MT4R5 and SupT1R5 cells 
but only in a faint one in HIV-infected cells.  (A) The number of upregulated vs 
downregulated genes in MT4R5 and SupT1R5 cells is depicted here. The number of genes 
A B 
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which are at once upregulated in our dataset as well as in the literature is indicated with a red 
circle (left panel). (B) Genes representing the gene signature in SupT1 cells 12 and 24 hours 
after HIV-1 infection and gene signature from MT4R5 and SupT1R5 cells after IFN-α 
treatment The similarity of gene expression profiles among experimental samples is 
summarized in a dendrogram above the cluster heat map, in which the pattern and the length 
of the branches reflect the relatedness of the samples. Upregulated genes are represented in 
red, genes with no fold change are represented in white and downregulated genes are 
represented in blue.  
 
A previous report using HIV-infected SupT1 cells and total RNAseq analysis revealed only 
limited genome-wide changes
29
 (Fig. 2, right panel). All of those changes were also present in 
our analysis which suggests that HIV-1 triggered changes are indirect by triggering the IFN-α 
axis.   
We then investigated to what extent the genes which were upregulated in both cells lines 
could be categorized to certain regulatory pathways/networks in MetaCore™ (Thomson 
Reuters v.6.19), i.e., canonical pathway maps, GO (gene ontology) and network processes. 
Canonical pathway maps showed that the genes upregulated in both cell lines were attributed 
to 10 different canonical pathway maps (from 260 existing ones) and were, as expected, 
predominantly immune response genes (Suppl. Table 2). In this pathway map analysis, we 
had 10 genes with unknown anti-viral effects, but with known molecular function; 5 genes 
with a known anti-HIV activity, and 9 genes with an anti-viral activity which have not yet 
been explored for their potential effects on HIV-1 (Suppl. Table 2). Some of these genes such 
as STAT1
30
, STAT2
30
 and IRF9
31
 are rather signal transducers or transcriptional factors, 
which will not be taken into account for further analyses. Of note, only 24 out of the 162 
genes upregulated in both cell lines were taken into account in the canonical pathway maps; 
for the other 138 genes no pathway information is available in the MetaCore databsase. 
Notably, genes with unknown function cannot be taken into account in any functional 
classification system. The limited value of the canonical pathway map analysis is also 
demonstrated by the lack of the known HIV-1 RF, such as APOBEC3G, Bst-2, SAMHD1, 
TRIM5, etc. showing up.   
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Subsequently, we looked at MetaCores categorization of the genes according to GO processes 
(Suppl. Table 3) and the Process networks and obtained a large number of genes accumulated 
in the different processes (Suppl. Table 4). From the 162 genes upregulated in both cell lines, 
76 genes were present in the GO processes. 37 genes were present in the Process networks 
and similarly to the gene present in some particular process. Like the canonical pathway 
maps, these analyses also showed that the upregulated genes in both cell lines were 
predominantly immune response genes. Although the known RF mentioned above 
(APOBEC3G, Bst-2, SAMHD1, TRIM5, etc.) were present in GO processes, they were not 
present in the process networks (except for MX2). The different known RFs were not 
accumulated in a particular GO process, but rather in almost each single process, together 
with several other genes (between 27 to 70 genes present in each single GO process).  
44 of the 162 IFN-α upregulated genes are consistently reported in the literature 
Since the distinct functional classifications did not point to a particular process, we looked for 
an alternative approach to analyse our NSG data: we compared the 162 IFN-α upregulated 
genes with data in the literature, which report genes upregulated either by IFN-α treatment32 
or, by HIV-1 triggered release of IFN-α in in vitro settings7,8 and genes upregulated from 
patient specimens obtained from patients with acute or chronic HIV-1 infection
6,43-46
. The 
literature search was performed using the keywords “IFN-α AND gene expression” or “HIV-1 
AND gene expression” in the PubMed database (Suppl. Table 5). This approach was built 
upon our original working hypothesis that ISGs able to block HIV-1 will come up in more 
than one cell system. 
We considered genes as relevant for our analysis which were reported to be upregulated in at 
least three different publications; 53 met these criteria, and 44/53 were also upregulated in our 
dataset – less stringent criteria, e.g., twice mentioning of genes of interest, would have faced 
us with even a higher number of potential candidates (more than 81) (Suppl. Table 5). We 
found that  i) 13/44 genes are anti-viral active, but their anti-HIV activity has yet to be 
studied; ii) 20/44 genes with reported anti-HIV-1 activity; iii) 11/44 genes without any known 
antiviral activity or which are intermediate signalling but certainly not effector molecules 
(e.g., STAT1
33
, IRF9
34
), or which increase viral replication (LY6E
35
)(Fig. 3).  
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 Figure 3. The 44 genes, which were at once upregulated in our dataset and in related studies 
in the literature belong either to genes with known anti-HIV function, known anti-viral 
activity and unknown activity.  
SAMHD1 nor MX2 play a role in the IFN-mediated HIV-inhibition in MT4R5or 
SupT1R5 cells. 
SAMHD1 is an IFN-type 1 and 2, MX2 a solely IFN-type 1 up-regulated RF – they act either 
during reverse transcription
36
 or prior to integration
37,38
, respectively, and are among the 162 
upregulated genes we found (Suppl. Table 1) and were also coming up in the genes enriched 
in the biological processes (Suppl. Table 3). Thus, we explored the role of SAMHD1 and 
MX2 in the IFN-α mediated effects by degrading SAMHD1 by Vpx (Fig. 4) and MX2 by 
knocking it down in the cell lines (Suppl. Fig. 5). We observed no reversal of the IFN-
mediated anti-HIV activity that negates any role of SAMHD1 and MX2 in the observed IFN-
α-mediated inhibition of HIV-1 (Fig. 4).  
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Figure 4. Neither SAMHD1 nor MX2 had any role in the IFN-mediated HIV-inhibition in 
MT4R5 and SupT1R5 cells. (A) MT4R5 cells were treated with 0 or 1000U/mL of IFN-α (left 
panel and right panel, respectively). 22 hours later, cells were treated either with VLP 
containing the Vpx protein (second row) or with dNTPs (third row) and 2 hours later infected 
with HIV-1 YU-2. 48 hours post-infection, cells were stained for intracellular (IC) p24 
expression. Data shown correspond to a single experiment representative of 3 independent 
B 
C 
A 
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experiments. (B) Luciferase activity in the different MT4R5 stably cell lines generated with 
MX2 shRNAs after infection with a luciferase reporter virus and treatment with different IFN-
α concentrations (left, middle and right bars: 0, 100 and 1000 U/mL). (C) Luciferase activity 
in the different SupT1R5 stably cell lines generated with MX2 shRNAs after infection with a 
luciferase reporter virus and treatment with different IFN-α concentrations (0, 100 and 1000 
U/mL). Each bar corresponds to the average of three experiments. Error bars correspond to 
SEM. Statistics were performed using a one-way analysis of variance test and a Dunnett’s 
post test. ** represents p<0.01, *** represents p<0.001 and **** represents p<0.0001. 
 
Discussion 
We argued that key pathways or effector genes switched on by IFN-α and inhibiting HIV-1 
are likely the same in different cell lines and that this approach would permit to identify 
unknown RF. Using MT4R5 and SupT1R5 cells, we found that i) IFN-α blocked HIV-1 
between reverse transcription and proviral integration; ii) the functional classifications of 
MetaCore did not provide a definitive subset of RF candidates; iii) a comparison of the genes 
upregulated in our cell lines and the literature identified a subset of 44 RF candidate and iv) 
neither MX2 nor SAMHD1 were responsible for the inhibitory effect of IFN-α observed. 
Thus, we still are challenged with a large number of potential hits, which needs their 
individual testing in the appropriate setting.   
APOBEC3G, TRIM5α, SAMHD1, BST2 and MX2 were discovered by comparing HIV-1 
permissive vs. HIV-resistant cells
27,39-42
. Another approach was based on a shRNA-based 
screen to identify proteins necessary for HIV-1 replication
43-45
. The latter approach gave a 
large number of hits; the significance of each would require functional testing. A very recent 
work reported the use of evolutionary genomic signatures and functional analyses for the 
identification of RFs
46
. We approached the issue of identification of RFs from another angle - 
we assumed that the same ISGs would interfere with HIV-1 replication in different HIV-1 
permissive cell lines treated with IFN-α and by that way may point to potential RF candidates. 
We have chosen the highly IFN-α responsive cell lines, MT4R5 and SupT1R5. Consistent 
with previous reports
47
, the anti-HIV-1 activity by IFN-α was strong and sustained in MT4R5 
cells but less prominent and only transient in SupT1R5. This discrepant effect might be 
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explained that SupT1R5 cells gets refractory or exhausted shortly after IFN-α exposure. 
Supporting this, we found that IRF2, which inhibits IRF1, which in turn promotes an anti-
HIV state
35
 and SOCS1, which attenuates the IFN-α axis48 are significantly upregulated in 
SupT1R5 but not in MT4R5 cells (data not shown).  
IFN-α blocked HIV-1 replication at the level of reverse transcription, but prior to integration, 
in the cell lines used, similar to IFN-α’s anti-HIV activity in primary CD4+ T-cells47 – the 
block at the same level of replication validates the use of our cell lines. For studying the IFN-
α signature in these two cell lines, we argued that 100 U/ml is optimal since it was the lowest 
dose with the maximum antiviral effect (IC90) and 6 hours because at that time point the IFN-
α signature is already deployed49, and we wanted to assess the first wave of ISGs.   
We first compared the IFN-α signature in SupT1R5 cells with the one reported in SupT1 cells 
infected with HIV-1. In line with previous reports
6,50,51
, we found a very prominent ISG 
signature in SupT1 cells triggered by IFN-α while only a very faint one in HIV-1 infected 
cells.  HIV-1 resulted in other genome-wide changes regarding apoptosis-related genes
7
, 
Toll/IL-1 pathway and pulmonary resistance
52
. The very faint expression of ISGs in HIV-1 
infected T-cells is not surprising since IFN-α production is defective in HIV-infected T-cells 
and macrophages
53,54
  
162 genes were upregulated in both cell lines subsequent to IFN-α treatment. Of note, the 
well-known RFs, APOBEC3G, Tetherin/Bst-2, SAMHD1, TRIM5α and the recently 
identified MX2 were among those genes which supports our assumption. However, these RFs 
were represented to a varying extent in the various functional classifications by MetaCore, 
and very importantly, they were distributed all over the various biological processes, and thus 
did not permit focussing on a particular process.  
We also had a look at the genes which were upregulated either in the MT4R5 or SupT1R5 
cells. They had no known antiviral activity except for AIM2 (against Vaccinia virus
55
) in 
MT4R5 cells and DDX60 (interferon-inducible gene in response to viral infection
56
) and 
PARP12 (against Venezuelan-equine encephalitis virus
57
) in SupT1R5 cells.  
In order to position our data and to narrow down the list of potential RFs candidates, we 
compared the 162 upregulated genes to previous analyses looking either at studies examining 
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the effects of exogenous IFN-α treatment32 or examining the effects solely upon HIV-1 
infection ex vivo (primary PBMCs
7
 or primary MDM
8
) or analyses of genes upregulated from 
PBMCs from rhesus macaques
52
 (chronic SIV/HIV-1 chimeric infection) or CD4+ T-cells 
from HIV-infected patients (chronic or acute HIV-1 infection)
6,58-60
. Indeed, the overlapping 
gene pattern of the different studies was close to the one we had in the two cell lines (Suppl. 
Table 5). We obtained 44 genes which were upregulated in the literature as well as in our cell 
lines. Of note, the least similar pattern to what we have was observed for primary MDM
8
, for 
reasons mentioned above. This approach seems to be valid since we identified a great 
majority of anti-HIV active genes (including well characterised RF) (20/44) and antiviral 
genes (12/44) and also since several known RFs (Bst-2, MX2, PKR, RSAD2, etc.) were 
included in this selection of genes, except for APOBEC3G, SAMHD1 and TRIM5α. We 
believe focusing on those genes would make sense for searching for HIV-1 RFs. Coming back 
the recent report using evolutionary genomic signatures and functional assays
46
, the 
researchers found new potential anti-HIV activity for IFI44L, APOL3 and APOL6. 
Interestingly, IFI44L is present in our list of 44 genes concomitantly upregulated in the 
literature (classified as “other activity”) and APOL3 and APOL6 are present in the162 
upregulated genes. 
Irrespective of the approach we use to analyse our data, we will eventually be challenged with 
functional testing of the RF candidates. The major question remains: How to identify the 
particular function of a gene as related to HIV-1? Indeed, MX2 and SAMHD1 were 
upregulated in MT4R5 and SupT1R5 cells. Since they act prior to proviral integration
42,61
, we 
considered them as promising RFs in our cell system; but this was not the case, pointing to 
another IFN-dependent mechanism(s) of HIV-1 inhibition in our cell system. Thus, testing 
candidate genes in the “wrong” assay system will result in false negative results. 
In summary, with our approach, looking at the IFN-α signature in two HIV-permissive cell 
lines, we obtained 162 ISGs which were present at once and which are potential RF 
candidates. By including other genome wide analyses of HIV-infected tissue, we defined a 
subset of 44 genes which we consider the most promising candidates to look at first.   
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Supplementary Material 
Supplementary Table 1: Genes upregulated by IFN-α in MT4R5 and SupT1R5R5 
Gene name 
Fold upregulation in  
Gene name 
Fold upregulation in Gene name Fold upregulation in Gene name Fold upregulation in 
MT4R5 SupT1R5 MT4R5 SupT1R5 MT4R5 SupT1R5 MT4R5 SupT1R5 
IFIT1 10.7 10.14 C19orf66 3.774 3.938 MYD88 2.32 1.665 NLRC5 1.628 5.058 
MX2 10.18 3.226 STAT1 3.771 4.876 BST2 2.296 7.041 DLL1 1.587 3.231 
OAS2 9.924 9.261 PHF11 3.755 2.701 RARRES3 2.289 3.56 HCG4P11 1.544 2.485 
IFI44L 9.578 11.15 NMI 3.63 1.872 HAPLN3 2.226 2.574 CHST12 1.533 1.463 
IFIT3 9.023 9.453 TRIM22 3.62 4.076 LAP3 2.194 1.588 NAPA 1.527 1.434 
USP18 8.87 6.968 SMTNL1 3.619 2.809 VSIG10L 2.192 1.558 RBM43 1.508 1.726 
IFI44 8.731 8.26 C5orf56 3.618 3.541 GBP3 2.186 4.143 RP11-
54O7.17 
1.501 1.352 
EPSTI1 7.968 9.458 HERC6 3.567 6.801 PNPT1 2.173 1.972 TREX1 1.495 1.556 
XAF1 7.936 6.561 CTD-
2240E14.
4 
3.527 3.58 CTD-
2521M24.4 
2.172 1.876 TRIM14 1.445 1.768 
IFI27 7.433 4.28 SP110 3.483 3.484 CTD-
2521M24.5 
2.124 5.909 TRIM56 1.414 1.379 
GBP1 6.97 4.603 CD68 3.423 3.325 APOL2 2.083 2.131 APOBEC
3G 
1.405 1.345 
SAMD9L 6.766 6.903 AC00995
0.2 
3.416 3.025 LY6E 2.075 3.765 CMTR1 1.387 1.31 
ZBP1 6.729 5.052 NT5C3A
P1 
3.408 1.525 GMPR 2.031 1.881 CTD-
2521M24.
6 
1.383 1.549 
CD38 6.04 1.776 HSH2D 3.382 4.231 RP11-
326C3.12 
2.006 2.527 CD274 1.382 2.007 
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IFIT5 5.981 8.474 RN7SL83
4P 
3.375 2.649 RBCK1 1.988 1.59 TTC21A 1.381 1.911 
ISG15 5.944 6.176 UBE2L6 3.271 3.408 NUB1 1.967 1.65 SP140 1.31 1.562 
IFIT2 5.942 8.637 PARP10 3.204 5.262 TRIM25 1.905 2.306 C2CD2 1.304 1.703 
DDX58 5.912 5.374 EIF2AK2 3.19 3.466 SAMHD1 1.889 3.419 HES4 1.301 1.219 
OAS1 5.801 10.11 HMGB1P3 3.168 3.208 MOV10 1.882 2.395 HLA-F 1.287 2.181 
RP11-
288L9.4 
5.57 6.539 SSTR3 3.143 3.921 SLFN5 1.879 1.639 LGALS9 1.285 5.684 
ISG20 5.458 3.274 NT5C3A 3.083 1.44 TAP1 1.842 4.255 CD164 1.264 1.126 
IFIH1 5.33 8.842 
AC116366.
6 
3.073 3.149 
RP11-
799D4.4 
1.829 1.332 
CTD-
2047H16.4 
1.244 1.756 
LGALS3BP 4.995 3.59 IRF9 3.03 4.091 UNC93B1 1.824 1.884 ZNFX1 1.208 1.634 
IRF7 4.971 6.405 STAT2 3.009 3.694 TAP2 1.823 2.329 RASGRP3 1.19 4.582 
TRANK1 4.801 2.99 STAP1 2.986 2.065 SLC8A2 1.821 1.745 RNF213 1.187 4.091 
IFI6 4.711 6.427 PRICKLE1 2.965 1.702 WDR86 1.807 2.235 PFKFB4 1.187 1.62 
SIDT1 4.676 1.061 APOL6 2.894 6.277 PTGIR 1.799 1.458 N4BP1 1.186 1.918 
RSAD2 4.628 8.988 IFI16 2.857 1.748 CHMP5 1.792 1.727 TRIM34 1.179 3.426 
IFI35 4.384 5.31 APOL3 2.796 2.616 TRIM5 1.782 2.076 CEACAM1 1.173 1.249 
RP11-
662G23.1 
4.37 3.642 IFITM3 2.669 2.302 TDRD7 1.774 2.679 PI4K2B 1.164 1.358 
OAS3 4.29 7.509 REC8 2.666 3.886 TNK2 1.764 1.708 SPATS2L 1.163 2.102 
OASL 4.266 7.542 TNK2-AS1 2.657 2.614 IFITM2 1.762 2.047 PSME2 1.161 1.681 
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RP11-
1094M14.8 
4.225 1.724 
RP11-
686D22.8 
2.589 4.389 AP000867.1 1.74 1.094 GSDMD 1.154 1.455 
OR52K3P 4.13 6.198 C3AR1 2.567 2.298 OTOF 1.737 2.15 
RP11-
23P13.7 
1.135 2.171 
HELZ2 4.018 5.627 SP100 2.531 3.061 PSMB9 1.719 4.023 ERAP2 1.123 1.077 
SLFN12 4.008 2.963 TRIM69 2.517 2.596 SP140L 1.715 1.654 EHD4 1.116 2.317 
DHX58 3.913 5.11 TRIM21 2.49 3.879 ADAR 1.702 1.888 
AC004840.
9 
1.098 1.46 
PLSCR1 3.868 4.335 HERC5 2.459 6.427 IL15RA 1.701 2.008 SPTBN5 1.095 2.613 
SAMD9 3.828 3.764 
CTD-
2521M24.9 
2.428 4.42 PML 1.666 2.527 TAPBP 1.094 1.306 
IFITM1 3.821 4.996 SLC2A12 2.409 1.964 PPM1K 1.649 1.695 GBP2 1.082 1.762 
         
BTN3A3 1.072 1.291 
         
TTC38 1.065 1.159 
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Supplementary Table 2. MetaCore canonical pathway maps analysis that depicts pathway of 
the genes characterizing the response to IFN-α in MT4R5 and SupT1R5R5. 
Maps p-value Genes from active data 
Immune response IFN-α/β signaling pathway 5.529E-17 
IFI6, STAT2, IRF9, ISG54, STAT1, PML, 
USP18, STAT1/STAT2, ISG15 
Immune response Antiviral actions of Interferons  7.558E-15 
PKR, OAS1, STAT2, OAS3, IRF9, ADAR1, 
OAS2, STAT1 
Immune response Innate immune response to RNA viral 
infection  
6.168E-07 IRF7, MDA-5, RIG-I, TLR3, LGP2 
Immune response Role of PKR in stress-induced antiviral cell 
response 
2.298E-05 IRF7, MyD88, PKR, TLR3, STAT1 
Development Angiotensin signaling via STATs  3.909E-05 STAT2, IRF9, STAT1 
Immune response  IFN-γ signaling pathway 3.112E-04 PKR, IRF9, STAT1 
Immune response IL-15 signaling via JAK-STAT cascade  3.476E-04 STAT2, IL-15RA 
Immune response Antigen presentation by MHC class I  6.293E-04 Tapasin, PSME2, TAP1 (PSF1) 
Development Prolactin receptor signaling  5.210E-03 OAS1, NMI, STAT1 
Development Thrombopoetin signaling via JAK-STAT 
pathway 
7.783E-03 TAP1 (PSF1), STAT1 
Genes with anti-HIV activity 
Genes with antiviral activity (excluding HIV-1) 
Genes with no direct antiviral activity or other functions 
 
Note: p-value represents the probability that the genes are included in each pathway by chance 
 
 
 
 
 
 
 
 
 
 
 
 108 
 
Supplementary Table 3. MetaCore gene ontology (GO) cellular processes analysis that 
depicts functional ontologies of the genes characterizing the response to IFN-α in MT4R5 and 
SupT1R5R5. 
GO Processes p-value Genes from active data 
Defense response to virus 6.7607E-63 
NLRC5, BST2, IRF7, PKR, MDA-5, IFI17, RIG-I, 
EFP, TRIM56, TLR3, IFI16, OAS1, SAMHD1, 
STAT2, APOBEC3G, Ceb1, OAS3, GBP1, IFITM3, 
RI58, IRF9, OASL, MxB, UNC93B, IFITM2, 
ISG54, RSAD2, IFI56, ADAR1, ZBP1, OAS2, 
ISG20, IFIT1, STAT1, RIG-G, PML, GBP3, Staf-
50, PL scramblase 1, STAT1/STAT2, DDX60, 
ISG15, LGP2, TRIM5 
Response to virus 3.0841E-53 
NLRC5, BST2, IRF7, MyD88, PKR, MDA-5, IFI17, 
RIG-I, EFP, TRIM56, TLR3, IFI16, OAS1, 
SAMHD1, STAT2, APOBEC3G, Ceb1, OAS3, 
GBP1, IFITM3, RI58, IRF9, OASL, MxB, 
UNC93B, IFITM2, ISG54, RSAD2, IFI56, ADAR1, 
ZBP1, OAS2, ISG20, CXCR4, IFIT1, H28, STAT1, 
RIG-G, PML, GBP3, Staf-50, PL scramblase 1, 
IFI44, STAT1/STAT2, DDX60, ISG15, LGP2, 
TRIM5 
 
Defense response to other organism 8.1402E-47 
NLRC5, BST2, IRF7, MyD88,  PKR, MDA-5, 
IFI17, RIG-I, EFP, TRIM56, TLR3, IFI16, OAS1, 
SAMHD1, STAT2, APOBEC3G, Ceb1, OAS3, 
GBP1,  IFITM3, RI58, IRF9, OASL, MxB, 
UNC93B, IFITM2, ISG54, RSAD2, IFI56, ADAR1, 
ZBP1, OAS2, ISG20, IFIT1, H28, STAT1, RIG-G, 
PML, GBP3, Staf-50, GBP4, PL scramblase 1, 
GBP2, STAT1/STAT2, DDX60, ISG15, LGP2, 
TRIM5 
Response to type I interferon 8.2312E-46 
IRF7, SP100, IFI17, TRIM56, IFP 35, OAS1, IFI6, 
STAT2, OAS3, HLA-F, IFITM3, IRF9, OASL, 
MxB, IFITM2, ISG54, IFI56, ADAR1, OAS2, 
ISG20, XAF1, IFI27, IFIT1, STAT1, RIG-G, 
USP18, GBP2, STAT1/STAT2, ISG15 
 
Innate immune response 1.7585E-44 
UBCH8, NLRC5, TREX1, BST2, IRF7, MyD88, 
SP100, PKR, MDA-5, IFI17, RIG-I, NUB1, EFP, 
MOV-10, TRIM56, IFP 35, TLR3, IFI16, OAS1, 
IFI6, SAMHD1, TRIM14, SP110, HERC6, STAT2, 
APOBEC3G, Ceb1, OAS3, GBP1, HLA-F, IFITM3, 
RI58, IRF9, OASL, MxB, UNC93B, IFITM2, 
ISG54, RSAD2, IFI56, ADAR1, ZBP1, OAS2, 
ISG20, XAF1, IFI27, IFIT1, STAT1, RIG-G, PML, 
USP18, GBP3, Ro52, GBP4, GBP2, 
STAT1/STAT2, DDX60, ISG15, LGP2, TRIM5 
Cellular response to type I interferon 4.7734E-44 
IRF7, SP100, IFI17, IFP 35, OAS1, IFI6, STAT2, 
OAS3, HLA-F, IFITM3, IRF9, OASL, MxB, 
IFITM2, ISG54, IFI56, ADAR1, OAS2, ISG20, 
XAF1, IFI27, IFIT1, STAT1, RIG-G, USP18, 
GBP2, STAT1/STAT2, ISG15 
 
Immune effector process 1.0615E-43 
NLRC5, BST2, IRF7, MyD88, PKR, MDA-5, IFI17, 
RIG-I, EFP, BTN3A3, TRIM56, TLR3, IFI16, 
OAS1, SAMHD1, STAT2, APOBEC3G, Ceb1, 
OAS3, GBP1, IFITM3, RI58, IRF9, OASL, MxB, 
UNC93B, IFITM2, ISG54, RSAD2, IFI56, ADAR1, 
ZBP1, OAS2, ISG20, IFIT1, H28, STAT1, RIG-G, 
PML, GBP3, Staf-50, PL scramblase 1, 
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STAT1/STAT2, DDX60, ISG15, LGP2, TRIM5 
Immune response 2.1907E-43 
UBCH8, NLRC5, Tapasin, TREX1, BST2, IRF7, 
MyD88, SP100, PKR, MDA-5, IFI17, RIG-I, 
NUB1, EFP, MOV-10, BTN3A3, TRIM56, IFP 35, 
TLR3, IFI16, OAS1, IFI6, SAMHD1, TRIM14, 
SP110, CD164, HERC6, STAT2, APOBEC3G, 
Ceb1, OAS3, GBP1, HLA-F, IFITM3, RI58, IRF9, 
OASL, MxB, UNC93B, CCR1, IFITM2, ISG54, 
RSAD2, IFI56, ADAR1, ZBP1, OAS2, ISG20, 
XAF1, C3aR, IFI27, IFIT1, H28, STAT1, RIG-G, 
PML, USP18, GBP3, PD-L1, Ro52, Staf-50, GBP4, 
PL scramblase 1, GBP2, STAT1/STAT2, DDX60, 
ISG15, LGP2, TRIM5 
 
Defense response 4.4943E-43 
UBCH8, NLRC5, 90K, Tapasin, TREX1, BST2, 
IRF7, MyD88, SP100, PKR, MDA-5, IFI17, RIG-I, 
NUB1, EFP, TAP1 (PSF1), MOV-10, TRIM56, IFP 
35, TLR3, IFI16, OAS1, IFI6, SAMHD1, TRIM14, 
SP110, APOL3, HERC6, STAT2, APOBEC3G, 
Ceb1, OAS3, GBP1, HLA-F, IFITM3, RI58, IRF9, 
OASL, MxB, UNC93B, CCR1, IFITM2, ISG54, 
RSAD2, IFI56, NMI, ADAR1, ZBP1, OAS2, 
ISG20, XAF1, C3aR, APOL2, CXCR4, IFI27, 
IFIT1, LYSP100, H28, STAT1, RIG-G, PML, 
USP18, GBP3, Ro52, Staf-50, GBP4, PL scramblase 
1, GBP2, STAT1/STAT2, DDX60, ISG15, LGP2, 
TRIM5 
 
Type I interferon signaling pathway 2.6913E-42 
IRF7, SP100, IFI17, IFP 35, OAS1, IFI6, STAT2, 
OAS3, HLA-F, IFITM3, IRF9, OASL, MxB, 
IFITM2, ISG54, IFI56, ADAR1, OAS2, ISG20, 
XAF1, IFI27, STAT1, RIG-G, USP18, GBP2, 
STAT1/STAT2, ISG15 
Genes with anti-HIV activity 
Genes with antiviral activity (excluding HIV-1) 
Genes with no direct antiviral activity or other functions 
 
Note: p-value represents the probability that the genes are included in each pathway by chance 
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Supplementary Table 4. MetaCore process network analysis that depicts cellular and 
molecular processes characterizing the response to IFN-α in MT4R5 and SupT1R5R5. 
Network p-value Genes from active data 
Inflammation Interferon signaling  1.447E-26 
IRF7, PKR, IFI17, TAP1 (PSF1), IFP 35, TLR3, 
IFI6, STAT2, GBP1, IRF9, MxB, IFITM2, 
ISG54, IFI56, ISG20, IFI27, STAT1, PML, 
IFI44, GBP2, STAT1/STAT2, ISG15 
 
Immune response Innate immune response to RNA viral 
infection  
1.797E-12 
IRF7, MyD88, PKR, MDA-5, RIG-I, TLR3, 
STAT2, IRF9, ADAR1, STAT1 
Inflammation Inflammasome  2.392E-05 
IRF7, MyD88, PKR, MDA-5, RIG-I, TLR3, 
ISG15 
Proliferation Negative regulation of cell proliferation  5.337E-04 
TIG3, MyD88, PKR, IFI17, CCR1, STAT1, 
SSTR3 
 
Immune response Antigen presentation  8.375E-04 
Tapasin, PSME2, PSMB9, TAP1 (PSF1), 
STAT2, HLA-F, CEACAM1, STAT1 
 
Inflammation IFN-γ signaling  5.164E-03 
PKR, IFI16, IRF9, STAT1 
 
Inflammation Jak-STAT Pathway  1.153E-02 
STAT2, IL-15RA, CCR1, CXCR4, STAT1, 
STAT1/STAT2 
 
Inflammation IL-12,15,18 signaling  2.210E-02 
MyD88, STAT1, STAT1/STAT2 
 
Development Regulation of angiogenesis  2.588E-02 CCR1, CEACAM1, CXCR4, STAT1 
Development Blood  vessel morphogenesis  2.846E-02 CCR1, CEACAM1, CXCR4, STAT1 
Genes with anti-HIV activity 
Genes with antiviral activity (excluding HIV-1) 
Genes with no direct antiviral activity or other functions 
 
Note: p-value represents the probability that the genes are included in each pathway by chance 
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Supplementary Table 5. 44 genes upregulated by IFN-α in MT4R5 and SupT1R5R5 are frequently reported in the literature. 
 
 
Endogenous IFN-α production, in vivo HIV-1 infection 
Endogenous IFN-α production, 
in vitro HIV-1 infection 
IFN-α treatment 
Gers-Huber et al. 
2015 
Bosinger et al. 
(PBMCs)52 
Hyrcza et al. 
(Primary CD4+ 
T-cells)6  
Rotger et al. 
(Primary 
CD4+ T-
cells)58 
Sedaghat et 
al. (Primary 
CD4+ T-
cells)59 
Smith et al. 
(Primary 
CD4+ T-
cells)60 
Audige et al. 
(Primary 
PBMCs)7 
Woelk et al. 
(Primary 
MDM)8  
Rempel et al. 
(Primary 
monocytes)32  
         
IFIT1 x x x x x x x x 
IFIT3 
 
x x x x x 
 
x 
OAS1 x x x x x 
 
x x 
OAS2 x x x x x 
  
x 
STAT1 x x x x x x x 
 
IFI44 
 
x x x x x x x 
MX2 x x x 
 
x x x x 
OASL 
 
x x x x x 
  
IFITM1 x 
 
x x 
 
x x x 
ISG15 x 
 
x x x 
 
x x 
GBP1 
 
x x 
 
x x 
  
IFI35 
 
x x 
  
x 
  
IFI44L 
 
x x x x x 
  
IFI6 
  
x x x x 
  
OAS3 x x x x 
    
IFI27 
 
x x x 
 
x 
  
IRF7 
 
x x x 
 
x 
  
PLSCR1 
 
x 
    
x x 
PSMB9 
 
x x 
     
TAP1 
  
x 
  
x 
  
BST2 
 
x 
 
x 
    
EIF2AK2 
 
x 
   
x 
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HERC5 
 
x x 
  
x 
  
HERC6 
 
x x 
  
x 
  
IFI16 
 
x 
 
x 
    
IFIT2 
     
x 
  
ISG20 x 
   
x x 
  
LAP3 
 
x x 
  
x 
  
LY6E 
 
x x 
  
x 
  
RSAD2 
 
x 
  
x x x 
 
TRIM22 
 
x x 
     
USP18 
 
x 
  
x x 
  
CD38 
 
x x 
     
DDX58 
 
x 
   
x 
  
IFIH1 
 
x 
   
x 
  
IFITM2 
  
x 
    
x 
IFITM3 
 
x x 
   
x 
 
IRF9 
        
LGALS3BP 
  
x 
  
x 
  
NMI 
        
SAMD9L 
  
x 
 
x x 
  
SP110 
 
x x 
     
UBE2L6 
 
x x 
     
ZBP1 
 
x 
   
x 
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Supplementary Figure 1. The cell lines MT4R5 and SupT1R5 are responsive to IFN-α. 
The capacity to upregulate ISGs was evaluated in the three cell lines MT4R5, CEM-SS and 
SupT1R5 treated with IFN-α at 1000 U/ml for 24h. Gene expression was then assessed by 
qPCR and normalized to that of GAPDH. Each circle represent an individual experiment 
(n=3). Statistics were performed using a paired Student’s t-test. P-values are indicated for 
each condition.  
 
 114 
 
Supplementary Figure 2. Peak of ISG upregulation in MT4R5 cells is observed at 6 and 
24 hours post IFN-treatment. Gene expression was assessed by qPCR and normalized to 
that of GAPDH for APOBEC3G, Bst-2, IFIT-1 and RSAD2. Cells were treated for 0, 6, 16 
and 24 hours with 1000U/mL of IFN-α. 
 
Supplementary Figure 3. HIV-1 protein production is strongly inhibited by IFN-α in 
MT4 cells. MT4 cells were treated with 0, 100 or 1000U/mL of IFN-α and subsequently 
infected with HIV-1 NL4-3. 48 hours post infection cells were stained for ic p24 expression. 
Data shown correspond to a single experiment representative of 3 independent experiments. 
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Supplementary Figure 4. IFN-α treatment strongly inhibits HIV-1 integration and 
partially HIV-1 reverse transcription. MT4 or SupT1 cells were treated 24 hours prior to 
HIV-1 infection with IFN-α (0, 100 or 1000U/mL) or treated with RGV 2 hours before 
infection. 48 hours post infection, cells were collected, lysed and integrated HIV-1 DNA was 
quantified using a two-step Alu qPCR. Integration of HIV-1 in MT4 (A) and SupT1 cells (B), 
normalized with the GAPDH cellular control. Levels of integration in RGV-treated cells are 
set to 100 as background of integration. Reverse transcription of HIV-1 in MT4 (C) and 
SupT1 cells (D), normalized with the GAPDH cellular control. T-20-treated cells are set to 
100 as background of viral entry. The reverse transcriptase inhibitors (3TC and EFV) and the 
fusion inhibitors where considered as a positive control for inhibition of reverse transcription. 
Bars represent the average of three independent experiments. Error bars correspond to SEM. 
Statistics were performed using a paired Student’s t-test. P-values are indicated for each 
condition.  
 116 
 
 
Supplementary Figure 5. MX2 is successfully downregulated in MT4R5 and SupT1R5 
cells. MX2 protein levels are depicted for MT4R5 cells (higher panel) and SupT1R5 cells 
(lower panel). β-actin was used as a loading control. The first 4 rows represent conditions 
without IFN-α treatment and the 4 last rows represent conditions with IFN-α treatment 
(1000U/mL).  
 
 
 
 
 
 
 
 
 
 
 117 
 
3.2 Development of a humanized mouse model for HIV infection 
3.2.1 Long-acting anti-retroviral drugs for treating HIV-1 in humanized 
mice 
Despite the availability of very efficient antiretrovirals in the developed countries, HIV-1 
pandemic increases every year. In order to generate novel treatments, it is necessary to 
increase our knowledge about viral replication, latency, antiretroviral treatment (ART), not 
only in vitro but also in vivo. We made use of the humanized mice as an in vivo model for 
studying HIV-1 replication, ART and we also showed that latency can be studied with this 
model. The results of these experiments were published in the manuscript below. 
Published: PLoS ONE 7(6): e38853. doi:10.1371/journal.pone.0038853, June 13, 2012 
Own contribution: 
I assisted Marc Nischang for all experiments in vivo (humanized mouse), including the 
isolation of CD34+ cells from cord blood, the transplantation of the newborn mice with 
CD34+ cells, bleeding of the mice, periodic health check of the mice, euthanasia of the mice 
and processing of the organs. 
 
 
 
 
 
 
 
 
 
Humanized Mice Recapitulate Key Features of HIV-1
Infection: A Novel Concept Using Long-Acting Anti-
Retroviral Drugs for Treating HIV-1
Marc Nischang1, Roger Sutmuller2, Gustavo Gers-Huber1, Annette Audige´1, Duo Li1, Mary-Aude Rochat1,
Stefan Baenziger1, Ursula Hofer1, Erika Schlaepfer1, Stephan Regenass3, Katie Amssoms2, Bart Stoops2,
Anja Van Cauwenberge2, Daniel Boden2, Guenter Kraus2, Roberto F. Speck1*
1Division of Infectious Diseases and Hospital Epidemiology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland, 2 Tibotec BVBA, Beerse, Belgium,
3Clinical Immunology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland
Abstract
Background: Humanized mice generate a lymphoid system of human origin subsequent to transplantation of human
CD34+ cells and thus are highly susceptible to HIV infection. Here we examined the efficacy of antiretroviral treatment (ART)
when added to food pellets, and of long-acting (LA) antiretroviral compounds, either as monotherapy or in combination.
These studies shall be inspiring for establishing a gold standard of ART, which is easy to administer and well supported by
the mice, and for subsequent studies such as latency. Furthermore, they should disclose whether viral breakthrough and
emergence of resistance occurs similar as in HIV-infected patients when ART is insufficient.
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viral load to undetectable levels in 15/19 (79%) and 14/14 (100%) mice, respectively. In successfully treated mice,
subsequent monotherapy with TMC278-LA resulted in viral breakthrough; in contrast, the two LA compounds together
prevented viral breakthrough. Resistance mutations matched the mutations most commonly observed in HIV patients
failing therapy. Importantly, viral rebound after interruption of ART, presence of HIV DNA in successfully treated mice and in
vitro reactivation of early HIV transcripts point to an existing latent HIV reservoir.
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Introduction
The HIV pandemic continues to spread. Even in the United
States and Europe with their relative universal access to combined
anti-retroviral treatment (ART), the prevalence of HIV-infected
people is increasing. The 2nd and 3rd generation antivirals are
very efficacious. The life expectancy of treated HIV-infected
individuals has significantly improved over the last two decades [1]
and, in turn, has contributed to the increasing prevalence.
However, ART has significant shortcomings, including adverse
events, psychological dependence, life-long adherence and cost.
Incomplete adherence results in the emergence of drug-resistant
HIV strains. Novel and simpler treatment strategies and, in the
best-case scenario, a cure are needed.
The HIV pandemic started with an ancestral SIV from a non-
human primate crossing into humans [2], and thus, it is not
surprising that HIV replication is limited to human and non-
human primate cells. Mouse models of HIV infection have been
generated by engrafting human lymphoid tissue into SCID mice
[3] and are receptive to HIV [4]. For example, SCID mice
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transplanted with fetal liver (liv) and thymus (thy) tissue were very
valuable for studying various aspects of HIV pathogenesis,
including HIV-induced pathology in the thy/liv implant, screen-
ing anti-viral compounds and hematopoietic stem cell–based gene
therapy [5]. However, these studies are limited to the thy/liv
implant.
Development of a human adaptive immune system in cord
blood cell–transplanted mice [6] renewed the interest in
humanized mice (hu mice): hematopoietic CD34+ cells were
preferentially transplanted into the liver of newborn mice or i.v.
at older age. The mice develop a lymphoid-like system of human
origin with T and B cells, monocytes, plasmacytoid and
conventional DCs, thymus and lymph nodes [7]. Their mature
T cells have a broad Vb repertoire, and more than 40% of T
cells display a naive phenotype [6]. This breakthrough was only
realized through the development of heavily immunodeficient
mice by crossing of SCID mice with non-obese diabetic (NOD)
mice and mice deficient in the gamma c (cc) chain of the IL-2
receptor or the generation of Rag1 or 22/2 cc2/2 knock-out
mice [8].
We and others demonstrated that these hu mice are highly
permissive to HIV infection when challenged with CCR5- or
CXCR4-tropic HIV strains and show viral dissemination and
progressive CD4+ T-cell loss [9,10,11,12,13].
To validate the experimental significance of hu mice for
studying HIV pathogenesis and their value for novel interventional
approaches, key aspects of HIV infection/pathogenesis must be
fulfilled. The model should recapitulate ART of disseminated HIV
infection with subsequent recovery of the immune system;
interruption of ART should result in a rebound of HIV replication
from the latent reservoir. Five studies reported the effects of ART
in HIV-infected humanized mice using different drugs and drug
combinations [14,15,16,17,18]. While these reports are very
promising that humanized mice may be the long awaited small
animal model for preclinical proof-of-concept studies, they lack
pharmacokinetic (PK) studies for the medicinal compounds used
except for the report by Choudhary et al [15] that would help to
compare the data obtained in humanized mice to a clinical
context.
A ‘‘standardized’’ ART scheme that completely suppresses HIV
RNA replication in hu mice would be highly valuable for pre-
clinical proof-of-concept studies for novel anti-retroviral com-
pounds and studies of latency that closely approximate the
situation in HIV-infected humans treated with ART.
Thus, we sought to determine if this mouse model is valuable for
studying antiretroviral treatment of disseminated HIV infection
and if it recapitulates key features, such as viral rebound, break-
through replication and viral rebound subsequent to interruption
of ART. We made a major effort to define the dose of
antiretroviral compounds added to the food pellets to compare
data to human studies. We also benefited from access to
antiretroviral compounds in special formulation that permit once
weekly dosing in mice. Thus, we also were able to study a novel
concept of anti-HIV therapy based on LA antiretroviral drugs.
Results
Engraftment with human cells at around week 15 when
hu mice were infected with HIV
Newborn NOG mice were transplanted with CD34+ haema-
topoietic progenitor cells isolated from umbilical cord blood. At
around 15 weeks of age, the engraftment level was 20.7%613.2
(avg 6 std) before HIV infection (Figure S1). Of all human cells,
CD4+ T cells were 23.1%614.5 (avg 6 std), CD8+ T cells
12.9%69, and CD19+ B cells 50.8%624.2. These engraftment
values and their cell subset distributions are similar as reported
previously [11,19,20].
Pharmacokinetics of 3TC, Tenofovir (TDF), TMC278-long-
acting (LA) and TMC181-LA
The easiest and most convenient way for long-term ART in hu
mice would be to add the ART to the food pellets. Mice have a
higher metabolism than humans, and thus, we converted the dose
of the distinct compounds used in humans by a formula as
described [21]. The dose calculated was 61.7 mg/kg/day for 3TC
and for TDF, considering food uptake of 3–4 g/d for a hu mouse
with a body weight of 20–30 g. We generated food pellets
containing 0.5 mg of 3TC and TDF per g of food. 3TC and TDF
belong to the group of nucleoside resp. nucleotide reverse
transcriptase inhibitors (NRTIs).
PK data validated this approach showing plasma levels in the
therapeutic range over the entire observation period with
fluctuations due to the wake-sleep cycle of the mice (Fig. 1A–D).
In contrast, azidothymidine (AZT) at 0.5 mg/g of food and
ritonavir (RTV) at 1 mg/g of food gave toxic concentrations
clearly above the therapeutic range or sub-inhibitory concentra-
tions, respectively (Figure S2). The plasma concentration of
TMC278-LA and TMC181-LA (at the higher dose) was still
clearly above the target concentration (Ctarget) even 14 days after
s.c. injection (Fig. 1E–F). TMC278 is the recently approved non-
nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine [22],
and TMC181 is a pre-clinical-stage protease inhibitor (PI)
belonging to the same chemical class as TMC114 (darunavir),
but displaying better potency while preserving similarly high
resistance coverage. The PK data of the long-acting drugs
permitted a once weekly application in mice.
HIV RNA plasma level is suppressed by ART and promptly
rebounds with treatment interruption
In a pilot experiment, uninfected mice appeared to tolerate
AZT, 3TC and RTV well. Thus, while awaiting the PK data of
these compounds, we started a first experiment to examine ART
in HIV-infected mice (Fig. 2). Mice before ART had an HIV RNA
baseline of 104.96105.2 copies/ml (avg 6 std). Unexpectedly, the
treated mice developed wasting within 2 weeks, which we
attributed to the ART and, in particular, AZT. We therefore
changed the ART immediately to TDF, 3TC and TMC278-LA,
and within 1 week, the mice recovered from the wasting disease.
Importantly, within 4–8 weeks, 14/21 (66%) mice showed a
decline of HIV RNA levels to under the detection limit of 800
copies/ml (Fig. 2A). One mouse with detectable HIV RNA at that
time showed suppressed HIV RNA when we bled it 72 days after
start of ART (Fig. 2A). Since we switched the ART in two mice
with detectable HIV RNA to monotherapy with TMC278-LA, we
are not able to make any statement about their eventual response
rate if the ART had been continued. Thus, the overall response
rate to the ART (3TC/TDF/TMC278-LA) was 79% (15/19
mice).
In an additional group of mice treated with AZT, 3TC and
RTV, we found various laboratory disturbances, most prominent
a very significant anemia (Figure S3). In concert with plasma AZT
levels clearly above the therapeutic range, we attributed the
wasting observed to AZT toxicity.
Nearly all mice receiving the 2 weeks of AZT, 3TC and RTV
treatment suffered from weight loss (Fig. 2E and F). Remarkably,
the mice with viral failure experienced more significant weight loss
than the others (Fig. 2G). Mock-treated HIV-infected mice showed
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a very stable weight course with fluctuations of less than 2 g over
time.
We subsequently divided the mice with suppressed HIV RNA
into two groups, seven mice were maintained on ART for another
5 weeks and, thereafter, treatment was interrupted. The other
seven mice were treated by TMC278-LA alone. ART interruption
resulted in viral rebound in all mice, indicating the existence of a
latent reservoir, such as that in HIV-infected humans (Fig. 2C).
Monotherapy with TMC278-LA was insufficiently potent to
suppress HIV RNA since 6/7 mice showed a breakthrough of
viral replication (Fig. 2D).
While there were no obvious symptoms or signs, we observed a
higher mortality in mock-treated HIV infected mice than in ART
treated mice. We associated this higher mortality with an unknown
HIV-associated phenomenon. This mortality was usually less than
20% and thus when working with small numbers of mice, there
Figure 1. PK data for 3TC, TDF, TMC278-LA and TMC181-LA. (A and C) Plasma levels of 3TC and TDF, respectively, over a day of mice on food
pellets containing 0.5 mg/g food of 3TC or TDF for 2 weeks. (B and D) Decay rate of 3TC (tK= 5.5 h) and TDF (tK= 3.5 h), respectively, when
replacing the food containing 3TC or TDF with standard food. (E and F) Plasma levels after one dose of either TMC278-LA (160 mg/kg) or TMC181-LA
(white dots: 200mg/kg; black dots: 400mg/kg) administered s.c. The data were obtained with mice on ART-containing food pellets for at least
2 weeks to permit PK equilibration. The shaded area in (A–D) indicates the therapeutic range as defined in humans [42,43]. The dashed line in (E and
F) indicates the target concentration (C target). Median effective concentration (EC) 50 values of TMC278 and TMC181 are 4.95 ng/ml and 1.29 ng/ml
respectively in vitro in MT4 cells cultured with 50% human serum. The different colours indicate the experiments done with the same food batch, and
whether we used mice transplanted with human CD34+ cells or not (White, red and yellow dots indicate humanized mice, green and blue dots
indicate mice without transplantation of human CD34+ cells).
doi:10.1371/journal.pone.0038853.g001
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may be divergence from this estimated mortality rate. In the 2nd
set of experiments presented (see below), we had no loss due to
‘‘spontaneous’’ mortality.
Emergence of drug-resistant HIV strains in hu mice
All mice on ART with 3TC, TDF and TMC278-LA which
experienced viral failure revealed the consecutive or simultaneous
emergence of the prototype 3TC mutation M184I and the
TMC278 mutation E138K (Fig. 3 and Table 1). All but one mouse
showed viral failure when treated with TMC278-LA monother-
apy. Of those mice with viral failure, all but one had the E138K
mutation either alone or with the M184I mutation (Table 1). It is
unknown if minor drug variants or mutations outside the amplified
RT region might explain the lack of any TMC278 resistance
mutation detected in the one mouse scored fully susceptible to
TMC278 [23].
ART with two long-acting drugs (TMC278-LA and
TMC181-LA) effectively treats HIV-infected hu-mice
Next, we sought to determine if a simplified ART of two long-
acting drugs interfering at different steps in the HIV replication
cycle is effective as maintenance therapy to keep HIV RNA under
the detection limit. Initial ART was with TDF, 3TC, TMC278-
LA and TMC181-LA. In mice with documented HIV RNA below
detection limit after 44 days of ART, we simplified the regimen as
planned. The other mice that still showed a marked viremia were
continued on the quadruple ART. The dual ART consisting of
TMC278-LA and TMC181-LA given once weekly s.c. was really
potent: all but one mouse (viral blip) had undetectable HIV RNA
(Fig. 4B). Note, that the HIV RNA of all mice which were
maintained on the quadruple ART became negative at 99 days
after start of treatment (Fig. 4A). This variable decay rate in
response to ART mirrors the distinct decay rate of HIV in patients
Figure 2. ART is highly efficient in disseminated high-titer HIV infection in hu mice. (A) Response to ART with AZT, 3TC and RTV, followed
by 3TC, TDF and TMC278-LA. Note that the initial regimen was poorly tolerated by the hu mice that resulted in reduced food uptake and thus a
somewhat lower response rate. (B) Mock-treated HIV-infected mice (n = 8). (C and D) Mice with suppressed HIV RNA were either kept on ART (n = 11)
(C) or switched to monotherapy with TMC278-LA alone (n = 10) (D). ART and monotherapy were interrupted to monitor the mice for viral rebound.
We included two mice with viral failure into the group treated with TMC-278-LA alone. |2 indicates that one mouse died within one week of bleeding.
(E and F) Weight monitoring of mice either constantly on combined ART (E) or switched subsequently to monotherapy with TMC278-LA (F).
Compilation of weight loss over time of all mice, i.e., mice on ART with viral failure (VF), mice on ART with suppressed HIV RNA and untreated HIV-
infected mice (controls) (G). Grey-spotted area indicates the time period hu mice were on ART with AZT, 3TC and RTV, grey-plain shaded the time
period on ART with 3TC, TDF and TMC278-LA. The coloured circles indicate the mice with viral failure.
doi:10.1371/journal.pone.0038853.g002
Figure 3. Humanized mice with viral failure under ART with 3TC, TDF and TMC278-LA show consecutive or simultaneous
emergence of the key mutation to 3TC or TMC278. A), B), C) and D) show the four mice with emergence of resistance under ART. The black
dots indicate that resistance testing had been done, white dots no resistance testing done.
doi:10.1371/journal.pone.0038853.g003
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starting ART. As expected the CD4/CD8 T-cell ratio was
significantly higher in the mice with suppressed HIV RNA than in
control mice (Fig. 4D).
ART-treated HIV-infected hu mice had HIV RNA under 50
copies/ml but detectable cell-associated HIV DNA
The limited amounts of blood in any running experiment held
the sensitivity of the Amplicor RocheH to 400–800 copies/ml.
Although it is unlikely, this detection limit does not exclude low
viral replication in the ART treated mice. The HIV RNA
measurement based on the final bleeding of the mice treated either
with the dual ART or the quadruple ART (3TC, TDF, TMC-
278LA, TMC181-LA) revealed that 8/10 mice had fewer than 60
copies/ml (Table 2), which emphasizes the efficacy of the ART in
the current setting.
In the mice from the second experiment (i.e., mice as shown in
Fig. 4), we determined if cell-associated HIV DNA was detectable
in splenocytes. Using a real-time PCR specific for YU-2, this was
indeed the case in 13/15 mice (Fig. 5A); in all untreated mice, we
detected levels of cell-associated HIV DNA higher than in treated
ones with the exception of mouse #417. This mouse showed a
low-level viremia despite ART that easily explains the relatively
high cell-associated HIV DNA. We observed no correlation
between cell-associated HIV DNA and engraftment levels or peak
viremia.
In vitro reactivation of HIV transcripts in spleen
specimens from hu mice in response to re-activating
compounds
In order to examine whether latently infected cells exist in hu
mice, we examined unspliced HIV Gag mRNA transcripts in
spleen specimens from HIV-infected mock- and vero-treated mice
prior and after in vitro reactivation. Since we were limited in spleen
specimens, we opted for a combination of mitogens in concert with
anti-CD3/CD28 and IL-7 to increase our chances of successful
reactivation. The short term assay we used as well as the anti-
apoptotic effect of IL-7 was certainly beneficial for counteracting
any toxic effects due to the application of such a cocktail. Indeed,
we did not observe any toxic effects 18 h after adding this cocktail
when we harvested the tissue for quantifying HIV mRNA
transcripts. As previously reported [16,17,18], we observed a
clear reactivation of HIV Gag transcripts after stimulation
(Fig. 5B). We did not isolate the human CD4+ cells to perform
in vitro reactivation studies – however, we have no reason to assume
that the cell subset harbouring latently HIV will differ from the
results published [16,17,18].
Discussion
We sought to determine if hu mice recapitulate key features of
HIV infection and treatment and to assess the value of long-acting
anti-HIV drugs for treating HIV infection. We found that i)
conventional ART with two NRTIs and a NNRTI efficiently
suppressed HIV viral load and allowed recovery of the immune
system; ii) cell-associated HIV DNA was still present in those mice,
and interruption of ART resulted in viral rebound; in vitro
reactivation of spleen specimens from successfully treated mice
yielded increased number of HIV mRNA transcripts as compared
to baseline; and iii) simplification of ART with two long-acting
drugs kept HIV RNA suppressed. Thus, HIV infection in hu mice
mirrors key features of HIV infection in humans, including high
titer viremia in untreated mice, suppression of HIV RNA when
treated with ART but emergence of resistance when treated with
insufficient regimens, viral rebound after treatment interruption,
and recovery of CD4+ T cells under ART. Thus, hu mice are a
highly valuable animal model to assess the antiviral potency of new
compounds or novel strategies to eradicate latent HIV.
Liv/thy SCID hu mice have been used before to investigate
novel compounds for their anti-HIV activity [5,24]. However,
detailed PK data were mostly lacking, thus making it difficult to
interpret the antiviral potency of the compounds. Furthermore,
conventional liv/thy SCID hu mice lack peripheral T cells [3].
Thus, SCID-hu Thy/Liv mice were rarely used to study
compounds to treat disseminated HIV infection. Most studies
administered the drugs either before or immediately after the HIV
challenge [25], and that recapitulates post- or pre-exposure
prophylaxis where less potent regimens are already effective.
The new generation of hu mice displays an elaborated
lymphoid-like system of human origin [6] and is highly susceptible
to HIV infection. However, studies with these mice lacked data
about their value for standardized pre-clinical testing. Five studies
[14,15,16,17,18] reported the efficacy of ART in HIV-infected
mice. In these studies, ART was started within 3 weeks after HIV
Table 1. Emergence of resistance in the mice under monotherapy with TMC278-LA.
Mouse
(Identifier)
day 30
(baseline)
day 73 (under ART
with 3TC, TDF,
TMC278-LA)
day 128 (38 days under
TMC278-LA alone)
day 150 (22 days after
interruption of TMC278-LA)
# 192** S* n.d." S S
# 242 S n.d. n.d. S
# 232 S n.d. E138K E138K
# 190*** S M184V n.d. M184I/E138K
# 189 S S M184I/K101E/E138K M184I/K101E/E138K
# 191*** S M184I M184I/E138K M184I/E138K
# 224*** S M184I n.d. M184I/E138K
*S = susceptible (wildtype strain).
**#192 showed suppressed HIV RNA under TMC278-LA monotherapy.
***#191, 224 showed viral failure under the ART regimen of 3TC, TDF and TMC278-LA. #190 gave a positive signal for HIV RNA but below the limit of detection (,800
copies/ml)
#221, 245 only baseline analyses have been done, and therefore data from these mice were not integrated in the table.
"#n.d. = not done.
doi:10.1371/journal.pone.0038853.t001
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infection (i.e., rather early after HIV challenge). In the first study,
HIV was suppressed in 3/6 mice by i.p. ART, and HIV recurred
when treatment was interrupted [15]. Surprisingly, a second study
did not observe viral rebound after treatment interruption [14]. In
subsequent studies, complete response rates were reported with an
intensified regimen (i.p. administration of emtricitabine (FTC),
TDF, an integrase inhibitor and enfuvirtide) [16] or high doses of
ART given i.p [17]. All but one [16] of these studies lack detailed
PK data on the administered drugs and data related to long-term
administration of ART and to the anti-HIV efficacy of ART in
chronically infected mice. Compared to the PK data we generated
in mice and considering the therapeutic range in humans, the
dosages applied in some of the studies reported are most likely 3–
5-fold over the therapeutic range.
For an effective mouse model, long-term ART must be non-
toxic and well tolerated by the mice. This requires solid PK data in
Figure 4. Two long-acting drugs, TMC278-LA (160 mg/kg) and TMC181-LA (400 mg/kg), are highly effective as maintenance
therapy. (A) Response to a quadruple ART consisting of 3TC, TDF, TMC278-LA and TMC181-LA over a treatment period of 150 days (the black circles
identifies the mice which remained over the entire time on ART (n = 7), the white circles identify the mice which were subsequently switched to a
treatment with double long-acting drugs (see (B)). (B) Sustained successful suppression of HIV RNA after switching mice with suppressed HIV RNA
under quadruple ART to a treatment with double long-acting drugs (n = 8). (C) Mock-treated HIV infected mice (n = 5). (D) CD4+ T-cells as determined
by the CD4/CD8 cell ratio in all treated mice (ART and double long-acting drugs) and mock-treated mice at the end of the experiment.
doi:10.1371/journal.pone.0038853.g004
Table 2. HIV RNA load at the terminal bleeding in mice on ART or on double long-acting drugs.
Mice on quadruple ART Mice on double-long acting drugs
Mouse identification number #411 #412 #417 #432 #459 #402 #413 #415 #457 #466
HIV RNA n.d.* n.d. 152 n.d. ,40 ,60 502 n.d. n.d. n.d.
Detection limit [copies/ml] 40 40 40 40 40 60 40 60 60 40
*n.d. = non-detectable.
- Humanized mice were sacrificed 151 days after HIV infection and 114 days after starting ART or double long-acting drugs.
- Detection limit: the volume of plasma available was slightly different for the mice euthanized and thus the lower detection limit varied accordingly between 40 and 60
copies/ml.
doi:10.1371/journal.pone.0038853.t002
Treating HIV Infection in Humanized Mice
PLoS ONE | www.plosone.org 7 June 2012 | Volume 7 | Issue 6 | e38853
the therapeutic range for humans. In our experiments, we added
the distinct anti-HIV compounds to the food pellet based upon
calculating food intake, weight and metabolic rate. We generated
PK data in the therapeutic range for 3TC and TDF. The long-
acting drugs TMC278-LA and TMC181-LA were injected s.c.
once weekly. We identified dosages that resulted in concentrations
clearly above the Ctarget 1 week after its administration. Notably,
plasma levels of NRTIs approximate only the concentration of the
anti-HIV active intracellular tri-phosphorylated compounds. Since
the half-life of the active moiety is longer than from the parental
compound [26], we were confident that the dosages would be
efficacious for treating disseminated HIV infection in our model.
Indeed, this was the case. We observed HIV RNA suppression in
79% in the first and 100% in the second experiment.
From the PK data, the mice in the first experiment were treated
for the first 2 weeks with only effective dosages of 3TC and AZT, a
dual therapy insufficient to suppress HIV; RTV plasma levels were
substantially below the therapeutic range. Furthermore, AZT
which was toxic for the mice resulted in decreased food uptake that
was reflected by substantial weight loss and sub-therapeutic dose
levels. The emergence of drug-resistant HIV was a logical
consequence of insufficient ART plasma levels. The observed
M184I mutations in our study are the most prevalent among
TDF/FTC-treated HIV individuals. Furthermore, we selected the
TMC278 E138K resistance–associated mutation in our mouse
Figure 5. Recovery of cell-associated HIV DNA (A) and increase of HIV mRNA transcripts in vitro from splenic tissue obtained from
HIV-infected mice with suppressed HIV RNA following activation. (A) DNA from infected HeLa cells (HeLa inf) and from the spleen of HIV-
infected mice served as positive controls, DNA from an uninfected humanized mouse (uninf) served as negative control. The specimens of the treated
and HIV-infected mice were from the experiments investigating the antiviral potency of the double long-acting drugs; (MNE = mean normalized
expression). B) Splenic tissue specimens from either HIV infected ART naı¨ve hu mice (HIV), ART treated mice (ART) or mice treated with the two long
acting drugs (Double-LA) were subjected to mitogens (PMA, PHA) in concert with anti-CD3/28 and IL-7. 18 hours later RNA was extracted and real-
time PCR done for quantifying HIV Gag transcripts. Specimens of two mice which were treated with double LA drugs did not show any HIV transcript
at all (data not shown in the graph); in five mice we did not detect any HIV transcripts prior to stimulation. The real-time PCRs were done in
duplicates. *this specimen is from a mouse (#417) with detectable HIV RNA at the time of euthanization (see Table 2).
doi:10.1371/journal.pone.0038853.g005
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model. These findings demonstrate that our model consistently
reproduced the Phase III trial results of the ECHO & THRIVE
studies, which showed that E138K and M184I combination was
the most observed resistance associated mutations in patients
treated with TMC278 and co-formulated TDF/FTC [27,28].
Indeed, our data indicate that the M184I mutation precedes the
E138K mutation; this suggests that patients with archived HIV
strains with the M184I are especially prone to viral failure with a
subsequent triple compound–based regimen with 3TC or FTC
and TMC278. This mimics what happens in patients with poor
adherence and emphasizes the preclinical proof-of concept value
of this mouse model for HIV infection.
HIV-infected mice displayed a distinct response rate to ART
(i.e., around 50% of all mice under quadruple therapy had an
undetectable HIV RNA at day 44, the other 50% at day 99)
(Fig. 4A). Since we were limited in blood draws, we have no
detailed data about the viral decay in these sets of mice. Notably,
we observed a rapid drop of HIV RNA in a majority of HIV-
infected mice within 10 days after initiation of ART when we took
blood in short intervals (unpublished data). In any case, the
response rate to ART may vary in HIV-infected hu mice similar to
the variable response observed in HIV-infected individuals starting
ART. It would be therefore sensible to perform HIV RNA
measurements over at least 2 months to document ART response
or failure.
In our experiments, blood draws yielded small amounts, but
terminal bleeds yields larger blood volumes, which are a critical
determinant for the sensitivity of the Amplicor RocheH. Indeed,
the larger blood volumes documented the success of ART with
HIV RNA copy numbers below 60/ml in most mice, thus
excluding that low-level viremia was still ongoing in the
successfully treated animals.
Interrupting ART resulted in prompt viral rebound in all mice.
The mice used for that purpose successfully responded to ART
and were treated for a longer period of time to assure the decay of
potentially low-replicating cells. We also found cell-associated HIV
proviral DNA in untreated and successfully treated mice, re-
enforcing the fact that HIV generates a latent reservoir in HIV-
infected hu mice. Besides, cell-associated HIV proviral DNA levels
in untreated mice were higher than in treated ones, similar to the
case in humans [29]. Similarly to findings reported [16,17,18], we
observed a clear increase of HIV transcripts when splenic tissue
from HIV infected mice with suppressed HIV RNA was
stimulated. These findings are promising for using hu mice for
studying the latent reservoir and in particular for studying
approaches to eradicate it. We observed no correlation between
cellular HIV-associated proviral DNA and engraftment level or
peak viremia. These data show that hu mice represent a model to
study latency and potentially novel treatment strategies. Viral
rebound or its absence in vivo will be a definitive end point of novel
eradication strategies aiming to cure HIV infection.
We also report the use of our HIV hu mouse model in the study
of TMC278 and TMC181 in a galenic formulation that results in
plasma levels above the Ctarget for at least 1 week after
administration (long-acting drugs) [30,31]. TMC278 corresponds
to the recently approved NNRTI, rilpivirine [32]. Note that
TMC181-LA is a prototype HIV long-acting protease inhibitor;
however, the compound is not itself a candidate for clinical
development. We tested TMC278-LA as adjunct to the backbone
of 3TC and TDF for treating disseminated HIV infection and
TMC278-LA alone or in combination with TMC181-LA for
maintenance therapy in mice with suppressed HIV RNA. As
expected, TMC278-LA was very potent in combination with the
NRTI backbone (see above). However, TMC278-LA as mono-
therapy was not sufficient to maintain HIV suppression. Indeed,
all mice showed a viral breakthrough. This prompt viral
breakthrough is consistent with the clinical experience in humans:
the NNRTI class must be given with a potent backbone [33].
Indeed, due to the long half-life of efavirenz (EFV) and nevirapine
(NVP), as opposed to other anti-HIV drugs, interruption of ART
containing either EFV or NVP at once results in a monotherapy
with the risk of the emergence of NNRTI-resistant strains [34,35].
This clinical observation documents the relatively low genetic
barrier of NNRTIs when given alone. In contrast, TMC278-LA in
concert with TMC181-LA was highly efficient with a response rate
close to 100% over time. In fact, clinical trials are under way to
examine simplification of ART (e.g., combination of the protease
inhibitor atazanavir and the integrase inhibitor raltegravir) [36].
Thus, this HIV mouse model would be superbly suited for a pre-
clinical proof-of-concept of novel ART strategies (e.g., nucleoside
sparing regimens, long-acting drugs).
Conclusions
In summary, we present data of ART responses/failures in
larger number of mice that eventually position this hu mouse
model as key tool in the evaluation of novel treatment strategies
and latency. Hu mice, indeed, recapitulate central steps in HIV
infection, including high-titer viral dissemination, response to
ART, viral failure in the case of non-adherence and very
importantly viral rebound after ART interruption. Viral rebound
after interruption of ART points clearly to a latent reservoir of
HIV. This model will be crucial when testing compounds for
activating the latent reservoir aiming to eradicate and eventually
cure HIV. We underscore this statement by documenting the
value of long-acting anti-HIV drugs for suppressing HIV that
might be very effective in certain clinical situations, e.g., PREP,
PEP or in patients with poor adherence, as a simplified
maintenance regimen, or in patients unable to swallow drugs.
Materials and Methods
Ethics statement
All experiments as well as procurement of human cord blood
were approved by ethical committees of the University of Zurich
and the Federal Veterinary Department and. The experiments
were conducted according to local guidelines (TschV, Zurich) and
the Swiss animal protection law (TschG). Human cord blood was
collected with informed written consent of the parents.
Generation of hu mice
Immunodeficient NOD/shi-scid/ccnull (NOG) [19] mice were
reconstituted and infected as described [9]. Briefly, newborn NOG
mice were irradiated 1–3 days after birth with 1 Gy and
subsequently injected intra-hepatically with 2.560.56105
CD34+ cells. CD34+ cells were isolated from human cord blood
with immunomagnetic beads (Miltenyi Biotec) with an yield of
0.5–46106 CD34+ cells from one donation (purity .90%).
CD34+ cells and ‘‘non-target’’ fractions were stored frozen in
liquid nitrogen until use. At around 15 weeks after transplantation,
the engraftment of human immune cells was checked by staining
peripheral blood mononuclear cells for the panhuman marker
CD45. In all experiments, mice were randomized into mock- or
ART treated groups.
Generation of food pellets containing anti-HIV drugs
Food pellets were made by mixing 2.5 g of 3TC, TDF and AZT
each, and 5 g of RTV with 5 kg of ground protein-rich, vitamin-
fortified food (Nafag 3432, Provimi Kliba AG, Switzerland) which
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was subsequently formed to food pellets and sterilized by gamma-
irradiation with 25 kGy. All batches of food pellets were analyzed
for the correct amount of drugs admixed by HPLC (see below).
Food and tap water were given ad libitum. TMC278-LA and
TMC181-LA were generated by wet milling the compounds to get
nanosizes and their subsequent formulation with non-ionic
surfactants [30,31]. They were injected s.c. at 160 and 400 mg/
kg, respectively.
HPLC-MS/MS method for measuring levels of TDF and
3TC in plasma and food pellets and TMC278 and TMC181
in plasma
Concentrations of drugs in the plasma and food pellets were
determined by a qualified research liquid chromatography and
mass spectroscopy (LC-MS/MS) method. For the analysis of diet,
food pellets were diluted with water (1:10) and homogenized.
Aliquots of each homogenate (50 mL) were solubilized with
methanol (three volumes) and extracted with an identical volume
of acetonitrile. Plasma samples (50 mL) were prepared identically
as the food pellet homogenates. Plasma and food pellets were
quantified using a specific LC-MS/MS method.
LC-MS/MS analysis was carried out on an API-4000 MS/MS
(Applied Biosystems), which was coupled to an HPLC system
(Agilent). The MS/MS was operated in the positive ion mode with
the TurboIonSpray-interface (electrospray ionization) and opti-
mized for the quantification of the compound (MRM transition for
TDF: 520.2.270; for 3TC 288.176; for TMC278 367.2.224
and for TMC181 585.2.429).
The calibration range was flexible and depended on the study
design. The limit of quantification was 0.5–10 ng/ml, depending
on the compound. The accuracy (intra-batch accuracy for
independent QC samples) was 80–120% of the nominal value
over the entire concentration range of the samples.
HIV infection and ART
Mice were infected i.p. with HIV YU-2, 16106 tissue-culture
infectious dose50 (TCID50) per mouse. TCID50 was determined in
human CD8+T cell depleted PBMC from three donors which
were stimulated by PHA and anti-CD3 beads (Dynal). HIV RNA
plasma levels were measured by RT-PCR (AmpliPrep/COBAS
TaqMan HIV-1 Test, Roche) at various times after infection.
Mice were monitored three times a week for symptoms or signs
of adverse events, according to a standard score sheet.
Flow cytometry
Human cells, T cells and B cells were measured by flow
cytometry of white blood cells stained for human CD45-APC,
CD4-PerCP-Cy5.5, CD8-PB, and CD19-PE-Cy7 (all from BD
Biosciences).
qPCR analysis of mouse organ samples
DNA and RNA from half of a spleen were extracted
simultaneously with the AllPrep DNA/RNA Kit (Qiagen). DNA
qPCR was as described [37], using HotStarTaq Master Mix
(Qiagen), 1 mM of each primer and 0.1 mM FH probe.
Experiments were done in duplicate with the real-time thermo-
cycler IQ5 (BioRad) and as cycling profile: 95uC 15 min, 606
(95uC 5 s, 55uC 5 s, 60uC 40 s). The following oligonucleotides
were used for HIV gag gene: mf319tq (probe): FAM59-TGC AGC
TTC CTC ATT GAT GGT-39TAMRA [38], ts59gag (sense): 59-
CAA GCA GCC ATG CAA ATG TTA AAA GA-39 [37] and
skcc (antisense) (59-TAC TAG TAG TTC CTG CTA TGT CAC
TTC C-39 [39]. The following oligonucleotides were used for the
reference gene GAPDH: mf70tq (probe): FAM59-AAG GTC
GGA GTC AAC GGA TTT GGT CGT-39TAMRA, mf45
(sense) 59-TCG ACA GTC AGC CGC ATC TT-39 and mf46
(antisense) 59-GGC AAC AAT ATC CAC TTT ACC AG-39.
Mean normalized expression (MNE) was calculated with qbase-
PLUS (version 2.0, Biogazelle). The following oligonucleotides
were used for HIV tat/rev gene mf84-YU-2 (sense) 59-ACA GTC
AGA CTC ATC AAA GTT CTC TAT CAA AGC A-39 [37],
mf226tq (probe): FAM59-AGG GGA CCC GAC AGG CCC-
39TAMRA [37] and mf83 (antisense): 59-GGA TCT GTC TCT
GTC TCT CTC TCC ACC-39 [37].
Since mice were infected with HIV-1 YU-2, the plasmid
encoding YU-2 was used as standard in the PCR reactions with a
detection limit down to 5 copies/reaction.
Reverse transcription
RNA was DNase treated using DNA-free kit (Ambion). For
reverse transcription random hexamer primers (Operon Technol-
ogies) and SuperScript III reverse transcriptase (Invitrogen) were
used. Reverse transcription was performed as described earlier
[40]; briefly cDNA synthesis was performed using 10 ml DNase
treated RNA in the presence of Ribolock Rnase inhibitor
(Fermentas) in a total volume of 50 ml as follows: 60 min at
50uC, 60 min at 55u, 15 min at 70uC and then 1 min on ice.
Subsequently 1 ml of RNAseH (NEB) was added to each tube and
incubated at 37uC for 20 min. Aliquots were stored at 220uC or
used immediately for real-time PCR analysis.
Ex vivo reactivation
Splenic cells of half of a spleen were thawed and split in two
equal parts and then incubated in RPMI containing fetal calf
serum (10%), IL-2 (10U/ml), penicillin (5%)/streptomycin (5%)
and L-glutamine (5%) at 37uC for 12 hours. Subsequently cells
were washed and then cultivated with or without mitogens (PHA
at 3 mg/ml, PMA at 10 ng/ml), anti-CD3/CD28 beads (Dyna-
beads, Invitrogen) and IL-7 at 20 ng/ml. 18 hours later, DNA and
RNA were extracted simultaneously with the AllPrep DNA/RNA
Kit (Qiagen) which was then used for quantifying the HIV mRNA
Gag transcripts.
Genotyping
Dideoxynucleotide-based sequence analysis was performed as
described [41]. Briefly, Dideoxy sequencing reactions were
performed on the purified amplicon (ABI Prism Big Dye
Terminator Cycle Sequencing Kit, Version 3.1, Applied Biosys-
tems) with a set of eight sequence-specific primers distributed over
the PR-RT sequence for both strands: F1, 59-GAGAGCTTCA
GGTTTGGGG-39; F2, 59-AATTGGGCCTGAAAATCC-39;
F3, 59-CCTCCATTCC TTTGGATGGG-39; F5, 59-
CACTCTTTGG CAACGACCC-39; R1, 59-CTCCCACTCAG-
GAATCC-39; R3, 59-CTTCCCAGAA GTCTTGAGTTC-39;
R5, 59-GGGTCATAAT ACACTCCATG-39; R6, 59-GGAA-
TATTGCTGGTGATCC-39. Reactions were purified with a
DyeEx Purification Protocol (Qiagen) and analysed with the
ABI3730xl DNA Analyzer (Applied Biosystems). Sequence data
files were grouped per sample identifier (ID) and aligned against
the reference HXB2 reference sequence by means of the
Sequencher TM Program V 4.1.4 (Gene Codes Corp.). A 25%
mixture scoring rule (similar to 20% mixture identification by 454
deep sequencing) was used for the electropherogram analysis.
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Calculations and statistics
Statistical analyses were performed using GraphPad Prism5.0
(GraphPad Software). Data were analysed by non-parametric
Mann-Whitney test. In all figures, points represent values of
individual mice, and lines depict mean values.
Supporting Information
Figure S1 Engraftment levels of hu mice before HIV
infection. The mice were checked for engraftment levels at a
median age of 132 days (25–75% percentiles: 103–136) as
quantified by staining peripheral blood for the panhuman marker
CD45. In addition, the percentage of CD4+, CD8+ and CD19+
cells were determined by flowcytometry.
(TIF)
Figure S2 PK data of AZT and RTV. (A and B) Plasma levels
of AZT and RTV, respectively, over a day of mice on food pellets
containing 0.5 mg/g or 1 mg/g food of AZT or RTV,
respectively. The mice used for analysis of PK data have been
on food pellets containing drugs for around 2 weeks for PK
equilibration. The shaded area indicates the therapeutic range as
defined in human. The different colours indicate the experiments
done with the same food batch.
(TIF)
Figure S3 AZT at the dose applied was highly toxic.Mice
were 2 weeks on a regimen with AZT as added at 0.5 mg/kg to
the food pellets and were subsequently euthanized. Extensive
laboratory chemistry and hematology work-up was done by the
Institute of Clinical Chemistry and the Division of Hematology,
USZ.
(TIF)
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3.2.2 High resolution mapping of HIV drug resistance evolution driven by 
APOBEC3G 
Authorship contributions 
I performed all the experiments and created figures 1 to 4. With Annette Audigé, Roberto 
Speck and Viviana Simon, I designed the experiments and wrote the manuscript. Viviana 
Simon performed the NGS and figures 5 and 6. 
Introduction 
Humans have evolved multi-layered defenses against invading pathogens. The APOBEC3 
family of seven cytidine deaminase enzymes is part of the host’s protective machinery [1]. 
HIV evolved, in turn, a number of strategies to evade precisely these antiviral mechanisms; in 
particular the HIV accessory protein Vif efficiently counteracts the antiviral activity of some 
of the most active APOBEC3 (e.g., A3G[1]).  
However, proviruses with footprints of past deamination have been found in many HIV 
infected patients suggesting that Vif inactivation occurs frequently. Moreover, HIV strains 
with Vif alleles unable to completely neutralize APOBEC3 enzymes have been identified 
suggesting that complete neutralization is not necessary for survival of HIV as a population[2, 
3]. Our collaborator Dr. Viviana Simon showed recently that HIV can exploit APOBEC3 to 
escape from nucleoside reverse transcriptase inhibitor (NRTI) lamivudine (3TC)[4]. For this, 
Dr. Simon and co-workers generated single nucleotide Vif-deactivating HIV mutants and 
found that partial A3G neutralization defects associated with Vif mutation 45G permit 
efficient replication in vitro in human peripheral blood mononuclear cells (PBMC). In the 
absence of any drug selection, these infections resulted, however, in a diverse proviral 
population in which 3TC drug resistance-associated mutations were found with high 
frequency[4]. These results suggest that hyper-mutated, defective proviruses can shape the 
phenotype of circulating viruses.  
Reminiscent of observations in HIV infected patients[20], Vif-deficient HIV failed to spread 
in the humanized mice while proviruses derived from humanized mice infected with Vif-
proficient HIV harbored numerous G-to-A mutations dinucleotide contexts preferred by 
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several distinct APOBEC3 molecules (GG or GA[21]). It has been a point of debate whether 
APOBEC3 driven mutagenesis contributes to the emergence of drug resistance[24].  
To address the question of how much does APOBEC3 deamination contribute to overall 
heterogeneity of HIV genomes, we choose to use antiretroviral drugs to perturbate the in vivo 
infection upon dissemination. This experimental system permits to create an environment in 
which viral escape has an immediate and measurable fitness advantage (i.e. emergence of 
drug resistant viruses). 
Material and methods 
In this section I will only focus on the parts that are not covered in the rest of the thesis. 
Cells and reagents 
293T cells and TZM-bl cells were obtained from the NIH; they were cultured in DMEM 
medium (Lonza, Switzerland) supplemented with 10% FBS (Lonza, Switzerland), 1% 
penicillin (Life technologies) and 1% streptomycin (Life technologies). MT-4 cells were also 
obtained from the NIH and were cultured in RPMI medium (Lonza, Switzerland) 
supplemented with 10% FBS (Lonza, Switzerland), 1% penicillin (Life technologies) and 1% 
streptomycin (Life technologies).  
3TC (Lamivudine) was purchased from GlaxoSmithKline (Epivir tablets). Tablets were 
grinded and weighed according to the 3TC content. 3TC was added to the food pellets as 
previously described[7] 
Viral stocks 
Viral stocks were generated by transfecting 293T cells with proviral DNA encoding the 
various Vif-mutants within the backbone of NL4-3 (obtained from the NIH) using PEI, and 
were washed 18 hours post-transfection. The 45G and the SLQ mutants were generated by 
site directed mutagenesis, using mutagenic primers and PCR techniques, replacing the codon 
45 by GGA nucleotides and the 144 to 146 codons by GCTGCAGCG nucleotides, 
respectively, as previously described[2, 25, 26]. 
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Viral supernatants were collected 48 hours post-transfection, filtered and frozen at -80°C until 
further use. Gag p24 concentration of viral stocks was quantified using an in-house 
ELISA[27] Tissue culture infectious dose 50 (TCID50) were determined by infection of 
TZM-bl with serial dilutions of viral stocks. 
Amplification of HIV from plasma virions 
RNA was extracted from 200ul plasma using Qiagen viral RNA kit as per manufacturer’s 
instruction.  
For the deep sequencing approach, cDNA was synthesized using the Thermoscript Kit 
(Invitrogen) and antisense ID cDNA primers (1528 5’- 
TTGCCYAATTCAATTTNNNNNNNNATTTCTGTATGTCATTGACAGTC, machine 
mixed; 1468 5’- TTGCCCAATTCAATTTNNNNNNNNNATTTCTGTATGTCATT 
GACAGTC, handmixed). The RT reaction was performed for 60 minutes at 55°C. cDNA 
products were column purified and eluted in 10ul H20.  
For the amplification of complete  Vif coding region, RNA from plasma collected at baseline 
or at later time points (week 8 or week 10) was reverse transcribed using random hexamers as 
described[29]. The full-length Vif region was amplified as previously described[29] and 
cloned using Strataclone blunt kit[30]. 6-12 individual clones were sequenced and manually 
aligned to Vif NL4-3 sequence. 
MiSeq Illumina 
The amplified PCR product containing the specific illumina adapters was run on a bio-
analyzer for quality control and quantity determination. 37 to 47 samples were diluted to 
10nM and further processed for MiSeq multiplexing sequencing (Illumina Inc., San Diego, 
CA). 60% of PhiX library (Illumina Inc., San Diego, CA) was spiked into the samples to add 
diversity. Runs generated 3.5 to 6 million paired-end reads (2 × 150 bp) covering the 47 HIV 
samples (37-47) as well as PhiX. Of the 13 million reads, over 6 million reads matched the 
HIV samples with a minimum of 13,017 reads per sample.  
The processing of the sequence data was done using several custom scripts (a mix of shell and 
perl), developed specifically for this project.  The sequences were binned into separate 
barcodes. For each set, the PCR-primers and tags were identified in the sequenced reads, and 
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each unique combination of HIV sequence and tags were identified and assigned a count, 
which was the frequency of occurrence of the sequence-tag combination in the sequencing 
data. This frequency represents the clonal amplification of the molecule and the multiple 
occurrences are just counted once.  After this compression of the data, the mutations in the 
sequences are identified and accurate inventory of the various mutations in each sample is 
made, and this allows us to identify the dynamics of the mutations under different treatments. 
Results and Discussion 
Partial neutralization of A3G permits replication in cell culture  
In order to verify that the mutant viruses are able to replicate in the presence or absence of 
APOBEC3 proteins in vitro, we infected MT4 T cells as well as mitogen activated (PHA 
1μg/mL for 48 hours) human CD34 negative cord blood mononuclear lymphocytes (CBL) 
with HIV WT, HIV Vif 45G and SLQ isogenic Vif mutant viruses. Of note, HIV WT is able 
to counteract A3G and A3F, HIV 45G is not able to counteract A3G and SLQ is not able to 
counteract A3G nor A3F and therefore has been considered as an equivalent of a Vif-deficient 
virus[26, 31, 32] (Fig. 1A). The three viruses replicated to similar levels in MT4 cells, which 
do not express any A3G[31]: 45G and SLQ replicated to a similar level as WT in the absence 
of A3G (MT4 cell line) but only WT and 45G replicated efficiently in primary cells, which 
naturally express A3G. In agreement with previous reports, HIV SLQ, which cannot 
counteract any of the APOBEC3, is highly attenuated in the presence of APOBEC3 (Fig. 1B).  
 
Figure 1: HIV Vif mutant viruses engineered to display selective APOBEC3 
neutralization defects. A. Model of differential APOBEC neutralization of HIV WT, HIV-
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45G and HIV-SLQ.  B. Spreading infection of the three viruses in primary cord blood 
lymphocytes.  
 
Partial neutralization of A3G is associated with lower viral fitness and complete lack of 
APOBEC3-neutralization leads to a lack of viral replication in vivo 
To assess the impact of differential neutralization of APOBEC3G/F on HIV infection in vivo, 
we infected humanized mice with the three different viruses and monitored viral replication 
weekly over four weeks by measuring plasma viral load and determined the peripheral blood 
CD4/CD8 T cell ratio overtime. As observed in vitro, no replication was detected for the SLQ 
mutant (Fig. 2A),  which is in line with recent work showing lack of replication in humanized 
mice infected with Vif-deficient CCR5-tropic HIV strains[21, 33]. Therefore, this experiment 
proves convincingly that Vif without its SLQ box which binds to the proteasomal machinery 
has no anti-APOBEC3 activity, and behaves indeed like a Vif-deficient virus. In contrast, the 
45G mutant showed a replication pattern in vivo that was different from the one observed in 
vitro: viral replication was similar to the one of the WT virus at 4 weeks, but significantly 
lower thereafter  (P=0.014 and P=0.0039 respectively), indicating a progressive decrease in 
viral fitness overtime. However, the pathogenicity of the 45G mutant was as high as the one 
of the WT virus, as seen by the similar ratio of CD4/CD8 T cells in peripheral blood overtime, 
thus, factors other than solely HIV viremia contributed to the progressive CD4+ T cell loss 
(Fig. 2B). The difference in the viral fitness of 45G between the in vitro and in vivo 
experiments is likely explained that 45G’s attenuation takes longer to become apparent, 
corroborating the value of studying HIV pathogenesis in humanized mice. The attenuation 
observed is most likely explained by a slow accumulation of deleterious mutations overtime 
in several proteins of the 45G virus due to the unopposed editing effect of A3G [34, 35]. We 
cannot exclude an additional non-editing effect of A3G in this partial inhibition, like RNA 
binding and subsequent inhibition of cDNA accumulation and integration in the host’s 
genome, as described previously in vitro[36-38]. Notably, the catalytic domain of A3G, 
responsible for its cytidine deaminase activity and the region responsible for the non-editing 
effect are at different locations[36, 39, 40]. 
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A      B 
  
Figure 2. Partial neutralization of A3G is associated with lower viral fitness and 
complete lack of APOBEC3-neutralization leads to a lack of viral replication in vivo. A. 
Viral replication of Vif mutants in humanized mice. Immune reconstituted mice were infected 
with either NL4-3 WT (n=10), NL4-3 45G (n=9), NL4-3 SLQ (n=4) or not infected (n=4) 12 
weeks post reconstitution. Plasma viremia was measured over time. Dots represent mean of 
the plasma viral loads for each group at each time point and bars represent SEM. B. CD4/CD8 
ratio over time. The ration of the frequencies of CD4+ and CD8+ T cells in peripheral blood 
of the infected mice was determined by immunostaining and flow cytometry weekly over 12 
weeks post infection. Dots represent mean of the ratios for each group at each time point and 
bars represent SEM. 
 
Partial neutralization of A3G in vivo has no cost on viral fitness under selective pressure 
To better understand how partially active HIV Vif alleles can exploit APOBEC3 to escape 
from particular antiretrovirals as shown previously in vitro[4] and in HIV-infected individuals 
failing antiretroviral treatment[3], we treated HIV-infected humanized mice with 3TC for six 
weeks starting four weeks post infection and monitored viremia and peripheral blood 
CD4/CD8 T cell ratio every two weeks during the treatment period (Fig. 3A). Two weeks 
after the start of the treatment, viremia was decreased in all WT-infected mice and in 5 of 6 
45G-infected mice (Fig. 3B). The mouse #120 that showed no decrease on the viral load had a 
higher viral load as compared to the other animals. It showed signs of wasting and 
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unfortunately it had to be euthanized. Between week 6 and 10 post infection, virus rebounded, 
in particular in the 45G-infected group.  
 
  
 
 
 
 
 
Figure 3: The humanized mouse model provides an in vivo model for HIV replication. A. 
The experimental time line is depicted. Eight immune reconstituted mice were infected with 
either NL4-3 WT or NL4-3 45G, 12 weeks post reconstitution. 3TC was added to the food 
pellets starting week 4. Plasma viremia and CD4+ T cells were measured over time. B. 
Replication of HIV WT and HIV 45G in humanized mice.  Viremia in the plasma was 
measured over a 10 week period. The left panel summarizes the replication of WT viruses and 
the right panel the replication of the 45G viruses. Productive infection (>3,000 copies/ml) was 
observed in six out of eight animals in each group. 
 
A comparison of the difference in viral load between either week 4 and 6 or week 6 and 8 
between HIV WT- and 45G-infected mice revealed that the decrease of viral load from week 
4 to 6 was similar in both groups (Fig. 4A and 4B, left panel). Thus, the Vif mutation did not 
affect the initial response to 3TC. In contrast, viral rebound between week 6 and 8 was 
significantly stronger for the 45G group, which is consistent with more rapid emergence of 
3TC resistance. One would spontaneously assume that the unopposed editing effect of A3G 
resulted in a more rapid and higher diversification of HIV, and in particular at the position 
184, rendering the 45G mutant more apt to replicate in the presence of 3TC[4]. 
A
B
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The peripheral blood CD4/CD8 T cell shows the same pattern for both groups: the ratio 
remained constant until the start of the 3TC treatment, increased between week 4 to 6 (when 
viremia decreased for both viruses (Fig. 3B)), and decreased thereafter (when viremia 
increased again (Fig. 4C)). Thus, also under selective pressure the 45G is as pathogenic as the 
WT virus. 
 
Figure 4: Overview of the virological and immunological characteristics of HIV WT and 
HIV 45G infection in humanized mice.  A. Summary of virological parameters of infection 
and lamivudine treatment responses. B. Plasma viral load changes depicted.  Dots represent 
individual mice and lines represent means. The grey line identifies no change. C. CD4/CD8 
ratio over time. Dots represent mean of infected mice for each group at each time point and 
bars represent SEM. 
Kinetics of viral drug escape in mice with A3G resistant and A3G sensitive viruses.  
In order to determine if resistance to 3TC appeared on 45G viruses faster than WT viruses, the 
RT region containing the codon 184 was sequenced, since mutations in this codon are 
responsible for 3TC resistance. While the WT virus codes for Met in position 184 (ATG), 
mutations induced by RT or A3G correspond to Ile (ATA) and mutations induced solely by 
RT correspond to Val (GTG or GTA). Amazingly, the input HIV strain was replaced already 
after 2 weeks of 3TC treatment to a great part by viruses with resistance signature of 3TC and 
this irrespective of the HIV strain used to challenge the mice (Fig. 5). This rapid emergence of 
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the M184I/M184V resistance mutations is rather identical to the resistance emergence in 
HIV-infected patients under 3TC monotherapy[41].  
 
Figure 5: Emergence and evolution of 3TC resistance in the plasma of mice infected with 
HIV WT or HIV 45G. A. The frequency of mutations at codon 184 of RT is depicted for the 
mice infected with WT virus. B. The frequency of mutations at codon 184 of RT is depicted 
for the mice infected with 45G virus. Red virus results from RT errors whereas blue virus is 
the result of RT as well as A3G. Green virus is WT. 
Looking closer at the type of resistance, we noted that a mixed population of HIV strains 
emerged with M184I and M184V substitutions in mice infected with WT HIV and a rather 
homogenous population with mainly M184I substitutions in mice infected with the 45G 
mutant. HIV strains with M184V mutations emerged in mice infected with 45G only when 
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Vif reverted to WT (Fig. 6). Thus, it seems that the A3G editing process is a determining 
factor in the 45G mutant. 
These results show that a partial neutralization of A3G (45G virus) does not induce faster 
drug resistance than WT virus in vivo. The Vif mutant 45G has been found in HIV-infected 
patients. In vitro analyses showed that it can partially neutralize A3G [2]. Additionally, this 
mutant was able to develop the 3TC resistance signature mutation, prior to 3TC exposure and 
more interestingly, it was able to transfer this resistance to the WT populations and shape 
populations via recombination, in vitro [4]. However, this experiment was performed in a 
very sophisticated way, by infecting a cell line with both viruses WT and 45G and then the 
cells were treated with a high dose of 3TC [4]. In this way, viral replication and 
recombination took place. Proof was lacking that these pathogenic events to happen in vivo. 
The mutation M184I increases the RT fidelity 4-fold and M184V 2.5-fold as compared to WT 
RT[42, 43] and thus viruses with M184I or M184V diversify less than WT HIV. The higher 
fidelity of the RT with M184I may prevent an excessive RT-driven diversification and thus, 
HIV strains with M184I might have a replication advantage as compared to HIV strains with 
M184V or WT RT. The gain of RT fidelity may outweigh the A3G editing effects in those 
mice infected with HIV strains deficient in the neutralization of A3G. However, the gain of 
viral fitness of the 45G mutant is only apparent under drug or immune pressure promoting 
specific mutation as illustrated here with 3TC.  
In two previous studies looking at the impact of different A3 proteins on HIV mutagenesis, 
A3-induced mutations were detected only in proviral DNA, consisting largely of stop codons, 
but in plasma HIV RNA no signs of hypermutation were found and no signs of drug 
resistance mutations were present[21, 33]. The major difference, again, is that we induced a 
selective pressure by treating the mice with 3TC that uncovered the significance of A3G-
driven mutations for HIV’s adaptation to drug or immune pressure. We have to be aware that 
the immune response in humanized mice is only partially effective; in particular the cytotoxic 
T lymphocytes (CTL) activity is impaired [44], Thus, the HIV RNA mutations we detected 
are induced merely due to the drug pressure – the concept we show here will certainly be 
valid also for the well known phenomenon of immune escape in humans. 
Regions in Vif that adapt and evolve in order to counteract A3G  
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In order to determine if the Vif gene was mutated or not through the experiment where we 
treated the mice with 3TC, we decided to sequence the Vif gene at baseline and at late points 
of infection (weeks 8 or 10 post infection). The baseline sequences (before 3TC treatment) 
showed no evidence of mutation for both WT and 45G mutant. We found evidence for Vif 
reversion/adaptation in two mice infected with 45G and in two mice infected with WT (Fig. 
6). For the mouse #130 (45G mutant), we observed mutations at positions G45E (reversion), 
from GGA to GAA (possibly A3G mediated), V10M from GTG to ATG (possibly RT 
mediated) and R90K from AGG to AAG (possibly A3F mediated).  For mouse #141 (45G 
mutant) we observed a mutation R41K from AGA to AGG (possibly RT mediated). For the 
mouse #126 (WT virus), the mutation was N190K from AAT to AAG (possibly RT mediated) 
and for mouse #125 (WT virus). Interestingly, both pairs of mice stand out with respect to the 
pattern of drug resistance (Fig. 5) and all of these mice, except #141, were reconstituted with 
the same cord blood. 
Intriguingly, the 45G mutant viruses showed APOBEC3-driven as well as stochastic 
mutations, as compared to the WT, which only exhibited stochastic mutations, pointing to the 
extremely fine-tuned editing machinery of the APOBEC3 system. The Vif gene, itself, is 
located 3’ of the central polypurine tract (cPPT) and excels by a very low A3G-driven 
mutational rate as compared to other HIV genome regions; this is most likely due to the fact 
that this region is only present for a very short time as single stranded DNA (ssDNA) during 
reverse transcription rendering it a short-lived target of A3G[45]; notably, A3G acts solely on 
ssDNA [46-48]. Thus, the APOBEC3-driven mutations we observed speak in favor that they 
were induced by the strong selective pressure we applied by putting the mice on 3TC. On the 
other hand, the RT is located 5’ of the cPPT, which corresponds to the hot spot of A3G-
activity, since this region is present as ssDNA for longer time [45] and explains the higher 
amount of mutations found in the RT region 
Taken together, these results show that under selective pressure (3TC treatment, in this case) 
Vif is able to adapt, in particular the 45G mutant with A3G/A3F and RT-mediated mutations 
and the WT with only RT-mediated mutations. 
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Figure 6. Evidence for adaptations of HIV Vif. A total of 47 individual sequences were 
performed in the full-length Vif gene for mice infected with HIV-WT: 125 and 126 and for 
mice infected with HIV-45G: 120, 122, 130 and 141. These sequences were aligned and 
compared to the NL4-3 WT used at baseline to infect mice 125 and 126 using a phylogenetic 
tree. Codon 45 of the RT is depicted for each sequencing performed. For 45G viruses it 
corresponds to E45G, for WT viruses it corresponds to E45E and for mutant viruses 
undergoing a reversion it corresponds to G45E. Other mutations observed in the Vif region 
are also indicated. Each dot represents an individual sequence, each color represents a 
different mouse 
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Concluding remarks 
This work also illustrates very convincingly the power of the Illumina platform for next 
generation sequencing HIV quasi-species from the plasma and in particular for detecting 
resistance mutations. Before 2007, the former sequencing studies in the field of HIV used 
rather exclusively the Sanger’s sequencing-based PCR amplification, which permitted to 
identify the sequence of the most prevalent HIV strain but did not allow to discriminate quasi-
species or to detect minor HIV populations. In addition, samples were subjected to Taq 
polymerase amplification errors [49, 50]. In the humanized mouse work described above by 
Sato et al. and Krisko et al. [21, 33], conventional Sanger’s sequencing-based PCR 
amplification was used. This could explain the striking difference between the papers by Sato 
et al. and Krisko et al.: Sato et al. found A3-driven mutations in viral DNA from splenocytes 
when mice were infected with  WT virus [21] while Krisko et al. found only such mutations 
in viral DNA for Vif-deficient virus from PBMCs, spleen, liver and lung [33].   
Nowadays, the 454 next generation sequencing is widely used to detect resistance mutations 
[51-54]. In direct comparison, the next generation sequencing techniques 454, PacBio RS 
(Pacific Biosciences), Illumina, and Ion Torrent (Life Technologies) were similarly 
efficacious for determining HIV co-receptor tropism [55]. In another work, two next 
generation sequencing techniques were compared: 454 from Roche and Illumina, using a 
mixture of ten HIV clones [56]. The authors concluded that for fixed costs, Illumina reads can 
provide a higher coverage and allow for detecting variants at lower frequencies. 
Other experiments also showed that the Illumina platform offers a better coverage of the viral 
genome compared to other methods, providing an improved characterization of the 
heterogeneity present in the studied samples [57-59]. For instance, it provides up to 3 billion 
reads per run, as compared to 1 million for the 454 sequencing and the cost per 1 million 
bases can be up to 100 times cheaper than the 454 sequencing [60, 61]. For HIV infection, it 
is very important to cover all or the big majority of the sequences present, due to the quasi-
species populations present on each patient, creating a very heterogeneous viral population.  
In summary, our results show that the lack of counteracting A3G leads to mutations in the 
HIV genome in several genes, which is primarily apparent under selective pressure, as exerted 
here by 3TC treatment. The selective pressure presented in this work could also apply to the 
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CTL immune pressure in HIV-infected patients. These mutations generated might be then 
transferred to the circulating populations and thereafter shape the viral population overall, as 
shown previously in vitro[4], although this remains to be determined in vivo.  
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3.2.3 Gene Therapy against HIV-1 using the humanized mice 
ART is the standard treatment against HIV-1, which does not cure HIV-1 and has the 
disadvantage of side events, emergence of drug-resistant strains, a need for life-long intake, 
psychological dependence, and cost. Gene therapy is among the most promising strategies to 
cure HIV-1. In this work we tested the gene therapy in the hematopoietic precursor cells of 
human origin (CD34+) that are transplanted into the humanized mice in order to generate an 
immune system of human origin. Since HIV-1 requires the co-receptor CCR5 for viral entry, 
we engineered a lentiviral vector containing miRNA against CCR5, we transduced the CD34+ 
cells with this vector and evaluated the protection of the gene therapy against HIV-1. The 
results of this work have been recently published into the Journal of Virology and are found 
below. 
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ABSTRACT
Gene-engineered CD34 hematopoietic stem and progenitor cells (HSPCs) can be used to generate an HIV-1-resistant immune
system. However, a certain threshold of transduced HSPCsmight be required for transplantation into mice for creating an HIV-
resistant immune system. In this study, we combined CCR5 knockdown by a highly efficient microRNA (miRNA) lentivector
with pretransplantation selection of transduced HSPCs to obtain a rather pure population of gene engineered CD34 cells. Low-
level transduction of HSPCs and subsequent sorting by flow cytometry yielded>70% transduced cells. Mice transplanted with
these cells showed functional and persistent resistance to a CCR5-tropic HIV strain: viral load was significantly decreased over
months, and human CD4 T cells were preserved. In one mouse, viral mutations, resulting presumably in a CXCR4-tropic
strain, overcame HIV resistance. Our results suggest that HSPC-based CCR5 knockdownmay lead to efficient control of HIV in
vivo. We overcame amajor limitation of previous HIV gene therapy in humanized mice in which only a proportion of the cells in
chimeric mice in vivo are anti-HIV engineered. Our strategy underlines the promising future of gene engineering HIV-resistant
CD34 cells that produce a constant supply of HIV-resistant progeny.
IMPORTANCE
Major issues in experimental long-term in vivoHIV gene therapy have been (i) low efficacy of cell transduction at the time of
transplantation and (ii) transduction resulting in multiple copies of heterologous DNA in target cells. In this study, we demon-
strated the efficacy of a transplantation approach with a selection step for transduced cells that allows transplantation of an en-
riched population of HSPCs expressing a single (low) copy of a CCR5miRNA. Efficient maintenance of CD4 T cells and a low
viral titer resulted only when at least 70% of the HIV target cells were genetically modified. These findings imply that clinical
protocols of HIV gene therapy require a selective enrichment of genetically targeted cells because positive selection of modified
cells is likely to be insufficient below this threshold. This selection approachmay be beneficial not only for HIV patients but also
for other patients requiring transplantation of genetically modified cells.
Combined antiretroviral therapy (cART) changed the face ofHIV medicine: patients have a life expectancy close to that of
uninfected people (1). However, cART has major disadvantages,
including adverse events, emergence of drug-resistant strains in
patients with poor adherence, a need for lifelong intake, psycho-
logical dependence, and cost. Thus, cART has not halted the pan-
demic (http://www.who.int/hiv/en/), and alternative therapies are
needed to cure HIV.
Gene therapy has been widely discussed as a possible strategy to
cure HIV and has been tested in phase I and II clinical trials. Autolo-
gousCD4Tcells (2,3)orCD34 cells (4,5)weregeneengineered to
express various anti-HIVmoieties, including a combination of three
RNA-based anti-HIVmoieties (tat/rev short hairpin RNA [shRNA],
TAR decoy, and CCR5 ribozyme) (4), a tat-vpr-specific anti-HIV
ribozyme (5), and a conditionally replicating lentiviral vector ex-
pressing a long antisense to HIV (3), or were gene edited by zinc
finger nucleases for CCR5 knockout (2). Gene engineering also gen-
eratedHIV-specific CD4 or CD8 T cells (6, 7). Overall, the effects
on HIV infection were modest, but importantly, gene engineering
proved to be safe in humans.
The concept of engineering an HIV-resistant immune system
received new impetus from the “Berlin patient,” who was infected
withHIV and was treated with hematopoietic stem cell transplan-
tation for acutemyeloid leukemia.He received bonemarrow from
a donor homozygous for the 32 CCR5 mutation, and thus, the
progeny cells did not express CCR5. His case was the first in which
a cure for HIV was documented (8) and provided hope that elim-
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inating CCR5 from the cell surface would be the “Holy Grail” for
the cure of HIV.However, anotherHIV-infected patient suffering
from anaplastic large-cell lymphoma also received a stem cell
transplant from a homozygous CCR5-null donor. Unfortunately,
in that case, X4-tropic HIV strains emerged that necessitated the
reinitiation of cART (9).
In view of themodest success of phase I and II clinical trials and
the data from stem cell transplantation, preclinical studies are
needed to define the best anti-HIV moieties and the minimal
number of gene-engineered cells required to advance gene therapy
in HIV. Humanized (hu) mice, which are generated by the trans-
plantation of CD34 cells, are of particular value in this context.
These mice excel in their multilineage hematopoiesis (10), are
highly permissive to HIV (11), and allow for the gene engineering
of human CD34 cells before transplantation (12). Indeed, vari-
ous anti-HIV moieties have been investigated in hu mice as gene
therapy options, including cellular factors, boosting the anti-HIV
immune response, and the HIV genome itself (12). These mice
were used in extenso to investigate the effects of targeting CCR5 by
shRNA (13–15) or zinc finger nucleases (ZNF) (16). All these
studies reported a decrease in CCR5 expression in circulating and
tissue leukocytes, which were not permissive to HIV ex vivo, but
only the study by Holt et al. reported a significant decrease of HIV
RNA copy number in vivo (16). The other studies either did not
analyze the effects on HIV infection in vivo (14) or demonstrated
no effect on viral load (15). The results of Holt et al. revealed
disruption of CCR5 in only 20% of all CD4 T cells. The fol-
low-up in that study was only 8 weeks. Gene engineering of hema-
topoietic stem and progenitor cells (HSPCs) with a lentiviral vec-
tor encoding the broadly neutralizing anti-HIV human antibody
2G12 showed suppression of HIV RNA but was studied only 7
days after a challenge with a virus containing the corresponding
epitope (17); gene engineering of an HIV-specific T-cell receptor
also lowered the HIV RNA but only modestly (18). A very elegant
study with CD34 cells edited with anHIV-1 long terminal repeat
(LTR)-specific Tre recombinase showed a potent lowering of HIV
RNA activity after HIV challenge in hu mice (19). All these data
are promising; however, we lack a long-term follow-up of the
effects of anti-HIV gene therapy in hu mice, the number of gene-
engineered CD34 cells needed in the various studies to obtain an
HIV RNA lowering effect, and a detailed characterization of the
hematopoietic system. Amajor advance was recently presented by
Barclay et al., who purified gene-engineered CD34 cells via the
expression of a truncated version of CD25 (20).
Various means are available for gene engineering of CD34
cells; each has its pros and cons. A great deal of experience exists
with shRNA (21); potential consmay be its potential to trigger the
innate immune system (22) and its less-than-absolute downregu-
lation of the target gene. Targeted gene disruption by ZFN, Talen,
or Crispr/cas has the advantage of complete disruption of the gene
of interest (23–25); however, the modest rate of gene engineering
of CD34 cells (26), the potential of off-target effects (27–29), and
the lack of clinical experience represent substantial hurdles for
wider use in vivo.
We recently reported a novel microRNA (miRNA)-based gene
knockdown (KD) strategy with improved knockdown relative to
that obtained bymethods conventionally used (30). A triple-hair-
pin cassette targeting CCR5 resulted in90% CCR5 knockdown
upon single-copy transduction in HeLa cells. The aim of the pres-
ent study was to assess whether gene engineering of CD34 cells
with this vector construct results in downregulation of CCR5 in
progeny cells in humice and whether it could protect against HIV
challenge ex vivo as well as in vivo. Since there is some evidence in
the literature that the number of gene-engineered CD34 cells is a
major determinant of the success of the anti-HIV moieties (15,
16), we also made a major effort to generate hu mice with a very
high number of gene-engineered CD34 cells. Finally, we charac-
terized in extenso the hematopoietic system subsequent to HIV
infection in hu mice with gene-engineered CD34 cells.
MATERIALS AND METHODS
Ethics statement. The procurement and use of CD34 cells from human
cord blood were approved by the Cantonal Ethical Committee of Zurich
(EK-1103). All adult subjects provided written informed consent. Animal
care and experimental protocols were in accordance with the “Swiss Ethical
Principles and Guidelines for Experiments on Animals” (http://www
.akademien-schweiz.ch/en/index/Portrait/Kommissionen-AG/Kommission
-fuer-Tierversuchsethik.html) and approved by the Veterinary Office of
the Canton of Zurich, permit 26/2011. Manipulations of mice were in
accordance with the regulations of the Veterinary Office of the Canton
of Zurich (http://www.veta.zh.ch/internet/gesundheitsdirektion/veta/de
/home.html).
Lentiviral vector production and titration. Lentiviral vector stocks
were generated using transient transfection of HEK 293T/17 cells with the
self-inactivating vector pCLX-R4-DEST-R2 encoding the microRNA to
CCR5 (30), the psPAX2 plasmid encoding gag/pol, and the pCAG-VSVG
envelope plasmid, as described previously (31). Lentivector titration was
performed using transduction of HeLa cells, followed by quantification of
green fluorescent protein (GFP)-positive cells 5 days after infection by
flow cytometry as described previously (31).
Generation of humanized mice. NOD.scid.IL2R/ (NSG) mice
were bred and maintained in individual ventilated cages and were fed
autoclaved food and water. Mice with a human immune system (human-
ized [hu]mice) were generated as described previously (32). Briefly, new-
born (5 days old) NSG mice received sublethal (1 Gy) total-body irra-
diation with a Cs source and then received 2  105 transduced or
untransduced CD34 human HSPCs with a 50-	l Hamilton syringe via
the intrahepatic (i.h.) route. For the fluorescence-activated cell sorter
(FACS)-sorted R5 knockdown animals, CD34 cells were sorted
postransduction into GFP-positive and -negative fractions, and then 2
105 CD34 GFP-positive or GFP-negative cells were injected i.h. into
respective cohorts. All manipulations of hu mice were performed under
laminar flow. Cell suspensions of the hu mouse organs were prepared in
RPMI 1640 medium supplemented with 2% fetal calf serum.
HIVstock and infectionofmice.Viral stocks were obtained by poly-
ethylenimine (PEI)-mediated transfection (Polysciences) of 293T cells
with either pYU-2 (R5 tropic) or JRCSF (R5 tropic) (provided through
the NIH AIDS Research and Reference Reagent Program). At 48 h after
transfection, virus was harvested, filtered (0.45 	m), and frozen at
80°C until use. Viral titers were determined as described previously
(33). Briefly, 50% tissue culture infectious dose (TCID50) was deter-
mined by infecting human CD8 T-cell-depleted peripheral blood
mononuclear cells (PBMCs) from three donors that were stimulated
by adding interleukin-2 (IL-2), phytohemagglutinin (PHA), and anti-
CD3 beads (Dynal 11131D; Life Technologies). Mice were infected
intraperitoneally (i.p.) with either HIV YU-2 or JRCSF at 2  105
TCID50s per mouse. Plasma HIV RNA levels were measured by reverse
transcription-PCR (RT-PCR) (AmpliPrep/COBAS TaqMan HIV-1
test; Roche) at various times after infection.
Flow cytometry. The cells in whole blood were counted in a Beck-
man cell counter. Cell suspensions were labeled with anti-human
monoclonal antibodies (MAb) targeting the following cell surface
markers: CD45-peridinin chlorophyll protein (PerCP), CD3-allophy-
cocyanin (APC), CD4-Pe Cy7, CD8-BVa, CCR5-phycoerythrin (PE),
CD34-APC, CD45RA-APC, and CCR7-PE (all from BD Biosciences or
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Biolegend). Washing and reagent dilutions were done with FACS buf-
fer (phosphate-buffered saline [PBS] containing 2% fetal calf serum
and 0.05% sodium azide). All acquisitions were performed on a Cyan
ADP (Beckman Coulter) flow cytometer. Data were analyzed with
FlowJo software (Ashland, OR). Cellular debris and dead cells were
excluded by their light-scattering characteristics. Transduced CD34
cells were sorted according to intrinsic GFP expression as measured by
a BD FACSARIA III cell sorter.
HIV challenge ex vivo. Spleens of five hu mice transplanted with
HSPCs gene engineered with the microRNA to CCR5 were dissociated
through a nylon mesh, and red blood cells were lysed with ACK buffer
(Lonza) for 3 min. Cells were sorted (99% pure) with an ARIA sorter
(BD Bioscience) into GFP-positive and -negative cells and were subse-
quently activated for 24 h with PHA (4 mg/ml) in RPMI 1640 culture
medium supplemented with IL-2 (100 U/ml) and 10% fetal calf serum.
Thereafter, cells were infected with a TCID50 of 3.310
5/ml of YU-2 for
6 h and washed three times. The supernatant of the last wash was used as
the baseline p24 antigen level measured by an in-house enzyme-linked
immunosorbent assay (ELISA) (34). Virus spread was then monitored at
days 1, 4, 6, 8, and 10 postinfection.
Analysis of HIV envelope sequences. (i) Nucleic acid extraction. For
viral envelope sequencing, total nucleic acid was extracted from 60 	l of
mouse plasma on an EasyMag extractor (bioMérieux, Switzerland) ac-
cording to themanufacturer’s instructions. The elution volumewas 50	l.
(ii) Reverse transcription and PCR. For cDNA synthesis, 9 	l of ex-
tracted nucleic acid was reverse transcribed in a total reaction volume of
20	l at 42°C for 30min using a sequence-specific primer,MSR5 (35), and
the PrimeScript One Step RT-PCR kit (TaKaRa Bio Europe/SAS, France).
After heat inactivation at 96°C for 5 min, amplification primers were
added to the reactionmixture, and DNA corresponding to positions 5956
to 8535 in isolate HXB2 (GenBank accession numbers K03455 and
M38432) was amplified for 20 cycles. Nested PCR in a total reaction vol-
ume of 40	l with Phusion Hot Start II DNA polymerase (Thermo Scien-
tific, Switzerland) was carried out to amplify gp120 (positions 6817 to
7812) and gp41 (positions 7789 to 8382).
(iii) DNA sequencing. Before sequencing, amplifiedDNAwas treated
with Illustra ExoStar 1-step reagent (Fisher Scientific, Switzerland). For
cycle sequencing, the BigDye Terminator v3.1 cycle sequencing kit
(LifeTechnologies, Switzerland) and specific sequencing primers were
used. Twenty-five cycles of heat denaturation at 96°C for 10 s, annealing at
50°C for 5 s, and synthesis at 60°C for 4 min were carried out on a 2720
thermal cycler (Life Technologies). Samples were further processed by
ethanol precipitation, followed by capillary electrophoresis on a model
3130xl genetic analyzer (Applied Biosystems, Switzerland). The sequences
were assembled and edited with SeqMan Pro from the Lasergene 11 pack-
age (DNAStar).
Statistical analyses. Statistical analyses were performed using Graph-
Pad Prism 5.04 (GraphPad Software). Data were subjected to either un-
paired t tests or paired t tests, as indicated in the figure legends. The P
values obtained were considered significant when 0.05. Statistical out-
lier analysis was performed using theGraphPadOutlier calculator with an
alpha of 0.01 (http://graphpad.com/quickcalcs/Grubbs1.cfm).
RESULTS
Transplanting CD34 cells with partial CCR5 knockdown does
not hinder HIV replication. We previously developed a highly
efficientmicroRNA calledmirGE that allows efficient knockdown
by single-copy transduction (30). In this study, we explored the po-
tential of a mirGE lentivector targeting CCR5 to produce an HIV-
resistant immune system inhumice.Theconstruct consists of a triple
hairpin, and the vector cassette contains GFP driven by the same
promoter as the miRNA that allows transduced cells to be identified
directly. To minimize possible cellular perturbations from multiple
vector inserts, we established a protocol that gave us a transduction
rate of 20 to 30%.This transduction ratewas based onpreviouswork
and should correlate with single-copy integration (36). In the first
series of experiments, mice were transplanted with mirGE-trans-
duced CD34 cells without further manipulation (R5 knockdown
mice); theCD34 cellswere amixtureof transduced (20 to30%)and
untransduced (70 to 80%) cells (data not shown). As controls, we
used mice transplanted with CD34 cells transduced either with a
control GFP lentivector (control-transduced mice) (30) or with un-
transduced CD34 cells (untransduced mice). Upon infection with
an R5-tropic HIV (YU-2), the percentage and absolute number of
GFP-positive CD4T cells were increased inR5 knockdown cohorts
andnot in control-transducedcohorts (Fig. 1a; see alsoFig. 3gandh).
The CD4 cell population, however, remained the same over the
observation period of 92 days (cohort 1) or showed a CD4 T-cell
loss only at day 134days (cohort 2) (Fig. 1b).We explain this increase
inGFPHIV-resistantCD4 cells as the result of preferential expan-
sion at the cost of untransduced CD4 T cells, while the lymphoid
system tries to keep the lymphoid T-cell number constant. However,
the rates of HIV replication were similar in R5 knockdownmice and
control-transduced mice at 92 and 134 days (Fig. 1c). Analysis of
absolute numbers of CD4 T cells (cohort 2) indicated that the con-
trol-transduced mice lost CD4 T cells, whereas CD4 T cells were
more or less maintained in the R5 knockdown mice (data not
shown).
In the R5 knockdown mice, CCR5 was downregulated in the
GFP-positive CD4 T cells, but CCR5 was detected on the GFP-
negative CD4 T cells in blood and spleen (Fig. 1d). In the con-
trol-transduced mice, CCR5 was detected on GFP-negative and
-positive CD4 T cells. We verified the efficacy of our gene engi-
neering approach by separating transduced from untransduced
splenocytes (R5 knockdownmice) by FACS and infected the pop-
ulations ex vivowithR5-tropicHIV.GFP-positive splenocytes had
no HIV replication (Fig. 1e).
These results suggest that CCR5 knockdown efficiently pro-
tects CD4 T cells from HIV infection, while CCR5-expressing
CD4T cells are eradicated. In ourmice, despiteHIV challenge, at
least a proportion of the70 to 80%untransduced hematopoietic
stem cells survived and continued to produce HIV-permissive
CD4 T cells, which sustained high HIV titers. It is still not en-
tirely clear what effect HIV infection has on CD34 cells and to
what extent they are depleted, if at all (37).
Transplantation of purified CCR5 knockdown CD34 cells
results in mice with “pure” populations of transduced cells in
vivo. The lack of resistance to HIV infection was likely due to the
chimerism of transduced and untransduced CD34 cells in our
initial experiments. Therefore, we sorted the CD34 cells after
transduction into CCR5 knockdown, GFP-positive and -negative
fractions obtaining a 90% pure population of GFP-positive
CD34 cells. Mice transplanted with GFP-sorted cells were called
FACS-sorted R5 knockdown mice. Analysis of the peripheral
blood in six of the FACS-sorted R5 knockdown animals showed a
single GFP-positive peak for human CD45 and CD4 T cells, sug-
gesting that only transduced CD34 cells were engrafted in these
mice (Fig. 2); the level of GFP-positive cells was amajor criterion for
successful gene engineering andengraftment.Mice transplantedwith
the GFP-negative fraction were called FACS-sorted negative mice.
They developed CD4 and CD8 T-cell populations with no GFP
expression (Fig. 2). In contrast, the control-transducedmice had two
distinct GFP-negative and -positive populations for CD45 and
CD4 T cells (Fig. 2). A summary of mice used in this study is pro-
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vided in Table 1. Mice with less than 5% human engraftment in the
peripheral blood before HIV infection were excluded.
Transplanting purified CCR5 knockdown CD34 cells dra-
matically lowered viral load and protected HIV target cells in
vivo. The FACS-sorted R5 knockdown mice had markedly lower
viral loads than the FACS-sorted negativemice over 28weeks (Fig.
3a). Peak viremia for the FACS-sorted R5 knockdown mice was,
on average, 4.2 103 copies/ml, and FACS-sorted negative mice
had 3.5  105 copies/ml. Viral loads for the untransduced, con-
trol-transduced, R5 knockdown, and FACS-sorted negative mice
were similar. The FACS-sorted R5 knockdown mice had lower
viral loads than all cohorts.
CD4 T cells (percentage of total CD3 T cells) from the
FACS-sorted negative mice declined steadily upon infection
(day 0, 55%; day 134, 20%) (Fig. 3b). In contrast, the FACS-
sorted R5 knockdown mice showed a steady increase in CD4
T cells (day 0, 33%; day 196, 65%). Furthermore, the absolute
numbers of CD4 T cells increased for the FACS-sorted R5
FIG 1 Homeostatic expansion of GFP-positive CD4 T cells in R5 knockdown mice despite sustained R5-tropic (YU-2) HIV infection. (a) Percent change of
GFP-positive CD4T cells in the peripheral blood of control-transducedmice (cohort 1, n
 8; cohort 2, n
 4) andR5 knockdownmice (cohort 1, n
 6; cohort
2, n
 5). Values aremeans SEMs. *, P
 0.0152; **, P
 0.0034; ***, P
 0.0002. P values were determined by two-tailed unpaired t test. Insets show the results
for individual mice. (b) Frequency of total CD4 T cells (percentage of total CD3 T cells) for the control-transduced and R5 knockdown cohorts 1 and 2. Values
are means SEMs. *, P
 0.0146. P values were determined by two-tailed unpaired t test. (c) HIV RNA copies per milliliter of blood plasma collected for the
control-transduced and R5 knockdown cohort 1 and cohort 2 over 92 and 134 days, respectively. Time of termination was chosen at random for the various
groups. The dashed line indicates 400 copies/ml, the detection limit of the HIV RNA assay. Values are means SEMs. (d) Percentage CCR5 expression on total
CD4T cells in peripheral blood and spleens of various cohorts ofmice. Values aremeans SEMs. For blood, asterisks indicateP values as follows: *,P
 0.0237;
*=, P
 0.0121; **, P
 0.0035; ***, P
 0.0007; ****, P
 0.0001. For spleens, asterisks indicate P values as follows: *, P
 0.041; ***, P
 0.0003. P values were
determined by two-tailed unpaired t test. (e) HIV replication is inhibited ex vivo in GFP-positive sorted splenocytes fromR5 knockdownmice. Splenocytes were
isolated from R5 knockdown mice 20 weeks after CD34 cell injection. Splenocytes were sorted into GFP-positive (n
 5) and GFP-negative (n
 5) fractions
at 99% purity and challenged with R5-tropic HIV (YU-2). The amount of HIV production in the culture supernatant was monitored by HIV p24 ELISA. Viral
loads were normalized to the peak viral load under each condition (means SEMs).
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knockdown mice but decreased for the FACS-sorted negative
mice (data not shown).
At euthanasia, for the FACS-sorted R5 knockdown mice, 70%
ofCD4T cells in the blood and 83%ofCD4T cells in the spleen
were GFP positive (Fig. 3c and d). In the control-transduced and
R5 knockdown groups, the values were, on average, 20% and 18%
in the blood and 21% and 20% in the spleen, respectively (Fig. 3c
and d). Similarly, the CD4/CD8T-cell ratios in the blood (end/
preinfection) and spleen were very low in the various groups ex-
cept for the FACS-sorted R5 knockdown group (Fig. 3e and f).
Absolute numbers of GFP-positive CD4 T cells expanded signif-
icantly upon HIV challenge in the FACS-sorted R5 KDmice (Fig.
3i), and CCR5 expression was downregulated in the blood and
spleens of the FACS-sorted R5 knockdown mice (Fig. 1d).
In summary, transplantation of GFP-positive sorted CD34
cells produced mice with high levels of gene-engineered CCR5
knockdown CD4 T cells in vivo. This resulted in long-term inhi-
bition of HIV replication in vivo and preservation of HIV target
cells in the blood and spleen.
Outlier analysis and follow-up of mice that did not meet ac-
ceptance criteria.The FACS-sorted R5 knockdownmice typically
controlled the virus long term (titers  104 copies/ml) while
maintaining a high level ofGFP-positiveCD4T cells in the blood
(Fig. 4a). In contrast, a single FACS-sorted R5 knockdownmouse
(number 954) showed an unexpected decline in GFP-positive
CD4 T cells with high HIV copy numbers, 105 copies/ml, on
days 57 and 92 (Fig. 4a). We performed an outlier analysis (see
Materials and Methods), and at four different times, viral loads
detected in mouse 954 were statistical outliers (Fig. 4a). Based on
this, mouse 954 was not included in the mean values and was
analyzed separately (see below). At termination, this mouse had
much lower splenic engraftment of total human splenocytes, with
31% human cells, than did the FACS-sorted R5 knockdownmice,
which had 54% (standard error of themean [SEM],11%). GFP-
FIG 2 GFP-positive CCR5 knockdown sorted CD34 HSPCs produced mice with “pure” populations of transduced cells in vivo. (a) FACS plots showing the
percent human engraftment of CD45 (percentage of live cells) and GFP-positive CD45 (percentage of human CD45) cells for representative control-
transduced, FACS-sorted R5 knockdown, and FACS-sorted negative mice before HIV infection. (b) FACS plots showing the percentage CD4 T cells (percent
CD3), CD8 (percent CD3), and GFP-positive CD4 T cells (percent CD4) in the peripheral blood before HIV infection of the samemice as in panel a. For
all cell subset analyses, the subgating was done as follows: total live cells and CD45, CD3, CD4, and CD8 cells. Mean fluorescence intensity (MFI) for GFP
is indicated.
TABLE 1 Mice used in this study
Trait
% GFP CD34 cells
pretransplantation
Total no.
of mice
No. of mice with:
% engraftment
(5%
hCD45)
% GFP CD4 T
cells (70%)
% GFP CD4 T
cells (20–70%)
% GFP CD4 T
cells (20%)
Untransduced NAa 15 11 NA NA NA
Control transduced 15–40 17 12 0 5 7
R5 knockdown 17–20 15 11 0 0 11
FACS GFP positiveb 12–32 20 10 6 4 0
FACS GFP negative NA 26 15 NA NA NA
a NA, not applicable.
b FACS GFP-positive cells prior to FACS cell sorting for GFP-positive cells.
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positive CD4 T cells were barely detected in the spleen of mouse
954 (6%), while the FACS-sorted R5 knockdown mice had, on
average, 83% (SEM, 2%) GFP-positive CD4 T cells in the
spleen (Fig. 3d).
The inclusion criterion we defined as successful reconstitution
for FACS-sorted R5 knockdown mice was 70% GFP CD4 T
cells in the peripheral blood before infection. Four mice did not
meet this criterion despite being transplanted with GFP-positive
sorted CD34 cells (Fig. 4b). Mouse 1113 had no protection
against HIV and had a limited expansion of GFP-positive CD4T
cells (23% on day 0 to 43% on day 137). Mice 958 and 1115 had
massive expansions of GFP-positive cells, reaching close to 100%
of the total CD4 T-cell population, which went in parallel with a
decrease in the viral load (Fig. 4b). For mouse 1608, the dynamics
of recovery of GFP-positive CD4 T cells and viral load were
slower, and recovery of GFP-positive CD4T cells on day 134 was
less extensive (Fig. 4b). These three mice (958, 1115, and 1608)
maintained a high CD4/CD8 ratio, and the percentage of GFP-
positive CD4 T cells in the blood increased upon infection from
24 to 80, 39 to 82, and 37 to 52%, respectively. These animals also
had high frequencies of GFP-positive CD4 T cells in the spleens,
i.e., 59, 60, and 83%, respectively.
FIG 3 SustainedHIV load inhibition in FACS-sorted R5 knockdownmice. (a) HIVRNA copies permilliliter in blood plasma from FACS-sorted R5 knockdown
(YU-2 [n
 5]) and FACS-sorted negative (n
 15 [YU-2, n
 9, and JRCSF, n
 6]) mice collected over 134 and 196 days, respectively. The viral load detection
limit is indicated by the dashed line (400 copies/ml). Values are means SEMs. Single asterisks indicate P values of 0.0486, 0.0188, and 0.0391 for days 57, 92,
and 134, respectively.P values were determined by a two-tailed unpaired t test. (b) Percent CD4T cells of FACS-sorted R5 knockdown (n
 5) and FACS-sorted
negative (n 
 15) mice. Values are means  SEMs. Double asterisks indicate P values of 0.0017 and 0.0018 for days 92 and 134, respectively. P values were
determined by two-tailed unpaired t test. (c) Percent GFP-positive CD4 T cells in the peripheral blood at termination. Values are means SEMs. ****, P

0.0001. P values were determined by two-tailed unpaired t test. (d) Percent GFP-positive CD4 T cells in the spleen at termination. Values are means SEMs.
****, P 
 0.0001. P values were determined by two-tailed unpaired t test. (e) Change of CD4/CD8 T-cell ratio in the peripheral blood, comparing the
CD4/CD8 T-cell ratio of each cohort end and preinfection. Values aremeans SEMs. **, P
 0.0026. P values were determined by two-tailed unpaired t test.
(f) CD4/CD8 T-cell ratio at termination in the spleens of various cohorts of mice. Values are means  SEMs. **, P 
 0.0059; *, P 
 0.039. P values were
determined by two-tailed unpaired t test. (g to i) Absolute numbers of GFPCD4 T cells or total CD4 T cells/microliter of blood of representative mice from
the control-transduced (n
 5), R5 knockdown (n
 8), and FACS-sorted R5 knockdown (n
 5) cohorts are shown. Values aremeans SEMs. Single asterisks
in panels h and i indicate P values of 0.0194 and 0.0369, respectively. P values were determined by paired t test.
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Strikingly, we observed this level of expansion (Fig. 4b) ofHIV-
resistant GFP-positive CD4T cells and a concomitant inhibitory
effect on HIV only in mice transplanted with CCR5 knockdown
GFP-sorted CD34 cells (these animals had 30% [4% SEM]
GFP CD4 T cells on day 0). This degree of expansion was not
seen in R5 knockdownmice (which had 5% 2%GFPCD4 T
cells before HIV infection). Based on these results, we estimate
that at least 20% of CD4 T cells need to be CCR5 repressed to
observe homeostatic expansion and relevant effects on viremia.
Preserved engraftment andpreferential expansion of central
memory T cells in FACS-sorted R5 knockdownmice upon HIV
infection. Engraftment as reflected in peripheral blood decreased
in all control cohorts but increased in the FACS-sorted R5 knock-
down mice (Fig. 5a). This effect on total engraftment was even
more impressive in the spleen. FACS-sorted R5 knockdown mice
had 10 times more human cells than control cohorts (Fig. 5b).
We evaluated the CD4 and CD8 effector (CD45RApos
CCR7neg), effector memory (CD45RAneg CCR7neg), naive
(CD45RApos CCR7pos), and central memory (CD45RAneg
CCR7pos) T-cell subsets in the blood and spleens of the FACS-
sorted R5 knockdown and representative FACS-sorted negative
mice (Fig. 5c to f). In the peripheral blood of the FACS-sorted
negative mice, the frequency of central memory CD4 T cells was
significantly decreased, and the CD8 central memory T-cell sub-
set was unchanged (Fig. 5c and e). In contrast, central memory
CD4 and CD8 T cells were increased in the FACS-sorted R5
knockdownmice. Similarly, more CD4 andCD8 central mem-
ory T cells were present in the spleens of the FACS-sorted R5
knockdown mice (Fig. 5d and f). We observed no differences be-
tween the cohorts for effector and effector memory cells (data not
shown). Notably, however, there was a trend toward a decrease in
naive CD4 and CD8 T cells in all cohorts (data not shown).
FIG 4 Outlier analysis and examples of viral load control due to homeostatic expansion of transduced cells. (a) Left graph, viral load of the FACS-sorted R5
knockdown mice (YU-2) and viral load of outlier FACS-sorted R5 knockdown mouse 954 (YU-2). Right graph, percent GFP-positive CD4 T cells of the
FACS-sorted R5 knockdownmice and mouse 954. Percent GFP-positive CD4 T cells is shown as a percentage of total CD4 T cells. P values were determined
by GraphPadOutlier calculator. *, P 0.001. (b) Viral load and percent GFP-positive CD4T cells of four individual FACS-sorted R5 knockdownmice (mouse
1113, JRCSF; mouse 958, YU-2; mouse 1115, JRCSF; and mouse 1608, JRCSF) that were excluded due to not reaching the inclusion criteria of 70%
GFP-positive CD4 T cells before HIV infection.
Functional Cure of HIV
July 2015 Volume 89 Number 13 jvi.asm.org 6767Journal of Virology
 o
n
 June 23, 2015 by UZH Hauptbibliothek / Zentralbibliothek Zuerich
http://jvi.asm.org/
D
ow
nloaded from
 
Evidence of shift from R5- to X4-tropic strain in onemouse.
As described above (Fig. 4), FACS-sortedR5 knockdownmice had
a low viral load and maintained high levels of CCR5 knockdown
CD4T cells.Mouse 954was clearly anoutlier: it hadhigh viral titers
and lost GFP-positive CD4 T cells (Fig. 6a). We hypothesized that
thismousemight have had a tropism shift of the virus fromR5 toX4.
WeperformedHIVpopulationsequencing(fromplasma)ondays57
and 196. As a control, we analyzed mouse 958 (Fig. 6b). Sequencing
revealed no mutations in mouse 958. Mouse 954 had mutations in
the V3 loop of the HIV envelope sequence (Fig. 6c), resulting in
amino acid substitutions to basic amino acids as indicated (Fig. 6d).
Substitutions in the V3 loop to basic amino acids have been reported
to result in a switch from R5 to X4 tropism (38).
DISCUSSION
In this study, we investigated a lentiviral vector-based, CCR5-tar-
geting miRNA as a tool for engineering an HIV-resistant human
immune system. We show that (i) the miRNA-based vector was
very efficient in downregulating CCR5 on T cells and prevented
their infection by HIV ex vivo, (ii) only mice that were trans-
FIG 5 Increased engraftment and central memory T cells in blood and spleens of FACS-sorted R5 knockdown mice. (a) Change in level of peripheral blood
engraftment expressed as the ratio of total CD45 at the end and preinfection. Values are means SEMs. **, P
 0.0031; ***, P
 0.0006; ****, P 0.0001. P
values were determined by two-tailed unpaired t test. (b) Absolute numbers of human cells (CD45) in the spleen at termination. Values are means SEMs. *,
P
 0.0229; **, P 0.0019. P values were determined by two-tailed unpaired t test. (c and e) Percent CD4 and CD8 central memory T cells in the peripheral
blood, preinfection and at the end time point. Values are means and SEMs. *, P
 0.0153; **, P
 0.0042; ***, P
 0.0004. P values were determined by paired
t test. (d and f) Percent CD4 and CD8 central memory T cells in the spleen at termination. Values are means SEMs. *=, P
 0.0472; *, P
 0.0106; **, P

0.0022; ***, P
 0.0001; ****, P 0.0001. P values were determined by two-tailed unpaired t test.
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planted with a preselected population of transduced CD34 cells
andmaintained gene-engineered CD4 T cells had a dramatically
reduced viral load (functional cure), and (iii) the HIV-infected
mice transplanted with miRNA CCR5 gene-engineered CD34
cells showed a dramatic expansion of memory T cells (i.e., the
miRNA-edited T cells were mainly of this phenotype). Thus, we
provide here preclinical proof of concept for gene engineering of
an HIV-resistant immune system through the use of vector-me-
diated miRNA expression and the need for a certain threshold of
gene-engineered CD34 cells for functional cure of HIV.
While gene engineering of HIV-resistant cells is a viable option
for cure of HIV, major issues remain to be solved. These include
finding the best antiviral moiety or combination, the most effica-
cious way to gene engineer the CD34 cells, and the threshold of
gene-engineered CD34 cells needed for functional cure.
Lentivirus-based transduction has been supplemented by
gene-targeting methods, such as ZNF or Talen nucleases, or the
Crispr/Cas system for gene editing (23–25). However, off-target
effects of these methods are still unknown, and gene engineering
in primary cells is only modestly effective (26). And even though
no adverse events have been reported, there is less experience in
clinical trials with gene-targeting methods than with lentivirus-
based transduction. Thus, we opted for lentivirus-based gene en-
gineering (39–41). Furthermore, we are the first to engage in
miRNA technology for knocking down the HIV coreceptor CCR5
in CD4 T cells via gene engineering of CD34 cells. miRNAs
closely mimic naturally occurring pri-miRNAs and thus are less
likely to cause oversaturation of the RNA interference pathway
and to affect cellular homeostasis than the widely used shRNAs
(42, 43). However, miRNAs are thought to have a lower capacity
to downregulate target genes than shRNAs. In this study, we used
a miRNA we developed with optimized features that efficiently
knock down target genes upon single-copy vector transduction
(30). Ex vivo-sorted cells were indeed resistant to a challenge with
CCR5-tropic strains. However, bulk transplantation of trans-
duced CD34 cells into mice resulted in a human lymphoid sys-
tem that replicated HIV similarly to untransduced hu mice but
preserved CD4 T-cell counts. Similar data have been reported
previously (15).
We hypothesized that the majority of HSPCs needs to be gene
engineered to see an effect on the HIV load; otherwise, the HIV-
permissive CD4 T cells that originated from the untransduced
FIG 6 Population sequencing of HIV in plasma: evidence for gene therapy failure. (a and b) Plots showing the percent GFP-positive CD4 T cells in peripheral
blood (as a percentage of CD3 T cells) on the left y axis andHIV load on the right y axis for mice 954 and 958, respectively. Mouse 954 had a high and sustained
viral load over time, with a complete loss of GFP-positive CD4 T cells. Mouse 958 experienced an expansion of GFP-positive CD4 T cells from less than 30%
on day 19 to more than 80% on day 196. (c) On day 57, both animals had a homogenous HIV population in the peripheral blood; sequencing data of HIV
envelope V3 loop are consistent with an R5-tropic HIV strain. On day 196, mouse 954, which experienced a complete loss of GFP-positive CD4 T cells (blood
and spleen), had detectable mutations within the V3 loop of HIV. Formouse 958, nomutations were detected in the V3 loop on day 196, indicating the presence
of a homogenous HIV population. (d) Changes to basic amino acids H and R. According to a Geno2Pheno (http://www.geno2pheno.org/) analysis of the
obtained sequence in panel c, there is only 18% confidence that the virus at day 196 of mouse 954 was not an X4 variant.
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CD34 cells would “outnumber” theHIV-resistant cells. Thus,we
used GFP to allow for efficient sorting of transduced CD34 cells
before transplantation. By doing so, we found that to achieve
long-term suppression of viral load, more than 70% of CD34
transplanted should be gene engineered.Walker et al. obtained an
average engraftment ( standard deviation [STD]) level of anti-
HIV vector-transduced cells of 17.5%  8% in the peripheral
blood and argued that these numbers of cells were insufficient to
see any decrease in plasma viremia (15). Furthermore, a very re-
cent publication from the same group sorted the gene-engineered
CD34 cells with a truncated version of CD25 (tCD25) before
their transplantation into 2- to 5-day-old NRG mice (20). They
found that mice transplanted with tCD25-purified CD34 cells
had normal multilineage hematopoiesis, similar to mice trans-
planted with untransduced CD34 cells. Upon HIV challenge,
tCD25-transplantedmice did not suffer fromHIV-inducedCD4
T-cell depletion as did the untransduced mice, and tCD25 mice
had a 1.5-log inhibition in plasma viremia compared to that of
mice with untransduced CD34 cells. Our data nicely comple-
ment the data provided by Walker et al. and Barclay et al. and
underline the importance of the number of transduced cells that
are required for efficient HIV gene therapy. Notably, three hu
mice transplanted with purified gene-engineered CD34 cells
showed at baseline 30% GFP cells which expanded substan-
tially upon HIV infection; the expansion went along with a de-
crease in viral load. The data for these threemice were reminiscent
of the data reported by Holt et al. showing that disruption of
CCR5 by zinc finger nucleases was achieved in 20% of CD34
cells and resulted in viral repression over time (16).
Obviously, in humans, GFP-based sorting would not be an
option, given the xenogeneic nature of the protein. However,
novel strategies for sorting of transducedCD34 cells based on the
expression of truncated cellular surface receptors, such as CD25
(20), the epidermal growth factor receptor (44), or the nerve
growth factor receptor (45), are very promising for achieving high
numbers of engrafted gene-engineered cells. An alternative ap-
proach to pretransplantation sorting would be in vivo selection of
transduced cells (46, 47). Regrettably, current in vivo selection
methods use potentially carcinogenic compounds, such as myco-
phenolate, methotrexate, or alkylating agents (i.e., O6-benzylgua-
nine/bis-chloroethylnitrosourea), that offset their use in a disease,
such as HIV, that is amenable to an efficient and well-tolerated
cART.Wewant to emphasize that in our gene-engineering efforts,
we aimed for single lentiviral copy integration. The two recent
phase I clinical trials used gene engineering protocols that resulted
in vector copy numbers ranging from 2 to 4 per genome of bone
marrow cells prior to transplantation without documenting any
adverse events over an observation period of 20 months (39,
40). Thus, ensuring CD34 transduction might present another
alternative for increasing the number of gene-engineered CD34
cells. These protocols appeared not to affect the long-term en-
graftment negatively in these phase I clinical trials.
In fact, we do not know the number of gene-engineeredHSPCs
needed to render the immune system resistant toHIV. As outlined
above, we aimed for a rather pure population of gene-engineered
HSPCs as proof of preclinical concept. However, we observed
HIV-lowering effects in somemice with 20 to 40% engraftment of
transduced cells, data similar to those reported by Holt et al. (16).
HIV, certainly by killing untransduced cells via its cytopathic ef-
fects, will promote the expansion of HIV-resistant cells. To what
extent the HIV-resistant cells will foster an efficient HIV-specific
immune response and thereby constrain HIV remains unknown.
Whether additional factors contribute toHIV-lowering effects re-
mains unknown.
White blood cell counts from HIV-infected mice generated
with FACS-sorted R5 KD cells showed an expansion of central
memory CD4 and CD8 T cells, while all other groups showed a
progressive loss of these CD4memory T cells and no change in
CD8 T cells. This pattern was also evident when looking at the
splenocytes. These memory CD8 T cells might have contributed
to the control of HIV. There was a decrease in the frequency of
naive CD4 and CD8 T cells in the peripheral blood in both
FACS-sorted negative and FACS-sorted R5 KD mice, whereas in
the spleen, the naive CD4 and CD8 T cells in the FACS-sorted
R5 KDmice tended to be higher (data not shown). The expansion
of central memory T cells is reminiscent of the immune reconsti-
tution seen in HIV-infected patients on ART (48).
HIV is known for its high mutational rate. In this respect, we
observed one mouse (mouse 954) with an escape mutation. De-
spite high levels (day 0) of engraftment of CCR5 knockdown cells,
this mouse had a high viral load and a complete loss of circulating
CD4 T cells. Population sequencing of the V3 loop indicated a
likely shift to X4 tropism, which might explain the uncontrolled
infection. The mutations were detectable in the blood only at rel-
atively late time points. This might be due to an initial compart-
mentalized replication of the X4-tropic strains in the thymus. We
previously showed that X4-HIV NL4-3 severely depleted the thy-
mus, whereas YU-2 had only minor effects (49). However, we do
not know whether the potential emergence was due to the CCR5
knockdown or was just a coincidence. Indeed, emergence of
CXCR4-tropic strains may occur without any immune or drug
pressure in humice infectedwith CCR5-tropic strains (50). In any
case, CCR5 knockdown should be done in concert with another
strategy to constrain HIV (i.e., including another anti-HIV moi-
ety, combining with efficient antiretrovirals, or boosting the im-
mune response in parallel to transplantation). Indeed, the solid-
ness of successful gene engineering by the expression ofmore than
one antiviral moiety may prevent HIV evolution (51). Gene engi-
neering could be combined with conventional ART: combining
two treatment modalities was efficient in cell lines (52), as induc-
tion therapy (53) or with anti-PD1 antibodies that decrease viral
load and increase the level of CD4 T cells in HIV-infected mice
(54). In any case, gene engineering efforts cannot promote more
virulent HIV strains, either for the individual patient or for the
general population.
In summary, our results provide the first preclinical proof of
concept that transplantation of miRNA CCR5 knockdown
CD34 cells can lead to long-term control of HIV viremia. Trans-
lation of our results to the clinical setting is relatively straightfor-
ward but will require the implementation of existing strategies for
pre- and posttransplantation selection compatible with human use.
At this point, our strategy demonstrates long-term viral control but
not yet a cure.However,while a cure remains the ultimate goal, long-
term viral control independent of antiretrovirals is a relevant inter-
mediate step, worth translating to the clinical setting.We believe that
a definitive cure of HIV might indeed come from a combination of
different approaches such as CCR5 knockdown combinedwith drug
therapy, vaccination, or a second gene therapy target.
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4.1  Identification of potential IFN-stimulated HIV-1 restriction factors  
The main aim of my thesis was to identify whether additional cellular host restriction factors, 
which are anti-HIV active, exist, and if so, to characterize their molecular mechanism(s) of 
action. It has been previously shown that IFN-α treatment blocks HIV-1 replication in CD4+ 
T cell lines[102, 103], in the monocytic cell line THP-1, as well as in macrophages[104], and 
that most HIV-1 restriction factors identified so far are known ISGs[105-107]. Thus, we 
assumed that additional RFs would also be ISGs and aimed doing a more detailed analysis of 
the genes upregulated by IFN-α treatment that might be causal for HIV-1 inhibition.    
For that purpose, we did NGS to identify potential RFs subsequent to IFN-α treatment in cells 
where HIV-1 was clearly inhibited by IFN-α.  We first tested various cell lines for their IFN- 
responsiveness - among the cell lines screened, MT4R5 and SupT1R5 cells showed the 
highest responsiveness to IFN-α as documented by the upregulation of some prototypical 
ISGs. Of note, MT4R5 and SupT1R5 cells lack APOBEC3G and Tetherin, which might mask 
the potential effect of other restriction factors. In any case, we infected the cells with wild-
type HIV-1: the HIV accessory genes, Vif and Vpu, present in the wild-type HIV-1, should 
have been able to counteract APOBEC3G and Tetherin even if some residual proteins 
subsequent to IFN-α treatment would have been present. In the MT4R5 cells IFN-α resulted 
in a clear dose-dependent and persistent reduction of newly produced HIV-1 virions, while in 
SupTR5 cells this effect was less pronounced and mainly present only at day 3 after infection. 
IFN-α apparently interfered with HIV-1 during reverse transcription and integration of the 
HIV-1 genome into the host chromosome since intermediate reverse transcription products 
and proviral DNA was substantially lower in IFN-treated cells. Thus, potential IFN-induced 
RF act at the pre-integration complex, transport into the nucleus or the integration process 
itself. Our results are consistent with previous reports, performed in primary macrophages, the 
monocytic cell line THP-1[104], and CD4+ T-cells[108], where IFN-α  blocks HIV-1 
infection between reverse transcription and integration. IFN-α may also be anti-HIV active at 
later stages in the HIV-1 replication cycle, but the assays we were using, did not allow 
searching for it. 
We argued that the genes responsible for the IFN-α mediated inhibition of HIV-1 in MT4R5 
and SupT1R5 cells would be the same, although the antiviral effect of IFN-α was only 
transient in SupT1R5 cells.  Thus, we determined what genes were upregulated in MT4R5 
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and SupT1R5 treated with IFN-α. For this, we  did NGS of MT4R5 and SupT1R5 cells 
treated with IFN-α for 6 hours – we choose this time  point since within this time frame the 
first wave of gene upregulation takes place[109] and we did not want to have confounding 
results due to 2
nd
 or 3
rd
 waves upregulation of genes. We assumed that the first wave of genes 
upregulated contains potential RFs, and not the 2
nd
 or 3
rd
 wave, but this assumption might be 
wrong.  We obtained a list of 162 candidate genes, which were upregulated at once in both 
cell lines. To further characterise the relevance of the 162 candidates, we performed a gene 
ontology analysis by looking at the biological processes, the enriched pathway maps and the 
process networks. All three approaches provided similar results - not very surprisingly, the 
162 genes were enriched in the immune response and antiviral response pointing to an 
antiviral state triggered by IFN-α. We focused on the pathway maps, since it provides a more 
stringent list of genes potentially important against HIV-1 replication and it helps us to define 
a selected number of genes as opposed to the biological processes and process networks that 
provide a large list of candidate genes. 
The pathway maps analysis provided an enrichment of relevant genes, in particular 6 genes 
with a previously reported anti-HIV activity (OAS1, OAS2, OAS3[110], ISG15[111, 112], 
PKR (EIF2AK2)[113] and USP18[114]) and 7 genes with previously reported antiviral 
activity (IFI6[115], IRF7[116, 117], ISG54 (IFIT2)[118], MDA-5 (IFIH1), RIG-I 
(DDX58)[117, 119], MX1[120] and NMI[121]). The identification of the 6 genes with anti-
HIV activity and anti-viral activity validates our approach of using NGS for the identification 
of anti-HIV restriction factors. Of note, the most “famous” RF, APOBEC3G, Tetherin/Bst-2, 
SAMHD1, TRIM5α and the recently identified MX2[122, 123] were present in the 162 
upregulated genes but not in the pathway maps, which reveals a limitation of our approach. 
However, these five classic RF were present in seven of the ten biological processes at the 
same time and some of them in the other three biological processes; therefore no biological 
process in particular contained the known anti-HIV RFs and would have permitted us to focus 
on a distinct biological process. Let us remind that the major IFN-α mediated inhibition, we 
observed, occurs somewhere between pre-integration complex formation and proviral 
integration, and that the anti-HIV active genes mentioned above (i.e APOBEC3G, SAMHD1, 
Tetherin/Bst-2, TRIM5α) interfere with HIV-1 replication at other steps in the HIV-1 
replication cycle as known so far, except for MX2, which acts between pre-integration 
complex formation and proviral integration[108, 124]. For example, OAS1, OAS2 and OAS3 
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act prior to the reverse transcription[110], PKR (EIF2AK2), during translation; ISG15 and 
USP18  during budding[111, 112, 114]. Therefore, these factors might not be the ones 
responsible for the restriction observed in MT4R5 and SupT1R5 or they act by a yet unknown 
mechanism(s). The following factors, IFI6[117], IRF7[116], ISG54 (IFIT2)[118], MDA-5 
(IFIH1)[117], NMI[121], and RIG-I (DDX58)[119], are antiviral active but no reports about 
their potential anti-HIV activity exist – thus, they should be explored for their anti-HIV 
activity. MX1 on the other hand has been tested against HIV-1 but it does not affect its viral 
replication[108]. 
Furthermore, we compared the gene expression pattern from MT4R5 and SupT1R5 cells with 
the one from MT2 and MT4 cells (parental cell line) treated with IFN-α presented in the 
literature[125]. The 304 upregulated genes in MT4R5 cells covered the 262 genes upregulated 
in the MT4 cells. Even though we used a one log lower dose of IFN-α (100U/mL), we 
observed higher fold-changes of the individual genes for MT4R5 cells and more genes than 
for MT4 cells. This is easily explained by the different techniques applied: we used NGS 
while in the previous study, they used microarrays. NGS grants a higher coverage and higher 
sensitivity than microarrays[126]. The gene expression pattern of SupT1 cells (parental cell 
line) upon IFN-α treatment has not been reported in the literature so far. 
We also compared the gene expression pattern from MT4R5 and SupT1R5 cells with the one 
from primary monocytes treated with IFN-α and with that of HIV-1 infection of primary 
tissue. Since HIV-1 infection induces a prominent IFN-α response[127, 128], this in silico 
analysis might give some hints whether the genes identified in IFN-treated MT4R5 and 
SupT1R5 cells might have a role in HIV-1 pathogenesis.  Of note, activation of the IFN-
system in HIV-1 may be a double-edged sword, on the one hand it may block HIV-1 
infection[129], on the other hand, it may sustain immune activation, increasing HIV-1 
pathogenesis[130]. Of the 162 genes we found, 44 were also reported in the literature in the 
context of IFN-α treatment or HIV-1 infection. Since it does not seem to be a difference 
between the genes upregulated in in vivo (chronic or acute) or ex vivo HIV-1 infection, the 
genes upregulated in SupT1R5 and MT4R5 cells do not seem to be particularly involved in 
HIV-1 pathogenesis. Of note, it was shown previously that there is no difference between the 
genes upregulated in CD4+ T cells from patients in acute or in chronic phase[128]. The large 
difference of genes upregulated within the same context might be explained by the different 
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cell types and the dose of IFN-α used. According to a recent publication, IFN-α induces the 
upregulation of antiviral genes at weak concentrations (robust genes) and at higher 
concentrations it upregulates other genes (tunable genes), involved in cell proliferation, 
chemokine activity, inflammation[131].  
Interestingly, the same genes enriched in the pathway maps (see above) with anti-HIV and 
antiviral activity are present among the 44 genes, upregulated in our cell lines, as well as in 
the literature, the only exception being IRF7 and MX1. On the other hand, 11 gens with anti-
HIV activity (PLSCR1[132-134], MX2[122, 123], IFITM1, IFITM2, IFITM3[135, 136], 
BST2[137], TRIM22[138], HERC5[139], IFI16[140], ISG20[141], RSAD2[142], 
LGALS3BP[143], and UBE2L6[144]) and 7 genes with antiviral activity (apart from HIV-
1)(IFIT1[145], GBP1[146-148], IFI27[149], ZBP1[150], OASL[151], IFI35[152] and 
IFIT3[133, 153]) were present in the 44 genes upregulated in our cell lines and in the 
literature but not in the pathway maps, indicating again a limitation of the gene ontology 
approach. 
Again, these genes with reported anti-HIV activities act at another step in the viral life cycle 
as at the one we observed (see results section 3.1). Only MX2 and IFI16 act at the same step 
as we observed.  However, silencing MX2 by shRNA did not affect HIV-1 replication in 
MT4R5 and SupT1R5 cells, suggesting that another cellular factor restricts HIV-1 replication 
in these cell lines. The lack of any anti-HIV activity of MX2 was surprising – we speculated 
that either MX2 has no inhibitory HIV-1 activity in MT4R5 and SupT1R5 cells although it is 
highly upregulated or that a co-factor is needed for MX2 to exert its anti-HIV activity.  IFI16, 
which acts as a DNA sensor and activates caspase, leading to apoptosis, acts between reverse 
transcription and integration[154] and therefore might be the RF in MT4R5 and SupT1R5 
cells. However, we did not observe any apoptotic effect when MT4R5 or SupT1R5 cells were 
treated with IFN-α and subsequently infected with HIV-1. Nonetheless, we believe exploring 
IFN’s effect on HIV-1 should be explored when IFI16 silenced in our cell lines prior to 
explore other potential RF.  
Strength on the one hand, but also a limiting factor on the other hand is that the initial 162 
genes identified in IFN-treated MT4R5 and SupT1R5 cells were selected based on their 2 fold 
upregulation and using the gene ontology approach. The synopsis of all the gene expression 
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studies done in various systems points to a rather “small” set of genes upregulated, which 
must be explored in depth for their anti-HIV activity. Although the gene ontology approach 
provides a valuable access to the function and partners of the different genes upregulated, it 
does not necessary provide a list with the definitive anti-HIV candidates. In particular, since 
we focused mainly on the pathway maps, several other genes identified by biological 
processes or the process networks could be excluded. If the genes identified using the 
pathway maps do not correspond to an anti-HIV RF, data should be analysed differently (e.g. 
using the biological processes), although it will be much more difficult to interpret due to the 
large number of genes enriched.  
Outlook: Since RIG-I (DDX58) is a gene responsible for the induction of IFN-α/β[119] and 
therefore is involved in a 2
nd
 wave of gene upregulation[155], we could in a first step silence 
RIG-I (DDX58) and determine if the anti-HIV effect of  IFN-α is abolished in MT4R5 and 
SupT1R5 cells. This could point to a particular transduction pathway and exclude all the 
effector proteins upregulated in the 1
st
 wave of gene upregulation. If the silencing of RIG-I 
(DDX58) does not counteract the antiviral effects of IFN-α, there is a second approach: The 
genes with antiviral activity enriched in the pathway maps could be tested, to determine their 
anti-HIV effects by overexpressing them in MT4R5 and SupT1 and depending on the data, by 
their silencing. Their overexpression and subsequent suppression of HIV-1 replication in 
MT4R5 and SupT1R5 cells would indicate that they are the RF that we are looking for and 
their silencing and subsequent loss of IFN-α anti-HIV effect would confirm that they are the 
responsible RF. Such RF would need to be tested in other cell lines and more important, in 
primary cells, to determine if its effect is relevant in the target cells of HIV-1, first in vitro and 
if the results are promising, in vivo. However, the gene ontology analysis has its limitations, 
for instance the classical RF did not show up in the pathway maps analysis. Therefore it 
would be risky to focus only on such a limited number of candidate genes.  It would make 
more sense to perform a blind screening with shRNAs targeting all 162 genes upregulated in 
MT4R5 and SupT1R5 cells, however this approach is very expensive and cumbersome. 
Since we identified the step at which viral inhibition takes place, i.e. between reverse 
transcription and integration, an alternative approach would be the immuno-precipitation of 
the pre-integration complex, with or without IFN-α and a subsequent identification of the 
proteins present only in the IFN-α treated cells, using mass spectrometry. The proteins bound 
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to the pre-integration complex only when the cells are treated are likely to be a RF. Of note, a 
similar approach was already taken to identify the host proteins in infected CD4+ cells[156], 
but not after IFN-α treatment, like we suggest. 
4.2 The development of humanized mice models to study mechanisms of 
HIV infection 
4.2.1 Long-acting anti-retroviral drugs for treating HIV-1 in humanized 
mice 
The second part of my thesis work focused on studying the impact of the RF APOBEC3G 
(A3G) in vivo in humanized mice, in particular the emergence of mutations linked to it. My 
first experience with humanized mice as a small animal model for studying HIV infection in 
vivo came from work done with my peer Marc Nischang. We showed that mice treated with 
cART including a novel long-acting (LA) non-nucleoside-analogue, TMC278-LA had 
undetectable viral load. Similar as in human, after suppression of viral load with cART and 
subsequent interruption of cART or replacement of cART with only TMC278-LA 
(monotherapy) led to a rapid rebound of the viral load. Thus, TMC278-LA is not potent 
enough as mono-therapy to supress HIV RNA. Furthermore, the viral rebound clearly points 
to a latent reservoir of HIV-1. The mice with viral failure showed emergence of resistance 
mutations, i.e., the key signature mutations M184I and E138K of the nucleoside reverse 
transcriptase inhibitor (NRTI) 3TC and of the non-NRTI (NNRTI), TMC278-LA resp.  
TMC278-LA in combination with a protease inhibitor, TMC181_LA, both in a nano-based 
long-acting formulation was so. As expected, this treatment also preserved the CD4+ T-cell 
count as quantified by the CD4/CD8 ratio, and it even resulted in recovery of the CD4+ T-
cells in those mice with a previous CD4+ T-cell decline. Thus, long-acting compounds which 
are given on a weekly or monthly basis might be a realistic treatment option in particular for 
HIV-infected patients with poor drug adherence. Ex vivo we provided convincing evidence 
that HIV establishes a latent reservoir by detecting proviral DNA in splenocytes obtained 
from HIV-infected mice with undetectable HIV DNA. Using a cocktail of compounds, this 
latent reservoir was reactivated as measured by the expression of HIV-1 Gag transcripts. 
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To summarize this work convincingly proves that humanized mice represent a valuable small 
mouse model for studying HIV pathogenesis and novel treatment approaches. The latent 
reservoir represents the major hurdle for cure of HIV. This mouse model will be very useful 
for studying novel treatment approaches for the eradication of this reservoir, i.e., we are now 
able to test different compounds for its potential to reactivate viral transcription in a model 
that approximates the human situation - compounds will be tested such as deacetylation 
inhibitors, methylation inhibitors or chromatin-modifying agents. The contribution I made in 
this work is reflected by a co-authorship on the publication.  
4.2.2 High resolution mapping of HIV drug resistance evolution driven by 
APOBEC3G 
I also worked on my own project using the humanized mouse, i.e. we studied the biological 
properties of the Vif-APOBEC3 axis, in particular the spectrum of APOBEC3 proteins, which 
hypermutate the HIV-1 genome, which are in turn neutralized by the HIV-1 protein Vif. We 
hypothesized that partial neutralization of APOBEC3-editing enzymes (as illustrated by the 
45G mutant) induces mutations that decrease viral fitness, but under certain conditions, such 
as under the pressure of the immune system or drug treatment, might be beneficial for viral 
escape. APOBEC3-editing enzymes counteract HIV-1 and other retroviruses by 
hypermutating their viral genome[65, 66]. APOBEC3G and APOBEC3F are neutralized by 
the accessory protein Vif present in wild-type HIV-1[67, 157]. The significance of these 
enzymes for HIV-1 infection is demonstrated by the lack of replication when challenging 
mice with HIV-1 strains deficient in Vif. However, partially active Vif might lead to a partial 
neutralization of the APOBEC3-editing enzymes, which might favor viral diversification and 
thus contributing to viral escape from the immune system or drug treatment. 
We looked at the mutagenesis induced by the cellular APOBEC3 deaminases in the context of 
viruses that harbor point mutations in the Vif protein. Vif has a region which binds to the 
different APOBEC3-editing enzymes[67, 68] and another region which binds to the 
proteasomal machinery, in order to send the bound APOBEC3-editing enzymes for their 
degradation[157, 158]. The 45G mutant is not able to bind and therefore degrade APOBEC3G 
but the other APOBEC3-editing enzymes[68]. The SLQ mutant has a mutation in the SLQ 
domain, which interferes with the binding of the proteasomal machinery and therefore is 
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unable to induce the degradation of the different APOBEC3 proteins and thus has been 
considered as an equivalent of a Vif-deficient virus [158-160]. This work was done in close 
collaboration with Dr. Viviana Simon (Mount Sinai School of Medicine, New York City).  
Dr. Simon and co-workers using a rather artificial system demonstrated the development of 
drug resistance when there is mixture of Vif mutants and Vif WT population of viruses[161]. 
In such experiments three conditions were tested in vitro at high concentrations of 3TC: HIV-
1 WT replication, HIV-1 Vif mutant 45G replication (cannot counteract APOBEC3G) and a 
combination of both. Only the combination of both viruses was able to replicate under these 
conditions, as opposed to the single viruses, indicating that the 45G mutant is able to transfer 
the drug resistance mutation to the WT virus, possibly by recombination[161]. 
Based on previous experiments in vitro, we wanted to show that 45G mutant virus is able to 
develop drug resistance faster than the WT version, in vivo, and therefore we performed the 
experiments in the humanized mouse. For this, we infected mice with either HIV-1 WT or Vif 
mutants 45G or SLQ (cannot counteract any APOBEC3).  
In vitro, using either PBMCs or cord blood cells depleted from the CD34+ hematopoietic 
precursor cells, we observed that the WT and the 45G viruses replicate at the same level, as 
observed by our collaborator[161]. In contrast, we observed surprising results in vivo: the WT 
virus and the 45G mutant replicated similarly during the first 4 weeks, but after 8-12 weeks, 
the replication of the 45G mutant decreased significantly which was not the case for the WT 
virus. Thus, the viral fitness of the 45G mutant is indeed lower than the one of the WT but this 
is only recognized after a certain lag time. The SLQ mutant HIV-1 strain, unable to degrade 
any APOBEC3 protein, did not replicate at all, showing the importance of the neutralization 
of the APOBEC3 family members for successful HIV-1 replication in vivo.  
To validate the hypothesis that selective pressure (e.g. drug treatment) might be beneficial for 
the viral escape of the 45G as compared to the WT virus, we infected humanized mice with 
either WT or 45G viruses and 4 weeks later started treatment with 3TC (food pellets) to 
determine if the 45G mutant develops drug resistance faster than the WT virus, as shown in 
vitro[161]. We monitored the viral load every two weeks and performed ultra-deep 
sequencing on the viral RNA from plasma in order to determine viral evolution overtime. 
While the initial decline in HIV-1 RNA was similar with both HIV-1 strains, the viral 
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rebound was significantly faster in the 45G-infected mice than in WT-infected mice. One 
could expect that the faster rebound observed in 45G-infected mice is due to a faster 
development of 3TC resistance mutations - however the NGS data showed that this is not the 
case: irrespective of wild-type or 45G strains, NGS data showed 3TC resistance in almost all 
mice after two weeks. A closer look revealed that the quasi-species in mice infected with the 
45G virus had mainly M184I mutations, which correspond to G-to-A mutations, typical of 
APOBEC3G, while the quasi-species in mice infected with the WT virus presented both 
mutations M184I and M184V, typical of stochastic mutations. The mutation M184I increases 
the RT fidelity 4-fold and M184V 2.5-fold as compared to WT RT[162, 163]. We speculate 
that the higher fidelity of the RT with M184I may prevent an excessive RT-driven 
diversification and thus, HIV-1 strains with M184I might have a replication advantage as 
compared to HIV-1 strains with M184V or WT RT. In other terms, the gain of RT fidelity 
may outweigh the APOBEC3G editing effects. However, the gain of viral fitness of the 45G 
mutant is only apparent under drug or immune pressure promoting specific mutation as 
illustrated here with 3TC since viral replication was attenuated overtime without 3TC 
treatment. 
In conclusion, a partial neutralization of APOBEC3 family members might be beneficial for 
HIV-1, not for a faster development of drug resistance mutations, as initially thought, but to 
increase viral fitness under selective pressure. In this case, the selective pressure was the 3TC 
drug, but this could also be extrapolated to other drugs or the selective pressure by the 
adaptive immune system. 
This work showed that APOBEC3G partial neutralization decreases viral fitness of HIV-1 but 
under selective pressure it increases viral fitness. And since HIV-1 is present as quasi-species 
population and has a high rate of mutation, mutations of Vif, rendering it partially active 
might happen in some strains, as shown in patients[68], APOBEC3G could actually favor 
HIV-1 drug resistance or immune escape. 
Additionally, this works illustrates very convincingly the power of the Illumina platform for 
next-generation sequencing of HIV-1 quasi-species from the plasma and in particular for 
detecting resistance mutations. Before 2007, previous sequencing studies in the field of HIV-1 
used rather exclusively the Sanger’s sequencing-based PCR amplification, which permitted to 
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identify the sequence of the most prevalent HIV-1 strain but did not allow to discriminate 
quasi-species or to detect minor HIV-1 populations[164, 165]. 
So far, in the HIV field, the Illumina platform has only been used a few times in vitro[166-
168]. The advantage of this method is that it is appropriate for divergent viruses, or for 
samples with low amounts of viral RNA, like in the case of patients under cART, allowing to 
detect most or all the different quasi-species populations[169]. Our study underlines the value 
of the Illumina NGS platform to detect HIV-1 resistance in plasma viral RNA with high 
accuracy.  
Outlook: It was discussed that the conclusions obtained in the experiments showing the 
increase in viral fitness of the mutant 45G under selective pressure (3TC treatment) require 
confirmation and further exploration due to the astonishing results. Therefore, new 
experiments have been set and have been ongoing in the last months, therefore the submission 
of the manuscript has been postponed. 
4.2.3 Gene therapy against HIV-1 using the humanized mice 
I was also involved in studying gene therapy approaches to render the immune system 
resistant to HIV-1 (manuscript published). My peer, Renier Myburgh had the lead in this 
work. Here, we transduced CD34+ hematopoietic stem and precursor cells (HSPCs) with a 
lentiviral vector containing miRNAs against the HIV co-receptor CCR5. CCR5 together with 
CD4 constitutes the HIV receptor complex – absence of CCR5 renders cells non-permissive 
to HIV. We observed a substantial decrease in the HIV load in the mice transplanted with 
HSPCs gene engineered with the above-mentioned lentiviral construct as compared to the 
control mice (functional cure); in parallel, we also observed a preservation of CD4+ T cells 
and a homeostatic expansion of memory CD4+ T-cells. This work clearly showed that gene 
therapy strategies are a promising approach to cure HIV-1.  
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